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σ Standard deviation 
τo Unquenched fluorophore lifetime 
υ Ionisation of a solution 








Despite a general increased awareness of infection control measures, the continual emergence 
of drug resistant bacterial isolates that are able to colonise a host with negative severe 
consequences is proving problematic. These bacterial strains tend to be particularly 
opportunistic; targeting the vulnerable and immuno-compromised host. Of particular interest 
to this project is paediatric burns and scalds, where an open wound potentially provides an 
ideal environment for bacterial colonisation. Within this vulnerable patient group the 
temptation remains to healthcare professionals to indiscriminately subscribe antibiotics 
unnecessarily. However, creation of a detection system that can be applied to a wound which 
can rapidly diagnose the presence of bacteria could help to alleviate the oversubscription of 
drugs, helping to prevent resistance. 
This project focuses on the stabilisation, modification, delivery and treatment of phospholipid 
based vesicles for applications in advanced wound care, with a focus on paediatric burns. 
Vesicles, commonly referred to as liposomes or nanocapsules, are attractive drug delivery 
composites, due to their biocompatible properties. They have the ability to entrap active 
compounds within their core, which can be released at the point of use, (in vivo or ex vivo) 
either through passive diffusion, or in response to local environmental stimulus.  
The different stabilisation, modification, delivery and treatment of vesicles within this project 
are depicted in the following figure. 
 
 





Chapter 5 - Dressing prototypes Chapter 6 - Vesicle sterilisation 
 
 
Chapter 7 - Vesicle modification Chapter 8 - Microplasma jet treatment of vesicles 
 
 
Abstract 1. The utilisation of phospholipid based vesicles.  
Within this work; Chapter 3 presents work on the modifications of vesicle composition to 
attain stability at 37 °C for 14 days. Chapter 4 presents work on the selective sensitivity of 
successfully stabilised vesicles to pathogenic bacteria. Chapter 5 presents work on the 
development of a prototype dressing incorporating stable, sensitive vesicles. Chapter 6 
presents an introductory investigation into potential vesicles sterilisation techniques. Chapter 
7 presents work based on the modification of vesicle properties through alterations of 
phospholipid structure, and conjugation of protective agents. The final research chapter, 8, 
presents an investigation into the interaction of a micro plasma jet with a synthetic biological 




Chapter 1 Introduction 
The need to manage wounds and treat illnesses has been a requirement since the evolution of 
complex species. Evidence of mankinds’ struggle with this can be traced to fragmentary 
records dating back 5000 years. Though treatment strategies were probably attempted prior to 
this, evidence has not survived to the present day. It is likely that ancient treatment strategies 
were based on concoctions that showed some positive therapeutic effect, or on religious or 
superstitious beliefs that were not wholly advantageous.  
The evolution of wound management has progressed from the (relatively simplistic) 
requirement to achieve healing and closure, to a need for treatment and prevention of 
infection, and this has continually pushed the boundaries of scientific discoveries. Prior to the 
revolutionisation of infection and wound treatment with antiseptics and antibiotics, the 
leading cause of death following survival of an initial wound was infection.
1
 
As a result of this, antibiotics are one of the most important medical discoveries, and their 
introduction coupled with modernisation of the healthcare system has saved countless lives.
2
 
However, the oversubscribing and misuse of antibiotics has led to resistance in many strains 
of bacteria. Figure 1-1 simplistically depicts potential methods of bacterial resistance to 
antibiotics. 
 
Figure 1-1. Bacterial mechanisms for antibiotic resistance, primarily achieved through 
enzymatic modification or degradation to inactivate or remove the active site, physical 












The emergence of antibiotic resistance is complicated by the fast travelling and evolution of 
resistance genes of bacteria. This resistance has become a major clinical problem and is 
emerging as one of the world’s greatest health challenges; the search for new antibiotics is 
pursued in direct competition with the evolution of bacteria.
4
  
To intensify the challenge of multi-drug resistant bacteria, the development of new antibiotics 
has slowed, due to the associated costs of unsuccessful potential drugs coupled with the 
inherent ability of bacteria to develop resistance. Despite a 60 % decrease in new candidates 
and approvals in the last decade, a report published by Research and Markets titled the 
“Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat 
Antibiotic Resistance” states that there are more than 100 antibiotic candidates in the 
pipeline, with nine candidates in phase three trials, and a promising further 31 at phase two. 
As an alternative, or in combination with antibiotics, the discovery and subsequent use of 
antimicrobials has shown promise in wound management as a result of their effectiveness, 
safety and diversity.
5
 Antimicrobials differ from antibiotics in that they are substances with 
inherent inhibitory properties, with minimal effects on mammalian cells; compared to a 
substance produced by a microorganism that can inhibit growth (bacteriostatic) or kill 
(bactericidal) other microorganisms.
6
 Prior to antibiotic resistance, investigations into 
potential antimicrobial agents were neglected. However following an increase in knowledge, 
research into promising and new candidates has resumed.
1
 In 2000 the World Health 
Organisation (WHO) presented a global strategy to prevent and contain antimicrobial 
resistance, based on an orchestrated multidisciplinary approach. However this approach was 
under funded with insufficient human resources to implement the strategy, and so despite 




1.1 Microbiology and microorganisms  
Microorganisms are defined as organisms that cannot be viewed without the aid of a 
microscope. Microbiology is the study of these organisms, their structure, physiology, 
molecular biology and functional ecology.
7
 Microorganisms are widely acknowledged as the 
first form of life to develop on Earth; their numbers, adaptability and distribution in even 







The founding of bacteriology is accredited to Ferdinand Julius Cohn in the 19
th
 century, 
however the discovery of bacteria dates back to Antoni van Leeuwenhoek in 1684. Bacteria 
are prokaryotic single celled organisms approximately between 0.1-10 µm in size. 
Prokaryotes can be initially classified according to their shape; spherical (cocci), curves, 
spirals and rods (bacilli). Further classification into broad groups can be achieved based on 
the presence of one or two cell membranes depending on whether they are gram negative 
(two) or gram positive (one). 
All bacterial cells contain a cytoplasmic membrane composed of proteins, phospholipids and 
cholesterol; forming a bilayer. The membrane is involved with the synthesis and export of 
membrane components, respiration, secretion of enzymes and toxins and actively up-taking 
nutrients into the cell. The shape of the bacteria cell is maintained by the presence of the cell 
wall, but the structure of this varies between gram negative and gram positive organisms. 
Gram positive bacteria contain a relatively thick peptidoglycan based wall, composed 
primarily of repeating sugar subunits cross linked with peptide side chains. Gram negative 
bacteria have a thinner peptidoglycan layer, and an additional outer membrane composed of 
lipopolysaccharides, and occasionally lipoproteins and porins that aid transport of substances 
across the cell envelope.  
The cell wall plays an important protective role for bacterial organisms and hence is often the 
target of β-lactams antibiotics; damage to the wall often leads to cell apoptosis. The cell wall 
is also a barrier against osmotic pressure variations. In addition to the cell wall, some bacteria 
are surrounded by a capsule composed of large polysaccharides. The capsule can aid 
attachment of the bacteria to host cells and shield the organism from host defences. 
The structure of prokaryotic cells differs significantly from eukaryotic cells. In addition to 
their size, shape and external membranes, they do not contain a membrane-bound nucleus, a 
complex endomembrane system or cytoskeleton. Prokaryotic cells also lack two cytological 
features found in prokaryotes, namely; a lack of energy producing organelle (their 
metabolism is not compartmentalised) and an inability to carry out endocytosis.
9
 
In prokaryotic cells, most of the DNA is contained within the bacterial chromosome, which 
aggregates to form the nucleoid, however some is extra-chromosomal arranged in circular 
plasmids. Plasmids contain genes that code for special properties as opposed to basic survival 
genes. Prokaryotes are essential to the earth’s biota. They play an integral role in catalysing 
18 
 
unique reactions, account for a large percentage of biodiversity and produce components of 
the earth’s atmosphere necessary for life. The number of prokaryotes is estimated to be 
between 4-6 x 10
30






1.1.2 Bacterial identification in a clinical setting 
Within a clinical environment, the identification of bacteria requires a more pragmatic 
approach; guidance on the likely cause of an infection is required in a more timely and 
inexpensive manner. Presumptive identification can be achieved using a few simple 
procedures, including microscopy – staining (rapid) and culturing of pure stocks – colony 
growth on agar (<24 hours), however faster methods are always being sought, leading to the 




1.1.3 Bacterial pathogenesis 
The interaction between a microorganism, ‘parasite’, and a human ‘host’ determines whether 
a tolerable (commensal or even symbiotic) relationship develops or an infection occurs. 
Pathogenicity is the ability of a microorganism to produce an infection, and this varied ability 
relates to the virulence factors that they produce.
6
 In addition to this, the virulence factors 
released by bacterial organisms are dependent on whether they are gram negative or gram 
positive. This will be discussed in more detail in 4.2 Bacteria with regard to the specific 
bacteria utilised as part of this investigation. 
 
1.1.4 Biofilms 
For over a century a generalised belief amongst microbiologists maintained that bacteria 
existed as single entities of non-cooperative unicellular bacteria species. Recently, a 
paradigm shift in understanding has led to knowledge of networks of coordinating cells, 
commonly known as a biofilm.
12
 The term biofilm describes association of a microbial 
organism with a favourable micro-environment. In natural environments, the biofilm is 
habitually a multi-species microbial community that is able to share genetic material at high 
rates and stay or leave the community with purpose; making it complex and highly 
differentiated.
13





 requiring intercellular signalling
15
 and demonstrating a gene transcription 
profile that is distinct from planktonic cells.
16
 Figure 1-2 depicts the biofilm formation 
process. 
 
Figure 1-2. Formation of a biofilm from individual planktonic cells through A) initial 
attachment, B) cell aggregation, C) biofilm accumulation and finally D) dispersion of biofilm 
and detachment of cells.
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The formation of a biofilm following colonisation of a human ‘host’ by a microorganism 
‘parasite’ can be tolerable / manageable; for example, in oral hygiene and the formation of 
dental plaque.
18
 Pathogenic biofilm is however more widely recognised within the medical 
health profession, with formation commonly occurring on wounds and medical devices such 




1.1.5 Quorum sensing 
Within a biofilm micro environment, bacteria are able to communicate cell-to-cell, allowing 
for regulation of colonisation and virulence factors. This phenomenon is known as quorum 
sensing (QS). Simplistically, QS ensures regulation of gene expression as a function of cell 
population density within a network, primarily through the release of small diffusible signal 
molecules, commonly known as pheromones or autoinducers. As the density of bacterial cells 
increases, the concentration of signal molecules also increases until a threshold concentration 
is reached whereby activation of a signal transduction cascade occurs, providing an auto-
regulatory system for sensing.
12
 This communication network makes it difficult for host 
20 
 
defences and external defence agents to form any resistance or barricade to both the cells 
present and their released virulence factors following colonisation. 
 
1.2 Innate host defences  
Arguably, the best mode of defence against a bacterial infection is the prevention of a 
pathogen invading the host body in the first place. This method is known as germ theory and 
was developed by Koch and Pasteur. It resulted in a medical revolution; the knowledge that 
tiny bacteria could sicken and kill people led to the creation of public health agencies, 
particularly related to water management, and prevented epidemics.
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The best physical barrier that animals have to bacterial colonisation is the skin. The skin is 
composed of several layers, notably the epidermis (outer) and dermis (inner). Colonisation is 
prevented or discouraged at unbroken skin through a combination of innate techniques. Some 
of these include: the constant shedding of dead surface skin cells removing any bacteria that 
is able to successfully bind, a high concentration of the protein keratin, produced by 
keratinocytes, not readily degraded by microorganisms; a relatively dry localised 
environment, and low acidic pH (approximately pH 5) and surface temperature (34-35 °C). 
Despite this, some colonisation and breaching of the skin barrier is achieved at hair follicles 
and sweat glands, however a further barrier of toxic lipids and lysozyme, capable of 




1.2.1 Bacteria defences 
Just as host-bodies have developed defences against bacterial penetration and pathogenicity, 
bacteria have evolved successful strategies for countering these effects. The pathogenicity of 
a bacteria depends upon its transmission pathway; either person-to-person contact, 
environmental exposure to a contaminant or through a vector, such as an insect. If successful 




Controlling and limiting the growth of microorganisms can be achieved by restriction of 
access to vital nutrients, manipulation of the physical environment towards pessimal 
conditions of growth, addition of metabolic pathway inhibitors, and application of 
chemotherapeutic agents that can selectively discriminate between host and microbial cells. 
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The impact of this inhibition is dependent upon whether the effect is transient or permanent. 
Within a wound environment these control mechanisms may become compromised, leading 
to conditions that are favourable for bacterial growth, resulting in infection. 
 
1.3 Wounds 
In general, a non-medical based definition of a wound is a break in the continuity of any 
bodily tissue as a result of an external violence, such as surgery. This definition neglects 
wounds caused by internal gradual tissue disturbances, such as ulcers, hence a more 
generalised definition and classification is required.  
Within the healthcare community, wounds are commonly classified as being either chronic or 
acute. A chronic wound is defined as one that has “failed to proceed through an orderly and 
timely process to produce anatomic and functional integrity or proceed through the repair 
process without establishing a sustained and functional result”.21 In practice this term is often 
used to refer to a wound that takes longer than three weeks to heal. In contrast, an acute 
wound is defined as one that is obtained directly from a trauma or an operative procedure, 
following which the healing pathway precedes in a timely manner with at least external 





1.3.1 Burn wounds 
Within this investigation a tentative focus towards burn wounds has been made. Burn trauma 
can be caused not only by exposure to heat, but through freezing, electricity, chemicals, 
radiation and friction. The severity of burn is dependent on the depth of tissue affected, and 
can lead to complications involving shock, infection, electrolyte imbalance and respiratory 
failure. In addition to these problems, if the patient survives, patients can suffer serious 
emotional and psychological distress due to long-term hospitalisation, scarring and 
deformity.
22
 The classification of burn depth is according to degree I-III, and this relates to 




1.3.2 Wound healing 
Healing can be defined broadly as a dynamic process of recovering from a trauma or illness 
by working toward realistic goals, restoring function, and regaining a personal sense of 
balance.
23
 Within wounds, healing can be defined as the act of restoring the integrity of the 
damaged tissue with replacement of lost tissue and the repair of damaged tissue, through 
either the natural biological body response, or intervention of a third party to accelerate or 
modify the damaged tissue.
24
 
The wound healing process within a simplified skin injury model, without any aid from 
external agents such as sutures or supports, can be thought to progress through four phases: 
 Initial and temporary repair – damage limitation in the form of haemorrhage into the 
wound with associated clotting, to prevent further blood loss. 
 Inflammatory response – inflammatory cells, leukocytes, and increased blood flow 
into the wound act to remove irreparably damaged tissue, aid salvageable tissue and 
protect against microorganism colonisation.
25
 
 Stimulation of epithelial cells – an in-growth of blood vessels with fibroblasts provide 
granulation tissue for the growth of epithelial cells from the edges of the wound to 
ensure wound closure, aided by underlying contractile tissue which shrinks to bring 
the wound margins together. 
 Remodelling – the wound may look visibly healed at this stage, however the earlier 
laid fibrous tissue is modified to give the final outcome: a scar. There are three 
possible forms a scar can take: 
1. Atrophic – indistinguishable from surrounding, unaffected skin 
2. Hypertrophic – elevated above the surrounding skin, but confined within the 
size of the original wound (frequently seen in burns) 
3. Keloid – elevated above and out-growing the original wound24 
In principle, all wounds must undergo similar steps to ensure sufficient wound healing. The 
presence and activity of reactive oxygen species (ROS), proteases, and other soluble 
mediators and cells are crucial for ensuring necrosis; debris and microbial habitation are 





1.3.3 Burn wound healing 
The process of healing within a burn wound is likely to follow a similar pathway to a 
standard wound.
26
 However the degree of a burn significantly affects the biological response. 
For example, in a deep dermal burn the damaged skin heals very slowly, if at all, and depends 
heavily on surrounding keratinocytes; the predominant cells in the epidermis. A major burn is 
accompanied by a large inflammatory response, ensuring an acute influx of inflammatory 
mediators and growth factors. This inflammatory response is linked to the eventual long term 
scarring effects, and so there is potential for applications and strategies that reduce the 
response without this affecting wound repair.
27
 This technology would prove beneficial for 
all patients, especially paediatric patients. 
 
1.3.4 Paediatric burns – relevant clinical examples 
Burn injuries to children account for the greatest length of stay of all hospital admissions, of 
which the majority (80 %) are scalds from hot liquids. An examples of a paediatric patient 
who spent time at the South West UK Children’s Burn Centre and his injuries are described, 
from information supplied by Dr Amber Young; paediatric burn specialist at the South West 
UK Paediatric Burn Centre. 
 Patient A – 13 months old suffering from 32 % TBSA face and body burns from a hot 
drink scald. Treated using a biosynthetic skin dressing Biobrane
TM






Figure 1-3. An example paediatric burn patient. Patient A suffering from 32 % burns a) with 
Biobrane
TM
 dressing and b) after 12 months fully healed. Information obtained from 
University of Bath Press Release – 06/07/2010 titled ‘Revolutionary medical dressing uses 
nanotechnology to fight infection’.  
24 
 
1.3.5 Burn wound treatment protocol 
Globally, there is not one definitive treatment for burn treatment. Different burn treatment 
centres around the world use varied dressings and techniques in the treatment of burns and 
this can be dependent on the thickness of the wound and the treatment centres preferences. 
There is insufficient data, limited in both quantity and methodological quantity, to support 
recommendation of a specific dressing as a treatment for all burns, and so many different 
types exist. The burn dressing strategies can be divided into two categories: open methods, 
consisting of topical antimicrobials, and closed methods, which use occlusive dressings.
28
 
The use of traditional dressings-for example, silver sulfadiazine (SSD) cream, used since 
1968 to minimize infection-and a combination paraffin/cotton wool layer dressing, have been 
reported to have problems adhering to the wound,
29
 and require frequent changes resulting in 
trauma to growing epithelialised cells and delayed healing. Additionally, the use of SSD 
cream is discouraged due to its reported toxic effect on regenerating keratinocytes, increasing 
the scarring that results.
30
  
The effectiveness of occlusive dressings for superficial and partial thickness burns have been 
analysed by the Cochrane Review.
31
 The dressings reviewed included: 
 Hydrocolloid dressings – composed of gelatin, pectin and sodium 
carboxymethylcellulose (CMC) in an adhesive polymer matrix, forming a gel in 
contact with wound exudates, aiding auto-lytic debridement of the wound.  
 Polyurethane film dressings – permeable to water vapour, oxygen and carbon dioxide, 
impermeable to liquid water or bacteria. The amount of time this dressing can be left 
in place is dependent on the amount of wound exudate. 
 Hydrogel dressings – high water content gels containing insoluble polymers. The 
ability of the dressing to absorb or donate fluid aids wound debridement and 
maintains a moist wound environment. 
 Silicon coated nylon dressings – composed of a flexible polyamide net coated with 
soft silicone containing no biological compounds, allowing dual action of direct 
wound contact and absorption of exudates. 
 Biosynthetic skin substitute dressing – mimics the skin epidermis and/or dermis 
allowing reepithelialisation while permitting gas and fluid exchange. 
 Antimicrobial (silver and iodine containing) dressings – act to reduce the risk of 
invasive infection by minimising the bacterial colonisation. 
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 Fibre dressings – for example, calcium alginate, which is bio-derived, biodegradable, 
absorbent and can be removed painlessly with saline irrigation. 
 Wound dressing pads – simple non-adherent dressings, knitted viscose dressings, and 
tulle and gauze dressings. These may contain antimicrobials or be non-medicated. 
The Cochrane Review attempts to address which of these dressings is the most effective in 
promoting healing and minimising discomfort and infection. Evidence from different studies 
supports the use of hydrogel, antimicrobial, biosynthetic and silicon coated dressings due to 
advantageous wound healing time, decreased number of dressing changes and associated 
patient pain compared to other commercially available dressings. 
There are important considerations for the development and measured effectiveness of a burn 
dressing or gel, and these include: 
1. The time required for the burn to heal. Measurement of this can be carried out by 
tracking the wound surface area over time.  
2. The number of dressing changes or reapplications required. 
3. The cost of the dressing. 
4. The level of pain associated with the application and removal of the wound dressing, 
based on physician and patient perception. 
5. The required length of stay in hospital. 
6. The incidence of infection. 
These considerations are often balanced, with priority given to a dressing which is effective 
at scar reduction, especially in paediatric burn-affected patients. An emphasis on scar 
reduction is preferable in young patients to minimise the lifetime trauma damage, as well as 
associated costs incurred through psychological and scar tissue management later in life.  
 
1.3.6 Recent research in burn injury 
Examples of other recent publications relating to burn wound care techniques include those 
reported by Saitoh et al., Kuroyanagi et al. and Sastry et al. In 2012, Saitoh et al. reported the 
development of a biocompatible, flexible, transparent and adhesive nanosheet dressing 
consisting of poly(L-lactic acid) (PLLA) with marked protection against wound infection and 
hence improved wound healing, measured through re-epithelialisation in mice models with 
partial thickness burns.
33
 Also in 2012, Kuroyanagi et al. reported the development of a 
hyaluronic acid and cross-linked collagen sponge containing epidermal growth factor capable 
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of promoting re-epithelialisation and a decrease in wound size in Sprague Dawley (albino) rat 
models with partial thickness burns.
34
 In 2013, Sastry et al. reported the synthesis of a 
biocompatible fish scale collagen / physiologically clotted fibrin biosheet dressing, 
incorporated with Macrotyloma uniflorum plant extract for enhanced antimicrobial 
properties, with the potential to act as a burn / wound dressing material.
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Within this field there is scope for continual development and improvement to current 
treatments and dressings used. An updated desirable properties specification of an ‘ideal’ 
burn wound dressing (for burns smaller than 20 % total body surface area (TBSA)) has been 




1.3.7 Clinical requirement 
An online survey into the properties of an ‘ideal’ burn wound dressing suitable for small 
burns (<20 % TBSA), involving 121 participants from 39 countries, has indicated a wish list 
of characteristics from a clinical perspective.
36
 Essential or desirable characteristics included: 
a lack of adhesion to the wound bed, pain free application and removal, absorbency, 
antimicrobial activity, a range of sizes and, in paediatric patients, thinner dressing options. 
From this list of characteristics most respondents agreed that the ‘ideal’ dressing is not 
currently available.
36
 Alongside these desirable attributes are those summarised in 1.3.5 Burn 
wound treatment protocol: minimised healing time, decreased frequency of dressing change, 
reduced cost (relating to dressing and hospital stay time) and scar reduction. 
Additionally, an emphasis can be made on reduced microbial loading within a healing 
wound. An increased amount of bacterial burden (bioburden) in a healing wound increases 
the quantity of harmful cytokines, elevates the metabolic requirements of the local tissues, 
stimulates a pro-inflammatory environment and up-regulates the in-migration of monocytes, 
macrophages and leucocytes; negatively impacting the wound healing process.
37
 As a result, 
decreasing / effectively eliminating the bioburden could ensure faster healing times, 
decreased scarring and reduced dressing changes. The presence of biocides applied directly to 
wounds, in gel form, or embedded within dressings, such as silver based agents, plays an 
important role in wound bioburden management. However, these biocide agents are applied 
indiscriminately; no knowledge of bacterial presence is known, and importantly, the potential 
bacterial strains present may even have resistance, or be capable of adapting to develop 





Detection and identification of bioburden present prior to application of biocide agents could 
ensure a directed treatment approach, however problems arise from the time required for 
identification of bacteria and associated dressing removal problems. The incorporation of a 
detection system within a dressing, which selectively indicates the presence of pathogenic 




1.4 Current clinical detection of wound infection 
Within a clinical environment, detection of the presence of bacteria in a wound is primarily 
based on subjective identification of physical and clinical characteristics and symptoms. 
These identification symptoms can include ‘classic’ indicators such as pain, erythema (skin 
redness), oedema (swelling due to fluid), body temperature changes and purulence (pus 
discharge). Secondary indicators such as excessive exudate, delayed healing, foul odour and 
wound breakdown may give a better, if slightly belated, indication of infection. However the 
relationship between presence / amount of bioburden in a wound and the extent to which 
these signs and symptoms manifest is not definitively clear.
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Following symptom-based suspicion of infection within a wound, confirmation and 
identification within a clinical environment can be achieved using a swab or fluid taken from 
the wound or dressing. Traditional identification methods involve culturing the swab onto a 
growth plate, isolation of individual strains, followed by gram staining, monitoring growth 
characteristics and antibiogram testing (susceptibility to antibiotics). Highly related species of 
bacteria cannot be phenotypically differentiated and accurate identification cannot always be 
achieved.  
Despite the range of microbial identification methods available, no optimal technique has yet 
been agreed upon. The length of time, cost, availability of equipment, level of complexity and 
reliability of results often determine which method should be used.  
 
1.4.1 Paediatric burn patient focus 
The classic and secondary indicators of infection, listed in 1.4 Current clinical detection of 
wound infection, are similar to the symptoms and side effects that accompany a burn. These 
indicators are magnified in a paediatric patient, where the innate immune system is less 
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developed, and TBSA of a burn is often larger. As a result of this, these indicators cannot be 
used to determine the colonisation of bacteria and presence of infection within a burn wound. 
If infection is suspected, the wound dressing must be removed and the bioburden must be 
eliminated through extensive debridement of the wound prior to re-dressing. If the bioburden 
is not removed, the infection can develop, leading to manifestation of toxic shock syndrome 
and potentially, death. However, this process is painful for the patient, expensive, can delay 
or prevent wound healing; which may result in avoidable scarring, and could even lead to 
further infection colonisation following re-dressing of the wound. It is important to note that 
this process may even turn out to be completely unnecessary, as the wound may not have 
even been colonised.  
Removal of the wound dressing could be avoided, and further scarring and pain could be 
reduced, with a wound dressing that signals definitively the presence of bacteria within a 
wound. Further development of this dressing detection system could include the 
incorporation of bacterial destroying agents that help manage and decrease the bioburden 
levels within a wound.  
 
1.4.2 An infection detection wound dressing  
The development of a wound dressing with the ability to detect and indicate the presence of 
pathogenic bacteria in a wound, within an appropriate time frame, could have many wound 
management applications. A dressing of this type could potentially ensure that painful 
removal of the dressing and debridement of the wound is avoided unless necessary. 
The success of this dressing relies on the incorporation of a sophisticated system of internal 
agents, capable of indication and /or antibacterial treatment, which are only released in the 
presence of pathogenic bacteria. Within this project phospholipid-based vesicles are utilised 
and specifically engineered to develop this sophisticated system, with an emphasis on 




Figure 1-4. The lytic response of vesicles in the presence of pathogenic bacterial toxins 
 
1.5 Aim of this work 
This investigative work is a continuation of the EU FP7 project Bacterio Safe, which aims to 
develop ‘a wound dressing which involves the sophisticated design of nanocapsules that 
release signalling molecules and antibiotic / antimicrobials in the presence of pathogenic 
bacteria’. This aim has been integrated, adapted and developed within this project to advance 
progress and address other applications of vesicles for advanced wound management and 
alternative therapies.  
This work is divided into 7 chapters and brief summaries into the aims of each of these are 
given here. Chapter 2 provides an overview of the experimental procedures and analytical 
instrumentation, including introductive descriptions of principals, utilised as part of this 
investigation. More information about techniques may be found at relevant points within each 
succeeding chapter. Chapter 3 concentrates on the development of vesicle structural 
composition, containing a signalling dye that is stable to certain environmental stimulus, such 
as increased temperature and changes in pH. Chapter 4 concentrates on investigating the 
sensitivity of successfully stabilised vesicle compositions, from chapter 3, to pathogenic 
bacterial toxins, whilst remaining unaffected by the presence of non-pathogenic bacteria. This 
system will ensure that harmful bacteria can be exclusively detected. Chapter 5 concentrates 
on the successful incorporation of these stable and sensitive vesicle compositions into 
matrices that can be utilised for topical application onto a wound. Chapter 6 aims to 
determine a sterilising method suitable for treatment of the vesicles to ensure that they can be 
incorporated into dressings suitable for wound applications. An emphasis is placed on the 
maintenance of vesicle structure following treatment. Chapter 7 concentrates on 
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incorporating additional functional and protective agents to provide vesicle systems with 
enhanced selective activities. 
Chapter 8 concentrates on investigating the depth of penetration and potential damaging 
effects of microplasma jet treatment using a synthetic biological sensor containing vesicles.  
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Chapter 2 Experimental and instrumentation 
This chapter provides an introduction to the formulation and treatment of vesicles within this 
project, and the range of analytical techniques used to characterise the results obtained. 
 
2.1 Materials 
Chemicals and solvents, of HPLC grade, were sourced primarily through Sigma Aldrich, with 
the following exceptions. The majority of the lipid derivatives were obtained from Avanti 
Polar Lipids (APL) (except from DSPC and DSPE which were obtained from Sigma 
Aldrich). Sephadex NAP-25 columns were obtained from GE healthcare. 6-, 12- and 96- well 
costar plates were obtained from Fisher Scientific. Carbopol 981 P NF was obtained from 
Surfachem. 
 
2.2 Vesicle formulation process 
Vesicles were composed primarily of phosphatidylcholine (PC) lipids, 
phosphatidylethanolamine (PE) lipids, and cholesterol. The vesicle components were stored 
at -20 °C, and dissolved individually in chloroform at a concentration of 0.1 moldm
-3
, 
followed by combination together to enable synthesis of different vesicle compositions. 
The vesicles were synthesised in a similar procedure to that carried out by Nayar, Hope and 
Cullis reported in 1993.
1
 100 µl total of different stock solutions was added to 200 µl of 
chloroform, followed by drying with nitrogen gas to form a thin film. 5 ml of 50 mM [5,6]-
carboxyfluorescein was added, heated to 75 °C, cooled, and freeze-thawed three times before 
pressurised using Nitrogen (10-15 bar) five times through two 100 nm polycarbonate 
membranes in the LiposoFast LF 50 extruder, at approximately 60 °C. Purification from 
unencapsulated dye was achieved using a Sephadex NAP 25 column and HEPES buffer. The 





Figure 2-1. Vesicle formulation process. Image acknowledgements to W. D. Jamieson  
 
2.2.1 Solvent free vesicles 
Preparation of vesicles involved hydrating lipid components, (DSPC, DPPC and DSPE), in 2 
ml 50 mM 5(6)-CF buffer under a nitrogen atmosphere at room temperature for one hour. 
After this time, cholesterol was heated to 120 °C following addition of 3 % (v/v) glycerol for 
20 minutes, until dissolution occurred. The temperature was lowered to 75 °C and the lipid 
components were added, followed by stirring for 30 minutes. To encourage formation of 
vesicles, and in parallel to the standard method used, this solution underwent three freeze-
thaw cycles, followed by extrusion in a LF-50 extruder through a 100 nm membrane, and 
purification through a NAP-25 column. 
 
2.2.2 Aqueous buffer preparation 
The aqueous buffer solutions were made according to the compositions given below. The 
chemicals were weighed using a HR120 A&D analytical balance able to resolve to 0.1mg and 
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dissolved in ultra-pure deionised water obtained from Thermo scientific Barnstead easy pure 
II purification system, sonicated as required, and stored at 4 °C.  
Chemical HEPES buffer – pH 7.4 5(6)-CF dye 
Deionised water 750 ml 100 ml 
NaCl 4.680 g 0.0585 g 
NaOH 0.168 g 0.5405 g 
HEPES 1.7895 g 0.2387 g 
EDTA 0.219 g 0.0285 g 
5(6)-CF - 1.8789 g 
Table 2-1. The composition of the HEPES storage buffer and 5(6)-CF dye.  
 
2.2.3 Cross linking of vesicles 
Vesicles formed with TCDA were irradiated with UV light, following purification and 
storage for a minimum of 5 hours at 5 °C; at 254 nm for 12 seconds using a commercial flood 
exposure UV source from Hamamatsu
TM
, for cross linking of polymerisable components.  
 
2.3 Microbiological assays 
All microbiology assays were carried out in a class II safety cabinet where aseptic techniques 
were utilised. Sterilisation of surfaces and gloved-hands was achieved using 70 % v/v 
ethanol. All equipment used for contact with microbes (e.g. pipette tips and tubes) were 
decontaminated through autoclaving; the heating of a sample to a minimum of 121 °C, 15 psi 
for 15 minutes. A ScanLaf class II Microbiological safety cabinet was utilised for all 
microbiological based work. 
 
2.3.1 Bacterial growth agar 
The agar, Luria (LA) and Tryptic soy (TSA), used for gram negative and gram positive 
bacterial growth respectively, were made from their dehydrated forms, according to the 
compositions given on the containers. The chemicals were dissolved in ultra-pure deionised 
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water obtained from Thermo scientific Barnstead easy pure II purification system, 
autoclaved, and whilst a liquid, poured into petri dishes. Formation of colonies on the agar 
prior to inoculation with a bacterial strain indicated contamination.  
 
2.3.2 Bacterial growth media  
Bacteria growth in media solution was carried out in the aqueous broth, Luria (LB) and 
Tryptic soy (TSB), used for gram negative and gram positive bacterial growth respectively. 
These were made from their dehydrated forms, according to the compositions given on the 
containers. The chemicals were weighed using a HR120 A&D analytical balance able to 
resolve to 0.1 mg and dissolved in ultra-pure deionised water obtained from Thermo 
scientific Barnstead easy pure II purification system, autoclaved, and stored. Cloudiness in 
solution following storage indicated contamination. 
 
2.3.3 Bacteria preparation 
Bacteria were obtained from glycerol stock cultures stored at -80 °C and streaked onto Luria 
Broth (LB) agar plates in the case of gram negative organisms, and Tryptic Soy Broth (TSB) 
agar plates in the case of gram positive organisms. These agar plates were place into an 
incubator at 37 °C for 16 hours. Following growth of individual colonies, and utilising 
aseptic techniques, a single colony was transferred from the plates into 10 ml of LB or TSB 




Figure 2-2. Preparation of an individual bacterial strain prior to addition to a sample  
Following overnight growth in broth, the cultures have reached the stationary phase of their 
growth cycle, Figure 2-3, however log phase growth is required prior to addition to samples 
and so 10 µl of this culture is re-suspended in 10 ml of LB or TSB.  
 
Figure 2-3. Bacteria growth curve. The log and stationary phase is desired for the bacteria to 
be producing and releasing toxins that have a potential effect of the stability of the vesicles  
Following re-suspension, the log-phase bacteria was applied to test samples in a 2:1 ratio, 
under constant agitation, at 37 °C for a minimum of 16 hours.  
 
2.3.4 Bacteria supernatant preparation 
Within this investigation the term ‘supernatant’ refers to the separable solution obtained from 
a bacteria culture following centrifugation and discarding of the pellet (whole bacterial cells). 
Bacteria were prepared as described above; however following overnight growth in broth the 
bacteria / growth medium solution was centrifuged for 20 minutes to form a pellet, followed 
by pressurisation of the solution through a 0.22 µm filter. The solution obtained could be 
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used instantly or frozen into aliquots. Supernatant was applied to test samples in a 1:1 ratio 
primarily for time periods of less than two hours. 
 
2.4 Dressing prototypes 
The delivery medium of vesicles was based on hydrogel formulations suitable for topical 
applications. These formulations were required to provide stability to the vesicles, and a 




The hydrogels used in this project to create a prototype wound dressing were synthesised at 
different concentrations and compositions using HEPES buffer as the aqueous phase and 
were pH adjusted as required. These different hydrogel agents were formulated to ensure 
provision of a stabilised environment for incorporation of the vesicles, whilst maintaining a 
structure appropriate for potential application to skin. Primary hydrogel candidates included 
Carbopol 981P NF, gelatin, hypromellose and agarose. Individual gels were composed of the 
following: 5 wt % gelatin, 1.5 wt % carbopol, 1 wt % agarose and 2 wt % hypromellose, with 
HEPES buffer and 30 % v/v of the stabilised and sensitive vesicle solutions. 
 
2.5 Vesicle sterilisation 
The decontamination, disinfection and sterilisation of vesicles was investigated using a 
variety of physical methods. These methods include sterilisation by applying radiation 
(electromagnetic or particle), increasing the temperature (heat) and filtration (micro-porous 
membranes). Within these techniques an emphasis was placed on vesicle stability following 
sterilisation. Vesicle stability comparisons were obtained using the fluorescence response 
after addition of a lytic agent or HEPES buffer to sterilised vesicles. Non-sterilised vesicles 




2.5.1 Gamma radiation sterilisation 
The gamma sterilisation of different vesicle compositions was carried out using a Gammacell 
GC1000 with a Caesium 137 (
137
Cs) radioisotope source. The 
137
Cs source was used at a 
calibration of 7.713 Gy, for 58 hours to give a sterilising gamma radiation dose of 25 kGy 
(carried out by the Blonde McIndoe Research Centre, UK). This sterilising dose is sufficient 
to ensure absolute sterilisation of vesicles. 
 
2.5.2 Heat sterilisation 
The sterilisation of vesicles to thermal moist sterilisation treatment was carried out by heating 
samples to 80 °C for 10 minutes, 30 minutes and 60 minutes, and using a standard autoclave 
machine, with a treatment time of 60 minutes at 120 °C.  
 
2.5.3 Filter sterilisation 
The filter sterilisation of vesicle samples was carried out following pressurisation of the 
vesicles through 0.1, 0.22 and 0.45 µm filter membranes. The 0.22 and 0.45 µm filter 
membranes, manufactured by Merck Millipore, were composed of mixed cellulose esters, and 
the 0.1 µm filter was composed of polyvinylidene fluoride (PVDF), both with a process 
volume capability of 100 ml.  
 
2.6 Vesicle modification 
Vesicle modification was investigated on the formed vesicles to improve both the specificity 
and stability of vesicles. 
 
2.6.1 Hyaluronic acid coupling 
The hyaluronic acid was prepared by dissolving in HEPES buffer (10 mg ml
-1
), followed by 
stirring for 4 hours; and activation with ethyl(dimethylaminopropyl) carbodiimide (EDC) (1 
eq) and N-hydroxysuccinimide (NHS) (1 eq). This was added in a 2:1 ratio to standard 
TCDA-DS vesicles (200 nm) containing the self-quenched dye 5(6)-CF, or modified TCDA-
DS vesicles containing 6 mol % stearylamine in the bilayer (added at the same point of 
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formulation as the other membrane components, followed by the formation of the dehydrated 
thin film). 
 
2.7 Treatment of vesicles with plasma 
Plasma was utilised to treat vesicles dispersed in a gelatin matrix as a synthetic biological 
sensor to monitor the effects of microplasma jet treatment on biomimetic vesicles. 
 
2.7.1 Microplasma jet 
The plasma jet assembly consisted of a glass capillary tube with an inner diameter of 0.8 mm 
that was surrounded by two external hollow electrodes separated 4 mm apart, as shown in B 
in Figure 2-4. The plasma was operated with 100 ml min
-1
 of helium at an applied voltage 
potential of 5.5 kVpeak-peak and a frequency of 10 kHz. These operational conditions produced 
a plasma plume of approximately 10 mm in length. The plasma jet was housed inside a 
custom-built reactor (Cantech Pty Ltd, Adelaide, Australia) equipped with a 3-axis sample 
positioning stage, mass flow controllers and a power supply, 
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 depicted in A in Figure 2-4. 
 A  B 
  
Figure 2-4. The micro plasma reactor and jet, where (A) is a photograph of the custom built 
micro-plasma reactor system and (B) is a schematic and photograph of the microplasma jet.  
 
2.7.2 Synthetic sensor 
The synthetic sensor was created utilising DSPG-DP vesicles (for composition see Table 3-5) 
containing 50 mM 5(6)-CF. These were added (30 % v/v) to 5 % gelatin in HEPES and 
placed onto sample petri dishes at a depth of 2 mm. A control gelatin matrix was also 
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prepared with non-encapsulated (5(6)-CF (30 % v/v)). Treatment of the synthetic tissue was 
performed at 2 and 3 mm separation distances (d) between the end of the glass capillary tube 
and the surface of the gelatin matrix and for treatment times of 15, 60 and 300 s. Treatment 
was performed at two different angles: either perpendicular or in parallel to the sample 
surface (comparison carried out by S. Hong). To analyse treatment from the neutral helium 
gas (no plasma) the treatment was carried out using the same flow rate of helium but with no 
applied voltage. As a control experiment treatment of 5(6)-CF-gelatin was also carried out.  
 
2.8 Methods of characterisation 
The following techniques were used to measure, characterise or observe the vesicles and their 
response to various agents, in addition to other related chemicals, at different stages of the 
investigation. 
 
2.8.1 FLUOstar Omega plate reader 
A FLUOstar Omega plate reader is a modular multi-mode microplate reader platform that 
allows flexible measurement of UV-Vis absorption and fluorescence intensity at a wide range 
of wavelengths. Fluorescence band pass excitation and emission filters of 485 ± 12 nm and 
520 nm were used, with a gain of 650. Optical density, utilised for monitoring bacterial 
growth, was measured at 600 nm (OD600).  
The general schematic of a spectrometer is given in Figure 2-5. Application of a light source 
with a high intensity, broad wavelength output is focussed onto and through an excitation 
monochromator. The monochromator ensures selection of the desired wavelength, which can 
then be focussed onto the fluorophore containing sample. A proportion of the incident light is 
absorbed of by the fluorophore, and consequentially emitted. Isolation of the emitted light 
from contamination is achieved by passing the emission through a second monochromator, 




Figure 2-5. Schematic of an epi-fluorescent spectrometer. Acknowledgements to W. D. 
Jamieson, PhD thesis 2013.  
Fluorescence intensity is defined in terms of arbitrary units (au). In addition to this the 
introduction of the stability response parameter (Equation 3-29) allows comparisons between 
different experiments to be made. 
Experiments were carried out using nunc 6 or 12 or costar 96 well plates, and endpoint or 
continual readings were obtained. The use of micro titre plates for fluorescence and 
absorption readings ensured that focussing and detection of emitted light from the 
fluorophore was required at an angle of 45° as opposed to the conventional 90° detection 
angle (relative to the path of the incidence excitation light). All measurements were 
completed in triplicate. 
 
2.8.2 Brightfield and fluorescence microscopy 
Brightfield microscopy allows for simple optical microscopy illumination following 
transmission of white light through a sample. Fluorescence microscopy utilises the emitted 




Brightfield and fluorescence microscopy was carried out using a Nikon Inverted Microscope 
TE-2000. Fluorescence images were captured through a Nikon filter with 455-485 nm 
excitation and 500-545 nm emission using a 4x objective. Images were recorded with a 
Nikon DXM1200C digital camera and processed using NIS-Elements Basic Research v2.2 
software. Fluorescence intensity profiles were recorded using the same exposure time of 48 
ms for all of the samples. Fluorescence intensity values for each treatment were produced 
from 60 data points by measuring 20 different positions at a distance of 45 µm across the 
centre of each treatment area. Experiments were performed in triplicate.  
 
2.8.3 Confocal microscopy 
Confocal microscopy is utilised in this project to visualise vesicles and assess the impact of 
micro plasma jet treatment containing a fluorescent dye (5(6)-CF) or a fluorescently tagged 
lipid (Texas red DPPE). As shown in Figure 2-6, an incident light is passed through an 
objective lens and directed onto a sample; emitted light then passes to the detector. A 3D 
image of the sample can be generated following detection of scans in the x, y and z 
directions. 
 
Figure 2-6. Confocal microscope schematic 
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Two different confocal microscopes were used for the purpose of analysis of these results. 
For analysis of vesicle containing samples the confocal microscopy images were obtained 
using a laser scanning Zeiss LSM510, equipped with a 488 nm laser. For analysis of plasma 
treated samples the confocal microscopy images were obtained using a Nikon A1-R 
Microscope, equipped with a 488 nm DAPI laser and a 10x CFI Plan Fluor DL objective. Z-
stack images through the sample were obtained with 5 µm incremental adjustments of the 
sample height. NIS-Elements Advanced Research software was used for image processing 
and analysis.  
 
2.8.4 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a technique utilised to measure size and visualise 
vesicles on a particle-by-particle basis, in polydispersed liquids at real time with minimal 
sample preparation. A laser light source illuminates nanoscale particles from approximately 
10 nm to 1000 nm, Figure 2-7. 
 
Figure 2-7. Schematic diagram of a Nanoparticle tracking analysis instrument 
A finely focused 635 nm laser beam is passed through a prism-edged optical flat, of which 
the refractive index is such that the beam refracts at the interface between the optical flat and 
the liquid sample layer placed above it. Due to the refraction, the beam compresses to a low 
profile, intense illumination region in which nanoparticles present in the liquid film can be 
easily visualised via a long-working distance, x20 magnification microscope objective fitted 
to an otherwise conventional microscope. The metalized surface reduces the amount of light 
scattering, which decreases the background noise, hence it is at the beam point of contact 
here that videos are obtained. A charge coupled device (CCD) camera, operating at 30 frames 
per second, is used to capture a video with a field of view approximately 100 µm x 80 µm. 
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Particle concentration and size measurements were obtained using a Nanosight Nanoparticle 
Tracking Analysis NS500. Sizes between 50-2000 nm could be detected, following 50 - 100x 
dilution. 
 
2.8.5 Dynamic light scattering 
Dynamic light scattering (DLS) allows accurate measurement of the size of particles in a 
solution through the scattering of a monochromatic light source by a particle. Vesicle 
diameter was obtained using a Zetasizer Nanoscale Dynamic Light Scatterer, manufactured 
by Malvern instruments, Malvern UK. Measurements were taken of multiple samples each 
with multiple readings and through the average of these values. 5-10 µl of sample was 
dispersed into 1 ml of buffer solution prior to measurement. 
 
2.8.6 Osmolality 
Osmolality measures the number of milliosmoles/kg (mOsm/kg) of solvent present within an 
aqueous solution. The osmolality   of a sample is defined in Equation 2-1 as 
   = υ x Nmol Equation 2-1 
Where υ is a measure of ionisation of a solution (υ = 1 if the solution is undissociated), and 
Nmol is the number of moles of undissociated substance within a solution. 
Osmolality can be found from measuring the freezing point depression of a sample, and 
incorporating the values into a rearranged form of Equation 2-2; 
    
                     
          
 Equation 2-2 
The freezing point depression of a sample can be compared against pure water to give the 
osmotic concentration. Pure water freezes at 0 °C; an aqueous undissociated ideal solution 
with an osmolarity of 1 osmol / kg H2O freezes at -1.858 °C. 
Osmometer measurements on vesicles and hydrogel preparations were carried out using a 
Löser Micro-Osmometer Type 15 to give an indication of compatibility between vesicles and 
hydrogel matrices. Calibration was carried out using distilled water. 50 µl of sample was 
cooled using a Peltier-element; a semiconductor which uses the Peltier effect to create a heat 
flux within the sample. A thermistor measures the temperature of the sample; at a specific 
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super cooling temperature a needle containing ice crystals is added to initiate the freezing 
process, followed by a rise in temperature due to latent heat of crystallisation. The linear 
correlation between osmolality and the freezing point allows osmolality to be determined; 
units are mOsm /kg H2O.  
2.8.7 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) is a thermoanalytical technique that measures the 
temperatures and heat flows associated with a phase transition of a material as a function of 
time and temperature applied, versus a reference sample. The thermal transitions were 
measured using a TA Instruments DSC Q20. Temperature ranges were obtained 10-15 °C 
above or below predicted transition temperature. Aluminium hermetic Tzero pans with lids 
filled with a sample volume of 10 µl, able to withstand temperatures between -180 to 600 °C, 
were used. Reference pans containing the relevant buffer solution, omitting the lipid, were 
utilised as a control. Data obtained was analysed using TA Universal Analysis software. 
 




C NMR samples were analysed using a Bruker AV300 MHz spectrometer. Sample 
preparation involved dissolving approximately 5 mg of substance in an appropriate solvent, 
commonly deuterated chloroform (CDCl3), DMSO or methanol depending on solubility, and 
transferring to a clean sealable NMR tube.  
 
2.9 Statistical analysis 
The data was processed using Microsoft Excel and OriginPro8. Statistical analysis was 
performed using a Student t-Test by comparing the means of each independent group (sample 
type) assuming that the variances of each group are equal. A p value of less than 0.05 (65 % 
confidence limit) was considered to be of significant difference, Equation 2-3; 
     
      
     
 Equation 2-3 
Where SE is the statistical error, σ is the standard deviation, VT is the cumulative sum of the 
values, and Vc is the sum of the count of the values. The propagation of combined errors was 
achieved using Equation 2-4; 
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      Equation 2-4 
Where PE is the propagative error, FE is the final error value, F is the final value, IE is the 
initial value error, I is the initial value and N is the new value calculated. 
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Chapter 3 Vesicle development - stability 
The quantity of books, research papers, and patents published on the use of vesicles to deliver 
encapsulated aqueous active agents, either in vivo or ex vivo to a potential patient has 
increased steadily since the 1980s, although they were initially discovered in 1964. 
Vesicles, also commonly referred to as liposomes or nanocapsules, are attractive drug 
delivery vehicles due to their biocompatible and bioavailable properties. Vesicles have the 
ability to entrap aqueous solutions of different lipophilicities within their core, surrounding 
them by inert naturally derived or synthetic phospholipids; as such they have been 





3.1 Vesicle applications 
The ability of vesicles to act as protective carriers for expensive, reactive or readily degraded 
active ingredients has ensured their popularity for a variety of applications. Delivery of an 
active agent to a target site, either in vivo or ex vivo can be problematic. This can either be 
due to penetration difficulties, e.g. through the stratum corneum,
3
 or as a result of active 
agent hydrolysis prior to arrival at intended site, e.g. enzyme mediated degradation.
4
 As a 
result of this, the majority of research into the utilisation of vesicles for active agent delivery 
has focused on modifying the vesicles’ lipid composition, which affects the physical 
characteristics, and vesicle size, to increase penetration of vesicle to target site and decrease 
the passive leakage of agents prior to arrival. 
Despite the range of industries that have adopted the use of vesicles to deliver active agents, 
it comes as no surprise that the most widely investigated area of their practical application is 
within medical applications; for drug delivery. 
 
3.1.1 Medical applications 
Vesicles provide an ideal model, reagent and tool in many areas of scientific research, 
including maths and theoretical physics, biophysics, chemistry, colloid science, biochemistry 
and biology.
5
 Uses within these fields include investigations into cell membrane and channel 
49 
 
properties, catalysis, energy conversion, stability and thermodynamics of finite systems and 
excretion, cell function, trafficking and signalling.
1
 
The popularity and interest surrounding the utilisation of vesicles for drug delivery has 
increased significantly in the last ten years. The concept of vesicles as drug delivery vehicles 
was introduced in the 1970’s, following initial investigations and publications into vesicles in 
the 1960’s. Initial results proved disappointing, due to colloidal and biological instability 
effects, and an inability to efficiently encapsulate drug molecules. However, following further 
fundamental research into understanding interaction characteristics and inherent stability, 
improvements ensured that some commercial ventures were launched.
6
  
The stability of vesicles and their internal components can be sub-divided into physical, 
chemical and biological stability categories. These divisions relate to storage conditions, shelf 
life time and interaction of host agents following application or in-vivo administration. A 
major breakthrough towards obtaining a desired stability was achieved through the use of 
inert hydrophilic polymer coatings, to create sterically stabilised vesicles. These are also 
commonly referred to as stealth liposomes, due to their inherent ability to evade host immune 
defences, prior to ultimate low rate removal by macrophages.
1
 
Current applications involving vesicle administration that are in the product or pre-clinical 
stage include anticancer therapy, where the adverse toxicity effects of the drug can be 
shielded from the host prior to extravasation at the tumour site
7










); vaccines against hepatitis A, influenza, 
hepatitis B, diphtheria and tetanus, where the purified virus is incorporated into the bilayer 
envelope (Swiss Serum Institute);
12




Importantly, the efficiency of vesicles as drug delivery vehicles depends on their 
composition, size, loading efficiency, stability, and their biological interaction with cells. 
 
3.1.2 Intelligent vesicles 
Vesicles which are engineered to respond to specific environmental triggers such as pH, 
temperature and ultrasound, or within a predictive time frame, are commonly referred to as 
intelligent vesicles.
14
 Responses can include leakage rate amplification, fusogenic activity or 
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interaction with specific cells. These engineered changes generally relate to the various phase 
transitions and fluidic properties of the bilayer, discussed further in 3.1.6 Bilayer fluidity. 
Briefly, phospholipid bilayers can exist in a low-temperature solid-ordered phase or a fluid-
disordered phase; and the temperature at which this transition occurs is known as the phase 
transition temperature Tc. These phase effects can be tailored depending on the phospholipid 
selected. Passive leakage of active agents from a vesicle is at its greatest at temperatures 
around the Tc due to the coexistence of two phases and the resulting defects between the 
boundaries.
15
 As a result of this, delivery of the active agent can be controlled by applying a 
temperature increase at the target location. An example of this, published in 2010 by Smet et 
al, investigates the delivery of the cytostatic agent doxorubicin encapsulated within 
temperature sensitive liposomes to cancerous cells in chemotherapy treatment. The process 
was monitored using magnetic resonance imaging (MRI) contrast agent tracers.
16
 
The transition between phases can also be achieved by increasing the total or average area of 
phospholipid polar head on the outer monolayer of a bilayer, through protonation of lipids 
containing weak basic groups or hydrolysis, triggering a configuration transition from 
lamellar to micellar. Alternatively, decreasing the total or average area of phospholipid polar 
head in the monolayer can induce membrane fusion and the release of active agents.
1
 A 
popular method for achieving this is the incorporation of stabilising PEG, to form PEGylated 
liposomes, commonly known as stealth vesicles. This protective PEG-coating ensures a long-
circulating profile in-vivo, enhances permeability and aids host retention.
17
 The PEG-coating 
can be readily detached under localised pathological conditions, such as acidic pH in 
tumours, ensuring delivery of active agents from the unprotected liposomes.
18
  
Intelligent vesicles play an important role in controlled agent activity; tailoring of this 
inherent intelligence depends on the phospholipids and other constituents incorporated into 
the bilayer membrane. 
 
3.1.3 Membrane lipids 
A typical biological membrane is composed of hundreds of lipid species, varying in acyl 
chain length, degree of saturation and level of complexity.
19
 One of the major structural lipid 
classes in eukaryotic membranes is the Glycerophospholipids; composed of a hydrophobic 
diacylglycerol portion which becomes chiral when derivatized to glycerol-3-phosphate, and 
contains saturated or cis-unsaturated fatty acyl chains of varying length. The phospholipid 
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membrane backbone is the L isomer, dictating stereochemistry: sn-glycerol-3-phosphate. An 
ester linkage between carbon chains gives phosphatidic acid (PA). Esterification of PA with 
another alcohol creates Phosphatidylcholine (PC) which accounts for >50 % of the 
phospholipids found in membranes, phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylglycerol (PG) and phosphatidylinositol (PI). The combination of the phosphate 
group and the head group yields the polar portion; with the acyl chains forming the non-polar 
components of the amphiphilic molecules. Glycerophospholipids spontaneously self-organise 




Figure 3-1. The structure of phospholipids; the acyl chain is the non-polar component and can 
be saturated or cis unsaturated, and the phosphate and other head group components form the 
polar portion of the amphiphilic molecule.  
Two other types of lipids found in membranes are sphingolipids; which are based on a long 
chain amino acid to which a fatty acid acyl chain is attached by amide linkage; and sterol and 
linear isoprenoids; which are compounds derived from five-carbon isoprene units and 
cyclised polyisoprene precursors. The variation in head groups and aliphatic chains found in 
nature ensures that biomembranes are typically composed of over a thousand different lipid 
types.
21
 A common feature of phospholipids in vesicles is their cylindrical shape and the 






3.1.4 Phospholipid packing formation 
The dual (amphiphilic) nature of phospholipids, to be both polar and non-polar, is integral to 
membrane structures. Variations between different phospholipid compositions ensure 
different phases are formed. The preferred phase formed is dependent on the different 
individual steric and ionic interactions that result from variations in sizes and polarity of 
phospholipid head group and acyl chain. The packing of phospholipids can be defined using 
the equivalent packing factor (f), Equation 3-1, assuming an environment where water is the 
aqueous phase, the solution is at a neutral pH and room temperature.
22
  
     
 
  
 Equation 3-1 
Where v is the volume of the acyl chain, l the maximum achievable length of the acyl chain 
(hydrophobic portion), and a is the cross sectional area of the polar head group. The area a 
can be determined using the van der Waals volume and hydration shell of the polar 
headgroup.
23
 The equivalent packing factor can be used to determine the organisation of 
individual lipids within different structures, shown in Figure 3-2.  
 
Figure 3-2. The effect of phospholipid structure on packing formation. The three lipids 
depicted have the same acyl chain length (l) but vary in head group area (a) and acyl chain 
volume (v). Lipids with a small head group area and large acyl volume favor formation of 
inverted micelles (i), lipids with similar head group area and acyl chain volume (relative to 
each other), resulting in cylindrical-like structures, favor formation of lamellar bilayers (ii), 
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Of course, the packing factor (f) defined in Equation 3-1 is only applicable to packing 
formations of single-phospholipid structures. For mixtures of lipids this equation requires 
expansion; the average packing factor (P) can be determined using Equation 3-2. 
     
          
             
  
        
           
 Equation 3-2 
Where vx and vy is the volume of the two lipids, ax and ay their corresponding polar head 
group area, h is the average thickness of the mixed layer and Re is the molar ratio (Ny/Nx). A 
packing factor of one indicates that the cross sectional area of the polar head group and 
spatial volume of the acyl chain are equal, indicating that the lipids are essentially cylindrical; 
a planar bilayer would form.  
The transformation of planar bilayer structures into closed bilayer structures, such as vesicles, 
depends upon an energy barrier trade-off. The interaction of an aqueous solution with an 
‘open’ planar bilayer will be energetically unfavourable, especially compared to the same 
aqueous interaction with a ‘capped’ bilayer. However, the spacing between individual 
molecules within an open bilayer will be energetically favourable compared to the energy 
involved in forming and maintaining a capped bilayer, where the intermolecular spacing 
between bilayer components is decreased. This is depicted in Figure 3-3. 
 
Figure 3-3. The interaction of an aqueous phase with a planar and capped bilayer. 
Within most systems, a tendency exists towards the lowest energy state. In this case, 
formation of capped systems, such as vesicles, provides the lowest energy system.
25
 
Synthetically, the formation of vesicles can be achieved using a variety of methods, although 
a common feature is the hydration of lipids with an aqueous solution. The bilayer edges seal 
to prevent acyl chain contact with the aqueous medium. Although this process is energetically 
favourable (it is often erroneously reported to be spontaneous), within a synthetic 
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3.1.5 Phase formation 
The commonly recognised lamellar phase bilayer is only one possible spontaneous lipid 
aggregate that can form when amphiphilic lipids are mixed with an aqueous solution. The 
formation and characteristics of phospholipid behaviour in membranes depend on the lipid-
lipid interactions and lipid-protein interactions. Three different polymorphic phase states can 
be observed depending on the lipids present in a localised membrane; cubic, hexagonal and 
lamellar, Figure 3-4.  




Figure 3-4. The three most common polymorphic phase states observed in membrane 
phospholipids; cubic, hexagonal and lamellar. It should be noted that the phospholipids in the 
hexagonal phase could be inverted.
26
  
These three membrane phase states are all relevant to biomembranes. The non-bilayer lipid 
hexagonal or cubic phases often relate to transient biomembrane shifts such as fusion, fission 
and pore formation.
20
 Within this project an emphasis has been placed upon capped lamellar 




3.1.6 Bilayer fluidity 
As previously discussed, the molecular structures of each phospholipid within a bilayer (in 
addition to other bilayer components) affect the properties of a bilayer. The bilayer fluidity is 
dependent on both these internal interactions and the temperature of the system. The level of 
bilayer fluidity affects the ease with which rupture of the vesicle membrane can be achieved. 
Within a lipid-pure bilayer there are primarily two common phases, which relate to the phase 
transition temperature (Tc) introduced briefly in 3.1.2 Intelligent vesicles. These phases are 




The liquid crystalline phase, at lower temperatures, is characterised by higher viscosities, 
fatty acid lipid tails are fully extended, packing of the overall system is relatively ordered, 
and van der Waals interactions between adjacent chains are maximal. Comparatively, at 
increased temperatures, the liquid gel phase is characterised by a lower viscosity and higher 
diffusion coefficient, resulting from partial melting of the acyl chains, yielding an 
increasingly disordered system in constant motion.
28
 As a result of this disorder, the fluid 
phase has a ‘self-healing’ ability – allowing rearrangement of the bilayer when necessary.  
The transition between the liquid crystalline phase and liquid gel phases is the Tc, and the 
temperature at which it is achieved varies depending on phospholipid composition – with an 
emphasis on acyl chain length and hence system disorder. The Tc of phospholipids can be 
measured using differential scanning calorimetry (DSC). The peaks correspond to the 
enthalpic ‘melting’ event indicating the transition from crystalline to gel phase, which occurs 
at higher temperatures as the acyl chain length increases.
29
 The difference in Tc for different 
isomers reflects the small variations in the packing of the membrane. This packing variation 
could potentially lead to different interactions between other components in the membrane, 
affecting the stability of the membrane to external stimulus.
19
 
In addition to acyl chain length, the presence of double or triple bonds in the lipid can lower 
the Tc of a membrane. The liquid gel phase to liquid crystalline transition temperature of four 
different relevant phosphatidylcholine (PC) molecules with acyl chains of 14 carbons 
(dimyristoyl PC), 16 carbons (dipalmitoyl DP), 17 carbons (diheptadecanoyl DH) and 18 




3.1.7 Lipid diffusion in the bilayer 
Lipids can diffuse within a bilayer by three different mechanisms; lateral diffusion, rotation 
and bilayer translocation, shown in Figure 3-5.  
 
Figure 3-5. The diffusion of lipids within a bilayer where A) depicts lateral diffusion between 
neighbouring lipids, B) indicates lipid rotation within the same position and C) depicts 
translocation of a lipid through a bilayer.  
Lateral diffusion occurs when neighbouring molecules can exchange places via Brownian 
motion, enabling lipids to travel within a monolayer. The diffusional rates for freely diffusing 







/s, fast enough for a single lipid molecule to diffuse around the erythrocyte plasma 
membrane in seconds. However, this lateral diffusion rate of phospholipids varies depending 
upon the various cell types and can be retarded (by factors up to 100). Bilayer translocation - 
more commonly known as “flip-flop” - involves the exchange of lipid molecules between 
leaflets through the movement of the polar head groups passing the non-polar centre of the 
bilayer. This process is energetically unfavourable, often occurring as an induced response 
through transient pores generated from ion concentration discrepancies across a membrane.
30
 
Rotation involves the spinning of a lipid around its axis, without any altering of its position.  
 
3.1.8 Unilamellar vesicles 
The formation of capped bilayers into vesicles is a requirement of this project. Vesicles can 
be divided into three classes based on their size; small, large and giant. Small unilamellar 
vesicles (SUVs) form from extensive sonication to give diameters between 20 – 50 nm. The 
extreme curvature of the bilayer can make encapsulation of large agents problematic, and 
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fusion between SUVs can occur as a result of an increased free energy per unit area relative 
to LUVs and GUVs.
31
 Large unilamellar vesicles (LUVs) can be made by the fusion of 
SUVs, or extrusion through polycarbonate membranes, to give diameters between 50 – 1000 
nm. In comparison to SUVs, LUVs can encapsulate a larger volume within their internal 
cavity, although their disadvantages include a fragility of structure and heterogeneous size 
distributions. Giant unilamellar vesicles (GUVs) have diameters between 5 – 300 μm akin to 
the sizes of eukaryotic cells. GUVs make ideal membrane mimics, however their large 
internal volumes can make them unstable due to variations in osmotic potential.
19
 The 
thickness of the membrane is independent of this size distinction, with a diameter of 
approximately 4 nm for SUVs, LUVs and GUVs. 
The size range of homogenous unilamellar vesicles commonly utilised in drug delivery 
applications is between 50-150 nm. This is a compromise between loading efficiency of 
vesicles (increases with increasing size as a result of a greater internal cavity volume) and 
liposome stability (decreases with increasing size, no longer optimal i.e. lysis, fusion or 




3.1.9 Biological membranes and vesicles 
Biological membranes are fundamental for cell compartmentalisation, they are multi-
functional, with the potential to provide cell energy in the form of ATP from charge (proton) 
and chemical gradients, regulate and organise enzyme activity, aid information transfer, and 
provide components for signalling and biosynthesis.  
Conventional unilamellar vesicles are considered useful in the modelling of eukaryotic cell 
membranes. Their structures are similar to prokaryotic cells, where shared characteristics, 
aside from composition, include a single compartment delimited by a single bilayer. This 
bilayer forms a space-defining, protective barrier that is fundamental for cell and organism 
survival.  
Prokaryotic and eukaryotic biomembranes consist of lipids, proteins and carbohydrates. Basic 
vesicle biomembranes form a bilayer based on amphiphilic phospholipids and sphingolipids 
arranged in two layers along an interface, with the polar head groups extending out and the 
non-polar acyl chains filling in the expanse in between. Within eukaryotic and prokaryotic 
cells, different unique compositions of varying phase-forming lipids and proteins can give 
multiple functionalities that allow the formation of embedded channels for the transport and 
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regulation of components into and out of a cell, ensuring the maintenance of charge and 
concentration gradients.
32
 Other bilayer functions can include the provision of cell energy 
from charge and chemical gradients, regulation and organised enzyme activity, information 
transfer, and provision of components for signalling and biosynthesis. Within research, 





3.1.10 Vesicle development – stability and sensitivity  
The potential opportunities involving the use of intelligent vesicles in both the cosmetic and 
medical fields indicate a wide scope of promising applications. Continually increasing 
knowledge about the stabilising profile of different lipid and chemical components, protective 
activity of possible coatings and phase transition temperatures of mixtures can be utilised to 
aid the discovery of vesicle compositions with a suitable profile for use within a paediatric 
burn wound dressing. The desired profile is depicted in Figure 3-6. 
 
Figure 3-6. The ideal vesicle profile for an application within a pathogenic-bacteria-signaling 
paediatric burn wound dressing, with an emphasis on stability during storage and application, 




3.2 Vesicles – encapsulation of a signalling agent  
Figure 3-6 indicates the stability and sensitivity profile required for the use of vesicles within 
a pathogenic bacteria signalling paediatric wound dressing. An important aspect of this is the 
detection / signalling agent that can be successfully encapsulated into the vesicles. An ideal 
candidate for this is a dye with a fluorescence profile. 
 
3.2.1 Fluorescence 
Photoluminescence is defined as the spontaneous emission of radiation from an electronically 
excited species or from a vibrationally excited species not in thermal equilibrium with its 
environment
34
 and can be classified as either fluorescence or phosphorescence. The 




Figure 3-7. Jabłoński diagram, representing the electronic states in a molecule, and the 
transitions between them; which form the basis of luminescence. This was developed by 
Aleksander Jabłoński in 1935. Acknowledgement to W. D. Jamieson, PhD thesis 2013.  
Electronic states can be classified as singlet and triplet, in the case of Figure 3-7, S0 and S1, 
and T1 respectively. A singlet state is one in which all of the electrons in the molecule have 
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their spins paired. Triplet states are those in which electron spin sets have become unpaired. 
A triplet state will always lie lower in energy than its corresponding singlet state. All 
molecules are assumed to be in the lowest vibrational level of the ground state at room 
temperature.  
Once the molecule is excited to the higher energy state     
   
, by absorption of electromagnetic 
radiation, several processes can occur to cause the molecule to lose its excess energy, a 
process known as decay. The two most important are fluorescence emission and vibrational 
relaxation. Fluorescence involves transitions from the low lying energy state      
   
 to 
vibrational levels of the ground state S0. Vibrational relaxation involves the decay of the 
electron to the ground state of an energy level from a higher vibrational level within the same 
singlet or triplet state, through a process known as internal conversion. Internal conversions 







 Decay through phosphorescence results from intersystem crossing 
(T1 → S0).  
The Franck-Condon principle, proposed by J. Franck in the early 1920’s, can be used to 
determine which vibrational energy levels in the S1 electronic state transitions are made into, 
following a consideration of nuclear motions. Nuclear motions are relatively very slow; 
hence electronic transitions are favoured between vibrational levels that are in the same phase 
shift as each other, ensuring that minimal disruption will be caused. As a result of this, 
transitions between vibrational levels, for example from S0 to S1, will be favoured between 
vibrational energies in the same phase. Consequently, the excitation transition from    
      
  
may not be the most energetically favourable. In 1950 M. Kasha proposed Kasha’s rule to 
state the favourability of low energetic burden transitions over higher electronic energy level 
transitions (i.e. excited state molecules quickly relax to the lowest level of that excited energy 
level -internal conversion is preferred). As a result of this, fluorescence and phosphorescence 




The Frank-Condon principle and Kasha’s rule dictate that a) phase matching between 
absorbed and emitted wavelengths causes a mirror effect (observable in spectra with multiple 
peaks), b) photons produced through electronic relaxation have a lower energy and 
wavelength than absorbed photons, and c) emitted photons will have the same wavelength 
regardless of the energy of the photon absorbed. 
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The molecular fluorescence of a sample is measured through excitation at the absorption 
wavelength, known as the excitation wavelength, and measuring the emission at a longer 
fluorescence wavelength. The difference in energy between the excitation and emission is 
known as the ‘stokes shift’ after Sir G. G. Stokes who described the phenomenon in 1852, 
shown in Figure 3-8. This arises from the photon energy in the emitted being less than the 
incident, accounted for by the vibrational relaxation and internal conversion pathways which 
require energy but do not yield emission spectra. 
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Stokes shift = 22nm
 
Figure 3-8. The absorption / emission spectra for the fluorophore 5(6)-carboxyfluorescein. 
The maximum excitation (λext) and maximum emission (λem) peaks occur at 493 nm and 515 
nm. These occur as a result of   
  ↔   
 
 transition energies, and the difference between these, 
as indicated, is the Stokes shift (22 nm).  
The absorption spectra for most common fluorophores are generally the mirror image of the 
emission spectra. This is a result of the phase matching within the vibrational energy levels 
within the ground and excited state (   
     
 ).  
There are two physiochemical characteristics of a fluorophore; the quantum yield (Q), which 
is the ratio of emitted photons to the absorbed photon, and the fluorescence lifetime (Ʈ).  
The quantum yield can be depicted in Equation 3-3, using the rate of fluorescence (kF) and 




     
  
       
 Equation 3-3 
As a result of the Stokes shift, and collision and conversion related energy loss, the quantum 
yield is never equal to one. The lifetime of fluorescence (Ʈ) is defined as the average time a 
molecule spends in the excited state before returning to the ground state, and a typical time 
span for this is 10 ns. The lifetime of fluorescence can be found using in Equation 3-4; 
    
 
       
 Equation 3-4 
 
The fluorescence intensity and emission spectrum may be affected by the fluorophores 
dipole, and hence by charge transfer, ionisation, and hydrogen bonding. The local 
environment, such as solvent type, presence of heavy metals and pH value can also have an 
effect, and these can be manipulated in chemical and biological systems.  
 
3.2.2 Quenching of fluorescence 
There are some distinct mechanistic techniques towards fluorescence quenching that result in 
a dissipation of energy without fluorescence occurring, including: 
 Förster resonance energy transfer (FRET) quenching – a dynamic method over long 
distances 40-100Å, involving energy transfer from the excited state donor to the 
acceptor. It is based on dipole-dipole interactions and is reliant on the donor-acceptor 
distance (R) at a rate of 1/R
6
. The dye-quencher complex has the same absorption and 
fluorescence spectra as the individual molecules. 
 Heavy metal quenching – halogenated compounds can act as collisional quenchers, 
through intersystem crossing to an excited triplet state, or electron donation from the 
fluorophore to the quencher. 
 Dexter / collisional quenching – diffusive collision encounters between the 
fluorophore and quencher during the lifetime of the excited state without fluorescence 
emission. 
 Static quenching – a ground state complex forming mechanism from hydrophobic and 
electrostatic interactions within short distances (<15 Å). It occurs through Dexter 
mechanism, and is dependent on e
-R
 and temperature. The dye-quencher complex has 





An important mechanism of quenching worth noting in more detail is collision quenching, 
during which an excited state molecule collides with another molecule, deactivating the 
fluorophore. This is a dynamic process in which the quencher and fluorophore are not altered, 




                       Equation 3-5 
Where Fo is the unquenched fluorophore, F is the fluorophore, Ksv is the Stern-Volmer 
quenching constant, KQ is the bimolecular quenching rate coefficient, τo is the unquenched 
lifetime, and [Q] is the concentration of the quencher. A large value of Ksv indicates an easily 
quenched species. 
Static quenching can also be achieved if the quencher forms a non-fluorescent complex with 
the fluorophore, where Ks is the constant derived from the association of the quencher-
fluorophore complex, given in Equation 3-5. 
The rate equations relating to fluorescence quenching are given below, where A represents 
the fluorophore, A
*
 represents the fluorophore in its excited state and kQ is the quenching rate 
constant. 
A + hυ → A* Rate = ka [A] Equation 3-6 
A
* → A + hυ Rate = kf [A
*
] Equation 3-7 
A
*
 + Q → A + Q* Rate = kQ [A
*
] [Q] Equation 3-8 
Under steady state:       
      
           
 Equation 3-9 
The intensity of fluorescence in the absence of the quencher is given by Equation 3-10;  
 If (0) = ka [A] Equation 3-10 
The intensity of fluorescence in the presence of the quencher is given by Equation 3-11;  
 If (Q) = kf [A
*
] Equation 3-11 
Therefore, the following fluorescence ratio is given by Equation 3-12; 
 
      
      
    
  
  
     Equation 3-12 
Plotting of If (0) / If (Q) versus [Q] gives a linear relationship, where the gradient is equal to 
Stern-Volmer constant Ksv, hence; 
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 Equation 3-13 
The quenching and fluorescence phenomenon will be utilised within this project as a 
signalling system to indicate degree of vesicle stability and sensitivity, and will be measured 
through vesicle lysis and resulting fluorescence intensity. 
 
3.2.3 5(6)-carboxyfluorescein 
An appropriate detection dye, with an extensive history as a marker for measuring the 
mechanical stability of vesicle membranes,
38
 was utilised for encapsulation within the vesicle 
formulations; 5(6)-carboxyfluorescein (5(6)-CF). This dye was first investigated by 
Weinstein et al. in 1977
39
 to track liposome endocytosis. 5(6)-CF is an organic fluorophore 
that is quenched and non-fluorescent at high concentrations (< 10 mM), but un-quenched and 
fluorescent at low concentrations (> 10 mM), shown in Figure 3-9.  
A 





































Figure 3-9. A graph to show fluorescence versus 5(6)-CF concentration (A), and two 
photographs showing dye concentration versus fluorescence, where (B) is taken using UV 
light and (C) is taken using white light. Acknowledgement to W. D. Jamieson, PhD thesis 
2013.  
Non-fluorescent quenching of 5(6)-CF has been primarily proven to be a result of 
dimerisation of the dye and energy transfer to non-fluorescent dimers, although collisional 
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quenching between dye monomers could play a role. These quenching processes do not give 
100 % quenching, and this is due to the interaction of the dye with the lipids in the vesicle.
40
 
5(6)-CF has two wavelengths of maximum absorbance, 465 and 490 nm, and an emission 
wavelength of 515 nm. Its structural polarity helps prevent passive leakage from vesicles, and 
it is known to have a pH dependence, with fluorescence increasing as the pH increases.
41
 The 
implications of this with regard to its proposed use as a pathogenic bacterial indicator in a 
wound dressing will be further investigated, and discussed in 3.5.1.1 Effects of pH and 
temperature on 5(6)-carboxyfluorescein.  
Importantly, 5(6)-CF can be incorporated into vesicles alongside other water-soluble active 
agents, for example drugs, and utilised to measure passive diffusion / delivery of agent over 
time or following an environmental stimulus change. The lack of toxicity of the dye has been 
investigated and confirmed by Lutty.
42
 As a result of this it has been used to fluorescently 
label proteins, nucleotides, nucleic acids and peptides, following interactions of the 





3.3 Vesicle formulation process 
Vesicles were composed primarily of different concentration compositions of PC and PE 
lipids, and cholesterol, and synthesised as directed in 2.2 Vesicle formulation process, with 
the encapsulation of the fluorescently active dye 5(6)-CF. 
 
3.3.1 Vesicle and dye concentration calculations  
The following calculations can be used to calculate the theoretical quantity of lipids per 100 
nm vesicle, total number of vesicles per synthesis, and the total volume of aqueous solution 
encapsulated. The quantity of lipids can be calculated based on an average 4 nm bilayer 
diameter; 








                           Equation 3-14 








                          Equation 3-15 
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Number of lipids in 
outer bilayer 
 
            
             
          Equation 3-16 
Number of lipids in 
inner bilayer 
  
            
             
          Equation 3-17 
Total number of lipids 
per vesicle 
                              
          
Equation 3-18 
Using the value calculated for the theoretical total number of lipids per vesicle (3.6 x 10
5
); 
the theoretical total number of vesicles per formulation process can be calculated. This 
calculation is based on 100 mM vesicles, composed of 78 mol % of the common 
phosphatidylcholine DPPC (with the remaining composition comprising of cholesterol and 
phosphatidylethanolamine DPPE). General vesicle compositions and the general structures of 
PC and PE (Figure 3-10) are discussed in the following sections. The amount of DPPC 
starting material will be 5.72   10-3 g and the vesicles formulated within a sample can be 
found; 
Moles of lipid (DPPC)  
    
  
 
           
            
               Equation 3-19 
Number of lipid 
molecules 
                                 
                    
Equation 3-20 




          
        
                     Equation 3-21 
The total theoretical encapsulated volume of aqueous agent inside the vesicles can then be 
calculated using; 
Internal volume of 
vesicle 
   
 
 
      
 
 
            
             
                
Equation 3-22 
Encapsulation volume 
per 5 ml synthesis
 
                            
               
Equation 3-23 
Encapsulation volume          






The 5(6)-CF dye will be encapsulated at a self-quenched concentration of 50 mM; 
Moles of 5(6)-CF  
    
  
 
           
             




     
      
 
          
             
                    
Equation 3-26 
From this, and Equation 3-23 the theoretical amount of 5(6)-CF released following total lysis 
of vesicles within a sample of 5 ml can be calculated; 
Moles of 5(6)-CF in 
vesicles 
                                    
               
Equation 3-27 




                              
                       
            
Equation 3-28 
From these calculations the theoretical number of vesicles synthesised in a 5 ml, 100 mM 




and the encapsulated and released amount of 
carboxyfluorescein following total lysis is 0.02 mg ml
-1
. These values will change depending 
on the lipids used to compose the bilayer, and the surface area of their individual polar head 
groups. 
 
3.3.2 General vesicle composition 
The vesicles developed in this project were composed primarily of saturated (n:0) or 
unsaturated (0 = 1,2,3...) phospholipids with differing carbon lipid chain lengths; dimyristoyl 
(DM, 14:0), dipalmitoyl (DP, 16:0), diheptadecanoyl (DH, 17:0), dioleoyl (DO, 18:1) and 
distearoyl (DS, 18:0). These are primarily phosphatidylcholines (PC), and the corresponding 
phosphatidylethanolamines (PE), Figure 3-10, both of which are common major structural 






Figure 3-10. The structure of phosphatidylethanolamine (DPPE) and phosphatidylcholine 
(DPPC), both of which are common major structural constituents of eukaryotic membranes  
 
3.3.3 Less common lipids 
To increase the stability of the vesicles synthesised, other components were incorporated into 
these formulations such as different lipids, of which some of the less typical ones are given in 
Table 3-1. The properties of these vesicles, which make them suitable for incorporation into 
vesicle membranes, are discussed in the following sections. 
Lipid 
component 








n = 6 = palmitoyl (16:0, 












14:0 PEG(n) PE 
 























3.4.10 Phase separating lipids 
Table 3-1. Less typically recognised lipids incorporated for their stabilisation potential, in 
varying mol % ratios. 
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Commonly recognised lipids, less common lipids, and other chemicals, have all been 
combined together to synthesise vesicles of varying compositions, en-route to an ideal vesicle 
composition, which is both stable, and sensitive to specific environmental stimulus, in the 
form of pathogenic bacterial toxins. 
 
3.3.4 Vesicle nomenclature 
Nomenclature of the vesicles synthesised and used within this project follows the naming 
pattern previously developed in the group,
45
 and is based on an easily identifiable acronym 
for the primary stabilising agent, followed by its primary lipid component. Examples of this 
are given in Table 3-2. 
Vesicle Name Main lipid constituent Secondary component Stabilising agent 
DMPC/DMPE DMPC (14:0) 78 % Cholesterol 20 % 
DMPE 2 % 
None 
DSPG-DP DPPC (16:0) 53 % Cholesterol 20 % 
DSPC 15 % DPPE 2 % 
DSPG 10 % 
TCDA-DS DSPC (18:0) 63 % Cholesterol 20 % 
DSPE 2 % 
TCDA 15 % 
Table 3-2. The relation of vesicle nomenclature to primary lipid / stabilising agent 
composition. 
A comprehensive library of over 70 different vesicle compositions can be found in the 
supporting information (SI-Table 1), along with an indication of their stability over 14 days at 
37 °C, in relation to the stability response parameter, given in Equation 3-29. 
 
3.3.5 Vesicle membrane solubilisation – a positive lytic control 
Detergents are defined as water-soluble surfactants that are effective at solubilising 
membrane components. The mechanism of action involves micelle formation, directly 
resulting from the amphiphilicity of the surfactant. Self-association of detergents into 
micelles occurs at a defined critical micelle concentration (CMC). At concentrations below 
the CMC, the amphipath is found in its’ monomer form; above the CMC, the monomer 
concentration is unchanged whilst the concentration of micelles increases. The critical 
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micelle temperature (CMT) also plays a role in micelle formation, and is defined as the 
temperature above which micelles form.  
The solubilisation of a bilayer into its constituent membrane lipids and other components can 
be achieved through addition of these water soluble detergents. At different detergent 
concentrations, the detergent molecules can intercalate into the membrane, and form 
detergent-lipid complexes, shown in Figure 3-11. Addition of the detergent above its CMC 
value ensures the formation of mixed micelles of varying structure and size. 
  
Figure 3-11. The stages of membrane solubilization following the addition of increasing 
concentrations of detergent to a membrane. At low concentrations, the detergent can 






, henceforth referred to as triton, but less commonly known as polyethylene 
glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether, is a widely-used non-ionic surfactant for the 
solubilisation of membranes and the recovery of membrane components under mild non-
denaturing conditions.
46
 The addition of triton results in vesicle solubilisation and the 
formation of mixed micelles within the bilayer, subsequently followed by the formation of 
surfactant stabilised holes on the vesicle surface, leading to complete solubilisation.
47
 
Triton was utilised at a concentration of 0.01 % v/v
38
 to breakdown vesicles in a positive 
control experiment. 0.01 % v/v triton was deemed to be effective on three trial vesicle 
formulations utilised in this study, as was 1 and 0.1 % v/v. This was determined following a 
small study into vesicle lysis, measured by fluorescent dye release, upon addition of different 









































Figure 3-12. The structure and lytic effect of triton, where A) gives the chemical structure of 
triton X-100
TM
 and B) the lytic effect on three different vesicle formulations, each 
encapsulating 5(6)-CF, of different concentrations of triton (v/v) measured utilising 
fluorescent intensity measurements.  
From Figure 3-12, an acceptable lysis of vesicles can be achieved with 1, 0.1 and 0.01 % v/v 
triton. As a result of this any of these concentrations are acceptable as a positive lytic control, 
within these experiments 0.01 % v/v triton was utilised. 
  
3.4 Vesicle development – measuring stability 
Within this initial investigation, the vesicle stability required will focus on point-of-use 
parameters. Specified guidelines, obtained from collaboration with the paediatric burn centre 
at Frenchay Hospital, UK, suggested a requirement for a product that can be placed upon a 
wound for more than 10 days, at an elevated skin surface temperature of 34 - 35 °C.
48
 This 
can be compared to undamaged skin temperature, which can be between 16 - 32 °C 
depending on localised conditions.
49
 In addition to this, the majority of pharmaceutical 
products, including wound dressings, are created to be stable at room temperature, which can 
be between 2-30 °C, and for extended periods of time (often in excess of 6 months). Stability 
considerations are often dependent on distribution and long term storage conditions, as well 
as point-of-use requirements. 
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Based on and expanding from this, the vesicles synthesised will be investigated for stability 
at pH 7, at a temperature of 37 °C and for a period of 14 days. The stability between vesicle 
compositions can be compared using the stability response parameter.  
 
3.4.1 Stability response parameter 
The long-term stability response parameter equation was created as a way of allowing easily 
understandable comparisons between the stability of different vesicle compositions. This was 
calculated using Equation 3-29:  
                                 
  
  
 Equation 3-29 
Where Fi is the initial vesicle fluorescence intensity value and Ff is the final vesicle 
fluorescence intensity value after addition of a lytic agent following a time study. For 
stability assays, Fi is the fluorescence value obtained following incubation for 14 days at 37 
°C. The addition of the surfactant triton was considered to deliver the maximum fluorescence 
obtainable following total vesicle disruption for most vesicle systems,
38
 however 
Staphylococcus aureus RN4282 supernatant (discussed in 4.2.1.2 The relevance of MSSA 
RN4282) was also utilised. A higher S value was deemed desirable for long-term stability - 
indicating a large fluorescence intensity increase on addition of the lytic agent. In initial 
stability studies an S value higher than two was required from a vesicle composition; if this 
was achieved further environmental stimulus testing could be carried out.  
 
3.4.2 Stabilising agents 
The incorporation of different lipids and other chemicals into a vesicle bilayer membrane is a 
common method towards achieving stabilised vesicles. The different agents incorporated into 
the vesicles, in varying mol %, and their overall stabilising outcome will be discussed and 
summarised in the following sections. Stability response parameter indications upon 
changing each of these variables can be found in the supporting information, SI-Table 1. 
 
3.4.3 Lipid chain length 
Four saturated PC lipids, varying only with regard to the number of carbons in their lipid 
chain lengths, were investigated. These PC lipids included DM (14), DP (16), DH (17), and 
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DS (18); the number parameter in brackets indicates the number of carbon atoms in the lipid 
chain. In each case the corresponding PE lipid was incorporated at a concentration of 2 mol 
%. This was due to their known prevalence in biological membranes
50
 and potential to act as 
a target / binding site for external lipid bilayer-targeting agents.
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The lipid chain length relates to the gel-to-liquid crystal transition temperature, Tc, discussed 
in 3.1.6 Bilayer fluidity. Values for the Tc of each of these lipids were obtained using a TA 
Instruments DSC Q20. This thermo-analytical technique measured the temperatures and heat 
flows associated with a phase transition within the lipid as a function of time and temperature 
applied, versus a reference sample, with results given in Table 3-3. 
PC Lipid Transition temperature 
DMPC 23.3 °C 
DPPC 38.2 °C 
DHPC 48.8 °C 
DSPC 54.6 °C 
Table 3-3. Gel-to-liquid crystal transition temperatures of the PC lipids. Data acquired with S. 
Hong and W. D. Jamieson.  
As previously discussed, passive leakage of active agents from a vesicle is at its greatest at 
temperatures around and above the Tc, due to the coexistence of two phases and the resulting 
defects between the boundaries.
15
 This means that vesicles composed primarily of DMPC 
will be affected by passive leakage and hence will be inherently unstable. The Tc of DPPC is 
very close to the temperatures investigated (37 °C), and so an increased level of passive 
leakage may be measured, although incorporation of other agents may be effective in 
increasing DPPC stability. DHPC and DSPC have relatively high Tc values, which should 
ensure good stability. However, this stability may have a negative effect on their 
susceptibility to other external environmental stimulus. 
 
3.4.4 Polydiacetylene polymers 
The use of polydiacetylene (PDA) polymers for the investigation of peptide-membrane 
interactions is well known. A colour transition (blue-to-red) can be used to indicate peptide 
conformation and lipid association.
52
 The structure of the relevant diacetylene monomer, 
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10,12-tricosadiynoic acid (TCDA), its polymer structure, and its colour profile at different 
concentrations following UV treatment is given in Figure 3-13. 
  
Figure 3-13. The monomer and polymer structure of 10,12-tricosadiynoic acid (TCDA) and 
colour profile at different concentrations following UV treatment. Photo Acknowledgement 
to J. Zhou, PhD thesis 2010.  
The colour transition of TCDA from blue to red can occur following the association with 
lipids, and / or on an application of external stimulus, including heat, organic solvents, 
mechanical stress, molecular recognition and UV light.
53
 However, the colour change can be 
quite diffuse, and the presence of the 5(6)-CF dye within the vesicles can mask any 
observable colour change. TCDA, when in a highly ordered state (i.e. closely packed) can 
undergo polymerisation, following initiation with 254 nm UV irradiation. The polymerisation 
of TCDA occurs through a radical initiated chain reaction within the membrane of vesicle, 
forming cross-links with itself, and potentially other unsaturated bilayer components.  
The pseudo-amphiphilic chemical structure of TCDA allows for easy incorporation into a 
phospholipid bilayer; the polar carboxylic acid can align with the hydrophilic head group of a 
phospholipid, and the acyl chain can align with the hydrophobic acyl chain of a phospholipid. 
Incorporation of TCDA into vesicle membranes was first reported by Kolusheva et al. in 
2000,
52
 and initial research into this concept within the Jenkins group was reported by Zhou 




3.4.5 Cholesterol concentrations 
Cholesterol is an essential component in biological membranes, where it is required for 
viability and cell proliferation. The structure of cholesterol includes a tetracyclic fused ring 







Figure 3-14 The structure of cholesterol. 
The presence of a hydroxyl group is very important; it gives this otherwise hydrophobic 
compound its amphiphilic character, allowing the formation of hydrogen bonds with water 
and other components of cell membranes and allows the molecule to orientate in 
membranes.
56
 Within a bilayer, the polar hydroxyl group is orientated towards the aqueous 
phase, with the hydrophobic steroid ring structure aligned and embedded within the chains of 
the phospholipid hydrocarbons.  
Cholesterol has been found to interact with phospholipids and influence their behaviour. 
Increasing cholesterol concentration broadens and can eliminate the gel-to-liquid crystal 
transition temperature, Tc, of the related lipids.
57
 It induces an intermediate state to the lipids 
it interacts with, playing an important role in inducing fluidity, both above and below 
corresponding lipids Tc.
58
 Cholesterol reduces the rate of motion of the phospholipid 
hydrocarbon chain and increases the order in the membrane, leading to a laterally more 
condensed membrane with a higher density of packing.
59
 As a result of this, cholesterol can 
increase the mechanical strength and decrease the permeability of the membrane.
60
 In 
addition to this, cholesterol may play a role in the susceptibility of cell membranes to 
interaction with bacterial toxins.
61
  
The maximum solubility of cholesterol within bilayers is reported to be below 50-66 mol 
%,
62
 depending on the lipid; above this value lamellar structures are unable to form. Different 
mol % of cholesterol, between 20 – 40 %, was investigated within a variety of vesicle 
compositions, all of which showed good thermal stability for over 24 hours at 37 °C. 
However, an optimum concentration of cholesterol was found to be 20 %; these were found 
to have the potential to form vesicles with the desired stability, and so the majority of vesicles 




3.4.6 Hybrid vesicles 
Hybrid vesicles is a term used within this investigation to describe vesicles with varying mol 
% compositions of lipids with different structures and acyl chain lengths, in an attempt to 
attain the stability parameters desired. Clustering, segregation and domain formation of lipids 
with different polar head groups and hydrophobic chain lengths have the potential to alter the 
phase transition temperature Tc of lipids within a bilayer.
63
 This change could result in an 
increased or decreased Tc of the clustered lipids. Increasing the Tc of certain lipids, for 
example DPPC which has a Tc of 38.24 °C, could decrease passive diffusion of active agent 
delivery at 37 °C, making it a better candidate for use within stable vesicle bilayers. Equally, 
decreasing the Tc of certain lipids, for example DSPC which has a Tc of 54.55 °C, could 
ensure that the lipid-vesicle system is susceptible to certain environmental stimuli, as 
discussed in further detail in 3.1.2 Intelligent vesicles. This project investigated mixing DP, 
DH and DS PC lipids together in different mol % ratios to attain the desired stability 
parameters. Some examples are given in Table 3-4. 
Vesicle Name Primary PC Secondary PC Other components Stability 
DSPC-DP1 DPPC 73 % DSPC 5 % 
DPPE 2 % 
Cholesterol 20 % 
Good 
DSPC-DP2 DPPC 63 % DSPC 15 % 
DPPE 2 % 
Cholesterol 20 % 
Good 
DSPC-DP3 DPPC 53 % DSPC 25 % 
DPPE 2 % 
Cholesterol 20 % 
Good 
Table 3-4. Example hybrid vesicle lipid compositions using DPPC and DSPC. Good indicates 
that the vesicles were stable for 1<14 days at 37 °C. A full list can be found in the SI (SI-
Table 1).  
The formation of hybrid vesicles with mixed PC compositions indicated potentially 
favourable stability. In addition, a beneficial increase in sensitivity to pathogenic bacterial 
toxin stimulus was demonstrated when lipids with a higher Tc were mixed with lipids with a 
lower Tc. The potential for favourable stability and enhanced sensitivity was therefore 
exploited, and following the addition of 10 mol % of glycerol containing lipids, stability 




3.4.7 Anionic lipids 
Phosphatidylglycerol (PG) is a ubiquitous anionic lipid that is present in low concentrations 
in animal and plant membranes (1-2 %) and higher concentrations in bacterial membranes 
(up to 20 %).
64
 PG is utilised within a cell as the biosynthetic precursor of cardiolipin; 
subsequently used to generate an electrochemical potential for substrate transport and ATP 
synthesis,
65
 lysobisphosphatidic acid and many other glycophospholipids.
66
 PG also has an 
increased presence in cellular membranes of organisms that carry out aerobic photosynthesis, 




Within this investigation, 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium 
salt) (DPPG) and 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (DSPG) 
were investigated in a variety of vesicle compositions at a concentration of 10 mol %. The 
negative charge on the phosphate group ensures the lipid is anionic at neutral pH values. The 
presence of both of these glycerol lipids in hybrid vesicles demonstrated an enhanced 
stability when compared to glycerol lipids incorporated into standard vesicles composed of 
one phosphatidylcholine lipid only; in the former case, a promising stability response 
parameter (at 37 °C for 14 days). Both of these glycerol lipids have phase transition 
temperatures that are very similar to their counter phosphatidylcholine lipids (41 °C DPPG, 
38 °C DPPC, 55 °C DSPG, 54 °C DSPC). Hence it can be hypothesised that the similar Tc’s 
may enable the formation of mixed phases with reduced boundaries between the different 
lipids, ensuring that vesicles are more inherently stable. In addition to this, the accumulation 
of glycerol in biological environments under stress has been reported to increase vesicle 




3.4.8 Cationic lipids 
Cationic lipids have been investigated extensively following the discovery that they can be 
used to form cationic liposomes capable of complexing and condensing DNA,
69
 giving them 
the potential to act as a delivery vessel for intracellular DNA.
70
 The success of this alternative 
transfection system was attributed to the electrostatic reaction between a cationic vesicle and 
anionic DNA, where the resultant vesicle net positive charge association with negatively 
charged cell surfaces and the fusion / destabilisation of cationic vesicles with plasma 
membranes, aids the intracellular release of DNA.
71
 The low toxicity, safety and versatility of 
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cationic lipids make this therapeutic route to gene transfer a promising alternative to viral 
vectors. 
The properties of cationic lipids and hence cationic vesicles make them an interesting 
potential candidate for applications within this investigation. The use of 1,2-dimyristoyl-3-
dimethylammonium-propane (14:0 DMDAP), a cationic lipid with a small-polar head group, 
was therefore hypothesised to provide a stabilising effect to vesicle compositions in anionic 
environments, whilst safely delivering an active agent. Following the incorporation of 
DMDAP into various membrane compositions (primarily DMPC based) at 5 and 10 mol %, 
no increased stability was observed. This effect is thought to be due to a low Tc and an 
increased sensitivity to external stimulus; resulting from the pH sensitive nature of cationic 
lipids and the potential ability of the cationic vesicles to fuse prematurely with anionic 
surfaces. 
 
3.4.9 Stealth vesicles  
Incorporation of PEG-phospholipids is a popular method of providing a protective vesicle 
shell, ensuring a long-circulation in-vivo, enhanced permeability and host retention.
17
 
PEGylated lipids have been thoroughly investigated by fundamental research into the 
modelling of the conformation of grafted polymer chains, steric stabilisation, bio-nonfouling, 
membrane self-assembly, and biomolecular interactions.
9
 These studies have enabled the 




The predictable and controllable nature of phase behaviour of PEGylated bilayer membranes 
is important in ensuring that the retention and release profile required for active agent 
delivery is maintained.
75
 Below the phase transition temperature in the gel phase, the 
presence of PEGylated lipids in the bilayer is believed to increase active agent retention,
9, 76
 
and a transition to the disordered liquid phase is thought to trigger release,
77
 as discussed in 
3.1.2 Intelligent vesicles. Within PEGylated bilayers, the concurrent formation of immiscible 
and homogenous phases depends upon corresponding aliphatic chain length, PEG content and 
temperature,
74
 and these factors must be considered for the design of vesicles with suitable 
stability response parameters. 
There is an extensive selection of PEGylated lipids available, with PEGn molecular weights 
commonly ranging from 350 to 5000. Within this investigation 1,2-dimyristoyl-sn-glycero-3-
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phosphoethanolamine-N-[methoxy(polyethylene glycol)-n] (ammonium salt) was utilised, 
with n equalling 550, 1000 or 2000. These were incorporated into various membrane 
compositions, which were primarily DMPC based, at 5 and 10 mol %. These formulations 
proved unsuccessful at attaining the stability profile required for this investigation, and this is 
thought to result from phase immiscibility and excessive passive diffusion at temperatures 
above the lipids Tc. It should be noted however, that formulations of PEGylated lipids with 
higher Tc lipids could potentially provide the stability required. 
 
3.4.10 Phase separating lipids 
Phase separating lipids enable the formation and stabilisation of rafts of similar lipids and 
other agents within a bilayer. These rafts can coexist in gel and liquid form.
78
 The phase 
separating lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) was investigated for its 
stabilising potential. DOPC is a doubly unsaturated lipid able to form stable, well 
characterised bilayer structures, and is commonly used in membrane models.
79
 The presence 
of unsaturation in both of the hydrophobic lipid chains can be hypothesised as a key 
explanation for the formation of the separated liquid-gel phases, and is a direct cause of its 
low Tc; -17 °C. In addition to lipid phases, DOPC enhances the formation of cholesterol-rich 
raft domains. 
 The incorporation of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) at concentrations of 
2, 4 or 8 mol % was investigated in vesicles with the aim to enhance phase separation and the 
formation of gel-liquid boundaries between vesicle components. The primary lipid 
component within these vesicles was DSPC, which was utilised due to its inherent stability 
relating to its high Tc (54.55 °C). The addition of DOPC, a lipid with a low Tc (-17 °C), was 
speculated to form phase boundaries that would be more susceptible to selected 
environmental stimulus. This low Tc is a result of unsaturation in the hydrophobic chain 
Vesicles comprising 2 mol % DOPC showed an increased stability at 37 °C for 14 days, 
although increasing the DOPC composition further to 4 or 8 mol % showed a decreased 
stability hypothesised to be as a result of an increased sensitivity to environmental stimulus. 
Results by Mady, who utilised phosphorus-31 NMR, show that increased DOPC 
concentrations can promote a pH dependent phase transition of a bilayer from lamellar (pH 4) 
to hexagonal (pH 8),
80
 see Figure 3-4. This transition is essentially an inversion of the 




3.4.11 Stable vesicle candidates 
Following investigation into different stabilising agents and the synthesis of more than 70 
vesicle compositions; a select few were deemed suitable for further investigations as shown 











pH 7 / 37 °C / 14 days 
DSPC/DSPE DSPC 78 % 
Cholesterol 20 
% 
DSPE 2 % 
None 1.7 
DOPC-DS DSPC 76 % 
Cholesterol 20 
% 




TCDA-DS DSPC 63 % 
Cholesterol 20 
% 




DPPG-DP DPPC 53 % 
Cholesterol 20 
% 
DSPC 15 % 




DSPG-DP DPPC 53 % 
Cholesterol 20 
% 
DSPC 15 % 




Table 3-5. Stable vesicle candidates and their stability response parameter (S) values. A high 
value for S indicates that after 14 days at 37 °C a high level of fluorescence can be measured 
following addition of a lytic agent (triton).  
The vesicle named DSPC/DSPE has been included here as a comparison; it is a vesicle which 
is inherently stable, with a promisingly low fluorescent value after 14 days at 37 °C. However 
upon addition of triton there was no increase in fluorescence, indicating the vesicle would not 
have the desired sensitivity to bacterial toxins. 
 
3.4.12 Stability versus sensitivity 
The stability of vesicles is very important in ensuring that the encapsulated active agent, in 
this case 5(6)-CF, does not passively diffuse out. However, that is not the only requirement of 
vesicles within this investigation. The vesicles, in addition to stability at pH 7 and at 37 °C, 
must be able to release the encapsulated agent in response to pathogenic bacterial species. 
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Prior to this, the stability of the most stable vesicle candidates, determined above, was tested 
in varying environmental conditions (pH and temperature) to ensure that the ideal vesicle 
composition could be found prior to inoculation with bacteria.  
 
3.5 Environmental stimulus 
As discussed in 3.1.2 Intelligent vesicles, vesicles can be tuned to be responsive to localised 
environmental changes in pH and temperature.
73, 81
 Although this responsive nature is 
beneficial within many applications,
16, 73, 81
 the sensitivity does not fit with the parameters 
required for this application. Consequently the stability of vesicles at a range of pH and 
temperature values is required.  
 
3.5.1 Effects of pH and temperature 
The vesicles utilised within this investigation must maintain their stability regardless of pH 
and temperature changes within the localised environment. This is because within a wound 
the pH and temperature cannot necessarily be controlled and localised changes could result 
from contact with the wound surface, exudate produced or during the growth cycle of any 
colonising bacteria.  
Within this investigation, the pH range used for investigation of 5(6)-CF dye and vesicle 
stability was between pH 5 to pH 8. An acidic pH, such as that found on normal skin, is 
believed to be favourable for wound healing.
82
 As the wound healing progresses the pH of a 
wound has been proven to change from alkaline to neutral to acidic.
83
 Hence it is now 
believed that different pH ranges are required for different distinct phases of the wound 
healing process. 
A report in 2013 by Sharp et al. investigated the potential correlation between wound surface 
pH, burn depth and healing time from 30 adult burn patients. The pH of the burn surface (0.4-
4 % TBSA and ranging from superficial to full thickness) was measured following admission 
and at each dressing change. Interestingly, the pH in healing and non-healing wounds was 
found to decrease with each dressing change. A correlation between pH value, depth 
(superficial – acidic, 6,1 full thickness – alkaline, 8.0) and rate of wound healing (healing – 
neutral 7.3, non-healing – neutral 7.7) was also found.84 Consequently from this, the vesicle 




3.5.1.1 Effects of pH and temperature on 5(6)-carboxyfluorescein  
Different fluorophores are known to have varying sensitivities to changes in localised pH 
conditions. These variations result from changes in ionisation of the molecule; 5(6)-CF is 
susceptible to protonation at low pH values and deprotonation at high pH values at both the 




Figure 3-15. The chemical structures of fluorescein and pKa values as pH changes. 
Initially, the 5(6)-carboxyfluorescein dye fluorescence was measured at different pH values 
(pH 5 - 8, adjusted with 1 M NaOH / HCl) at three different concentrations; the concentration 
that is loaded into the vesicles during synthesis (50 mM), an intermediate quenched 
concentration (25 mM) and a concentration representative of the unquenched fluorescence 

















































Figure 3-16. The effect of pH on three different concentrations of 5(6)-CF dye. 50 mM is the 
quenched concentration loaded into the vesicles during synthesis and 1 mM represents an 
unquenched dye concentration following release from the vesicles. B) is a photograph of the 
unquenched 1 mM dye at pH 5 to pH 8 under UV light.  
Based on Figure 3-16, a relationship between unquenched dye fluorescence and pH can be 
measured and observed. The fluorescence intensity increased as the pH changes, with a 
maximum intensity measured at pH 8. This pH-signal dependent relationship could be 
problematic at a wound interface, where localised acidic conditions could decrease the signal 
observed. To overcome this, the vesicles could be protected from the variable nature of the 
wound environment, i.e. localised changes in pH, through careful control of the pH of the 
medium in which vesicles are stored and delivered. Potential prototypes of delivery and 
protection are discussed further in chapter 5.  
In addition to pH, the effect of temperature on the 5(6)-CF dye was also investigated at 5 °C 
and 37 °C for 18 hours at the pH values measured above (5, 6, 7 and 8). At 37 °C the 
fluorescence of the quenched dye (50 mM and 25 mM) was unaffected, although the 
unquenched dye (1 mM) had a slightly increased fluorescence after 18 hours, Figure 3-17.  
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Figure 3-17. The effect of incubation at 37 °C for 18 hours on 1 mM 5(6)-CF at pH 5, 6, 7 
and 8. A slight amplification in intensity could be measured following storage.  
This slight amplification could prove beneficial at a wound interface, where increased 
temperatures are likely and fluorescence signals will be visually observed. At 5 °C the 
fluorescence of the quenched and unquenched dye was unaffected (data not shown). 
 
3.5.1.2 Effects of pH and temperature on vesicles  
A decrease in pH is known to potentially decreasing electrostatic head group repulsion, 
increasing the likelihood of hydrolysis of bilayer components and cause the protonation of 
basic head group moieties and fatty acid chains. This can potentially destabilise the vesicles. 
In addition to this, it has been reported that vesicle compositions containing substantial 
amounts of PE lipids are able to undergo a phase transition from bilayer lamellar structures to 
inverted micelle structures at an acidic pH.
86
 PE has been reported to be essential in bilayer 
membranes for protein and bacterial attachment and targeting,
87
 hence it has been 
incorporated into vesicles within this investigation at 2 mol %. At this low concentration the 
unfavourable destabilising transition should be avoided. 
The effects from changing pH and temperature values were investigated using the vesicle 
candidates that indicated favourable stability in initial investigations from Table 3-5. The 
stability of vesicles at pH 5, 6, 7 and 8 was measured using fluorescence intensity 
measurements at day 14, following storage at 37 °C. After this time the surfactant triton was 
added, and the results were analysed according to the stability response parameter, Equation 
3-29, and given in Table 3-6. Using this parameter ensured that relative fluorescence increase 
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values are obtained, even at acidic (pH 5) conditions where the 5(6)-CF dye fluorescence 
response is decreased. 
Vesicles pH stability at 37 °C 
(Stability Response Parameter, S) 
 5 6 7 8 
DSPC/DSPE 2.9 (±0.1) 2.6 (±0.1) 1.7 (±0.1) 2.1 (±0.2) 
DOPC-DS 4.9 (±0.2) 6.4 (±0.4) 2.3 (±0.3) 1.2 (±0.1) 
TCDA-DS 3.2 (±0.2) 3.6 (±0.1) 3.7 (±0.2) 1.1 (±0.2) 
DPPG DP 5.1 (±0.4) 4.5 (±0.5) 3.8 (±0.4) 1.9 (±0.6) 
DSPG-DP 8.5 (±0.7) 4.7 (±0.6) 5.1 (±0.4) 1.4 (±0.9) 
Table 3-6. The stability response parameter of stable vesicle candidates after incubation at 37 
°C for 14 days at pH 5, 6, 7 and 8, followed by lysis with triton. A high S value was desirable 
at all pH values; indicative of good stability for 14 days, followed by successful lysis of 
vesicles on addition of triton. 
From the stability response values given in Table 3-6, where a high value is favourable and 
indicative of good stability followed by successful lysis, it is possible to argue that each of 
these vesicle compositions would be suitably stable in an acidic to neutral pH range. 
However an increased level of passive diffusion was shown to occur at pH 8, indicating 
instability in alkaline conditions. The vesicle DSPC/DSPE may have an increased sensitivity 
to lytic agents at acidic or alkaline pH values, demonstrated by its increased response after 14 
days to triton, and hence its increased S value at pH 5, 6 and 8 compared to the S value 
obtained at pH 7. 
The effect of temperature on vesicle stability was initially investigated at 37 °C for 14 days. 
Further stability investigations were carried out with storage of the vesicles at 5 °C, -20 °C 
and -80 °C for 14 days (pH 7). The effect of flash freezing (submerging in liquid nitrogen) 
followed by storage at -20 °C for 14 days was also investigated. These temperature 
conditions were chosen as they were determined to be potentially relevant as vesicle storage 
and transport temperatures prior to product application. Each of the vesicles showed a similar 
level of stability, and so data for one stable vesicle candidate, namely DPPG-DP, along with a 









































5 °C 11.1 (±1.7) 
-20 °C 4.3 (±0.1) 
-80 °C 7.7 (±0.6) 
Flash freeze at 
-80 °C 
14.5 (±3.0) 
Figure 3-18. The stability of DPPG-DP vesicles at 5 °C, -20 °C, -80 °C or following flash 
freezing. The vesicles were stored for 14 days followed by addition of triton; the original data 
for day 1, day 14 and day 14 plus triton is shown, as well as the stability response parameter 
values calculated.  
The vesicles were determined to be sufficiently stable at these temperatures, indicating that a 
decrease in temperature does not promote passive leakage, hence it was possible to conclude 
that storage of vesicles at 5 °C prior to use is optimum. The stability and count of vesicles at 
higher temperatures – between 20 °C and 40 °C, assumed to be representative of both room 
temperatures and elevated body temperatures - was investigated using Nanoparticle Tracking 
Analysis.  
 
3.5.1.3 Temperature stability of vesicles - Nanoparticle Tracking Analysis 
Nanoparticle Tracking Analysis (NTA), manufactured by Nanosight, is a relatively new 
technique developed in 2006 to measure nanoparticles. This technique allows size 
measurements and visualisation of vesicles on a particle-by-particle basis, in solutions in real 
time with minimal sample preparation. NTA visualisation provides size, count and 
concentration measurements.  
NTA, similarly to dynamic light scattering, utilises Brownian motion to make measurements 
and visualise rapidly moving nanoparticles individually. A variation of the Stokes-Einstein 
equation can be used to calculate the particle diffusion coefficient Dt, from the average 
trajectory (distance moved) of particles in x and y, the temperature T and solvent viscosity ƞ, 
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Equation 3-30, and from this the particle hydrodynamic diameter can be identified, Equation 
3-31.  
     
      
 
 Equation 3-30 
     
   
    
 Equation 3-31 
NTA was used to investigate the effect of temperature on the size, count and concentration of 
vesicles. An example (TCDA-DS vesicles) is given in Figure 3-19. The experimental 
protocol involved making automated measurements, of 60 second videos, at a starting 
temperature of 20 °C which increased slowly to 40 °C at 2 °C intervals, over a period of 
approximately 30 minute. The videos could then be analysed using the associated software to 
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Figure 3-19. Measuring the effect of increasing temperature from 20 °C to 40 °C at 2 °C 
intervals on the stability of TCDA-DS vesicles, using NTA, where A) is the actual graph 
obtained with all of the data displayed (diameter in nm on the x-axis) and B) indicates the 
reduction of vesicles present in the sample after each incremental increase (based on 20 °C 
arbitrarily being assigned as 100 % of the total possible vesicles present)  
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The results displayed in Figure 3-19 suggests a large dependency of stability on the 
temperature of the local environment, with a reduction of 30-50 % of total vesicles at 36-40 
°C, taken as a conservative guide of the average skin surface temperature in paediatric burn 
patients.
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 Three of the stable vesicle candidates, see Table 3-5, were then compared to the 
less stable vesicle DMPC/DMPE, and concentration count measurements were made at +2 °C 
intervals between 20 °C and 40 °C. The difference between the concentration count minimum 
and maximum is given in Figure 3-20, and a smaller difference indicated increased vesicle 
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Figure 3-20. Vesicle concentration count using NTA carried out on three stable vesicle 
candidates, see Table 3-2, and a comparable vesicle which showed thermal instability, 
DMPC/DMPE. A concentration count was obtained at +2 °C temperature increments from 20 
°C to 40 °C, and the calculated difference is plotted. A smaller value was indicative of similar 
concentration counts between 20 °C and 40 °C and hence was desirable.  
Despite the difference in concentration count, the actual number of vesicles still in solution at 




 for each of the three stable 
vesicle candidates, recognised as a significantly large number of vesicles. However, the large 
error values obtained potentially indicate that more readings are required for accurate 
conclusions to be made. The results from Figure 3-20 indicate that the three stable vesicle 




3.6 Vesicle stability – conclusions 
The stability of a large range of vesicles of varying compositions have been investigated for 
their potential to act as a vehicle system. The encapsulation of a fluorescent dye (5(6)-CF) 
ensured that lysis of bilayer membranes and passive leakage of internal components could be 
tracked and measured. Vesicle formulations were required to demonstrate stability at pH 7, at 
37 °C for a period of 14 days, and the stability response parameter was developed to allow 
comparisons between compositions to be made. 
From this comprehensive investigation into a range of vesicle compositions and their stability 
five stable vesicle candidates, given in Table 3-5, were identified. These vesicles have 
indicated an increased stability against passive diffusion, according to the stability response 
parameter, S, defined in Equation 3-29. Further investigations into the stability of these 
vesicles with regard to a range of pH values (5, 6, 7 and 8) and temperature ranges (5 °C, -20 
°C, -80 °C and flash freezing) for 14 days have indicated that these compositions show good 
potential for continued investigation.  
Further work could be carried out into the development of other vesicle compositions 
utilising the wide variety of phospholipids currently commercially available. This would 
increase the library developed as part of this investigation, (SI-Table 1), and offer alternative 
vesicles that have the potential to attain the desired characteristics for incorporation into a 
wound dressing. In addition to this, the developed vesicles could be investigated at a wider 
range of pH values, for longer periods of time, and at a more comprehensive range of 
temperatures.  
It should be noted that a significant decrease in vesicle concentration count was measured 
above 36 °C, using Nanosight NTA. This is a result of the transition temperature of the 
phospholipids incorporated within the bilayer being similar to the given temperatures, and 
hence an increased likelihood of passive diffusion and lysis occurring. Despite this, the actual 





 for each of the stable vesicle candidates measured; a large number of 
vesicles which would arguably still be sufficient for observing a response following lysis. 
The sensitivity of these five stable vesicles candidates, with regard to selective susceptibility 
to pathogenic bacterial toxins, can now be investigated, to determine if they would be 
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Chapter 4 Vesicle development - sensitivity 
The tailoring of vesicle sensitivity with regards to membrane lysis and the release of active 
internal agents in the presence of pathogenic bacterial toxins is a key requisite of this 
investigation. This response must be achieved selectively; the vesicles must remain un-lysed 
in the presence of non-pathogenic bacteria. The vesicles identified as showing an increased 
stability to environmental stimulus, such as pH or temperature changes over a defined period 
of time (14 days), shown in Table 3-5, can now be tested with specific relevant gram negative 




4.1 Research using microorganisms 
The extent to which microorganisms can infect a host can vary, and as such they can be 
divided into four classes on the basis of their threat to laboratory workers and the community, 
should contamination occur. According to classifications made by the World Health 
Organisation (WHO) in 1979, class 1 encompasses microorganisms with low individual and 
low community risk, class 2 encompasses microorganisms with moderate individual but low 
community risk, class 3 encompasses microorganisms with high individual but low 
community risk and class 4 encompasses microorganisms with high individual and 
community risk. Within a laboratory environment, contamination can occur through the 
lungs, the mouth, and the skin or into the eyes.  
The relevant strains of bacteria were prepared as described in chapter 2. Broth and agar 
utilised for growth of the gram positive and negative microorganisms provided the ideal 
enriched environment, based on salt content and provision of growth promoters and carbon 
metabolites. The bacteria are required at an inoculation optical density (OD) value of 0.01, 
measured on a Jenway 7300 Spectrophotometer. This OD was difficult to measure accurately, 
and so an OD of 0.1 was obtained by dilution in broth, followed by a 10 fold dilution. This 
can then be added directly into the vesicles.  
OD is a measure of absorbance of a culture of cells and is measured according to the Beer-
Lambert Law, where A = absorbance, Io = incident light intensity, I = transmitted light 




      
  
 
      Equation 4-1 
The absorbance of a bacterial culture was measured at 600 nm, and is a measure of the degree 
of light scattering caused by the cells in the culture, relative to a standard, to estimate the 
number of cells in a culture.  
 
4.2 Bacteria  
Investigations into the sensitivity of vesicles were carried out initially with four strains of 
bacteria (referred to as standard bacteria strains in other sections of this report). This was to 
determine the vesicle response, through release of a fluorescent dye, to the presence of lytic 
agents. The three organisms and four strains used within these investigations are 
Staphylococcus aureus MSSA 476, Staphylococcus aureus MSSA RN4282, Pseudomonas 
aeruginosa PAO1 and Escherichia coli DH5α. Of these; three strains S.aureus MSSA 476, 
S.aureus RN4282 and P.aeruginosa PAO1 are pathogenic, and E.coli DH5α is non-
pathogenic. Each of these will be discussed in more detail. 
 
4.2.1 Staphylococcus  
The genus Staphylococcus contains pathogens common to both humans and animals that are 
responsible for infections of skin or wounds. In some cases these colonising-bacteria can 
cause infections that are life-threatening. Staphylococci are gram positive cocci of between 
0.8-1.0µm in diameter; they are non-sporulating, resistant to drying and readily dispersed in 
dust particles through the air and on surfaces. In humans, three major species are recognised; 
S.epidermis, S.aureus and S.saprophyticus. Aside from their disease profile, these can be 
differentiated according to whether they are negative (S. epidermis, S.saprophyticus) or 
positive (S.aureus) for coagulase, a surface protein that causes blood to clump.
2
 Within this 
investigation species of S.aureus were utilised for applications involving vesicles. 
 
4.2.1.1 Staphylococcus aureus 
S.aureus is a non-motile, yellow pigmented, cluster species commonly associated with skin 
and other infections. Examples of these include impetigo, boils and scalds, food borne 
diseases, wound and implant infections and toxic shock syndrome and sepsis. S.aureus is an 
97 
 
opportunistic virulent pathogen that is currently the most common cause of infections in 
hospitalised patients. This is due to its extensive amount of virulence factors, and its ability to 
evolve new virulent and drug-resistant variants. It has particular relevance to this 
investigation as it is the most common colonising bacteria in burn wounds. It is able to adhere 
to cells, spread in tissues and form abscesses, and produce extracellular enzymes or 
exotoxins. The common toxins and pathogenicity factors are given in Table 4-1: 
Toxin produced Effect 
Enterotoxins Released following colonisation of food - food poisoning 
Exfoliative or epidermolytic Peeling layers of epidermis 
Hemolysins Lysis of erythrocytes 
Leukocidins Lysis of leucocytes and macrophages 
Toxic shock syndrome (TSST) Vascular collapse, rash with desquamation, systemic 
shock 
  Pathogenicity factor Effect 
Microbial surface components 
recognising adhesives matrix 
molecules (MSCRAMMs) 
Mediate adherence to host cells 
Protein A Evade host defences 
Fibronectin-binding protein Mediates binding to fibronectin 
Fibrogen-binding protein Clumping factors 
Capsule Evade host defences 
Coagulase Generates protective fibrin layer around S.aureus 
Staphylokinase Fibrinolysis 
Proteases Degrade matrix and antibacterial proteins  
Lipases Promote interstitial spreading of organism 
Hyaluronidase Degrades hyaluronic acid 
α-hemolysin Lyses erythrocytes and damages platelets 
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β-hemolysin Degrades sphingomyelin  
Leukocidin / leucotoxin Lyse Leukocytes 
Table 4-1. Toxins and pathogenicity factors produced by S.aureus.
3
  
S.aureus is part of the natural flora of the nasopharynx (the upper respiratory tract) of healthy 
individuals known as carriers (approximately 33 % of the population), where it is thought that 
other microorganisms compete successfully for resources and therefore pathogen growth is 
limited. There are five general stages of S.aureus infection during which extracellular 
proteins are secreted to damage the host cell (pathogenesis). These are colonisation, localised 
infection, systemic dissemination and/or sepsis, metastatic infection and toxinosis.
4
  
The resistance of S.aureus to the β-lactam antibiotic was first described in the 1960s, 
however methicillin resistant staphylococcus aureus (MRSA) strains spread rapidly between 
the 1980s to 1990s, with 40-60 % of all bacterial infections now being resistant.
5
 Within this 
investigation Methicillin susceptible staphylococcus aureus (MSSA) 476 is utilised. MSSA 
476 is a community acquired strain isolated in 1998 from a 9 year old patient who had no 
predisposing risk factors. MSSA 476 is composed of 2,799,802 bp chromosomes in size with 
2,565 genes. Although it is resistant to penicillin and fusidic acid, it is susceptible to 
commonly used antibiotics including gentamicin, ciprofloxacin and tetracycline.
6
 MSSA 
RN4282 is a naturally occurring strain that produces and secretes small amounts of 




4.2.1.2 The relevance of MSSA RN4282  
Toxic shock syndrome (TSS) is a severe systemic toxin mediated disease, produced by some 
strains of bacteria, but most commonly S.aureus. It is characterised by shock, pyrexia (fever), 
gastrointestinal disturbance and problems with the central nervous system. These symptoms 
mimic many other childhood illnesses, and so it is often misdiagnosed. It is the most common 
cause of unexpected mortality in children with small burns, with a mortality of ~50 % if left 
untreated. At particular risk to TSST colonisation are skin damaged children under four years 
old, who have not yet developed antibodies to the toxins produced by the bacteria. Paediatric 
burn patients have an increased risk of developing TSS as a result of the damage to the 
protective skin barrier and impaired immunity. In addition to this the damaged area provides 
advantageous environmental conditions for toxin production following colonisation. These 
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conditions include an aerobic environment, a neutral pH, elevated levels of CO2, raised 
temperatures and increased quantities of host serum available for use as a food source. The 




4.2.2 Pseudomonas aeruginosa 
Pseudomonas aeruginosa (P.aeruginosa) is a versatile, mobile gram negative rod-shaped 
bacteria that grows ubiquitously on plant and animal tissue. In addition to this it can colonise 
soil, marshes and coastal habitats; forming biofilm structures on wet surfaces.
9
 Despite the 
virulence characteristics more commonly recognised and associated with P.aeruginosa, it is 
worth noting that some strains play an important role in soil ecology, with the ability to 




P.aeruginosa was previously thought to be innocuous, or even beneficial, to host organisms, 
however its ability to take advantage of breaches in host defences ensures that it is now 
considered an opportunistic pathogen. Consequentially, P.aeruginosa targets the immuno-
compromised. It is a significant source of bacteraemia in burn patients, it can colonise at 
surgical sites (where the skin has been breached), and be problematic for cystic fibrosis 
patients, resulting in pulmonary failure. These negative colonisation effects are amplified as a 
result of its intrinsic resistance to antibiotics and disinfectants.
10
  
P.aeruginosa bacteria contain regulatory pathways that are capable of eliciting a feedback 
response, ensuring that the density of cells within their own population is controlled. This 
feedback control is known as quorum sensing, and assists in biofilm formation, discussed 
previously in 1.1.4 Biofilm and 1.1.5 Quorum sensing. This process involves the expression 
of an enzyme that synthesises acylated homoserine lactone (AHL), which is actively diffused 
out of the cell and therefore reaches high concentrations if there are a high number of the 
same cells present. As the homoserine lactones accumulate they function as chemotactic 
agents, recruiting nearby P.aeruginosa cells and developing biofilms.  
The virulence and pathogenic factors of P.aeruginosa include adhesins, lipopolysaccharides 
and exotoxin A (ExoA). Adhesins can selectively attach to specific host cells, 
lipopolysaccharides, such as ExoS and ExoU, can be injected directly into the cytoplasm of 
host cells, and exotoxin A is involved in binding to host cell protein synthesis receptors; 





P.aeruginosa PAO1 is the most widely used lab strain of P.aeruginosa. It has an intrinsic 
resistance to many front line antibiotics due to its low outer membrane permeability and the 
presence of antibiotic efflux pumps.
11
 The bacterial genome sequence of PAO1 is 6.3 million 
base pairs, of which a large number code for control and command systems, enabling a 




4.2.3 Escherichia coli 
Escherichia coli (E.coli) are a versatile microorganism, with commensal strains having the 
ability to colonise the gastrointestinal tract within hours of birth (of a host) and coexisting in 
good health with mutual benefit for decades. These commensal strains rarely cause disease 
except in immune-compromised hosts, although adaptive E.coli strains are known that have 




E.coli is a gram negative rod-shaped bacterium, of which both pathogenic and non-
pathogenic strains are commonly utilised for model systems of bacteria study. These strains 
of bacteria are commonly known as enteric, due to specific innate characteristics. For 
example, they can be non-sporulating, non-motile or motile by flagella, and able to produce 
acid from glucose. As with all gram negative bacteria, E.coli contains endotoxin in their cell 
walls. This can be liberated on cell lysis, resulting in complement activation and endotoxic 
shock. 
E.coli is commonly resistant to the antibiotics penicillin and amphicillin; however it is 
susceptible to cephalosporins, trimethoporim and aminoglycosides. Strains isolated from 
hospitals often have an increased resistance to antibiotics, resulting in localised geographical 
areas with a greater susceptibility to infections that are difficult to treat.
3
 E.coli DH5 is a non-
pathogenic laboratory strain named after the biologist Doug Hanahan in 1985, originating 
from the K12 sequence through a sequence of useful mutations. DH5α is a cell line based on 






4.3 Bacterial toxin interactions with membranes 
The interactions of bacterial toxins with membranes can occur through several mechanisms. 
A relevant example of a toxin capable of interacting with membranes is phospholipases (PL). 
Within cells, these are membrane active enzymes essential for mediation of intracellular and 
intercellular transformations. They can function as hydrolysing enzymes to generate required 
bioactive compounds, such as diacylglycerol, phosphatidic acid, lysophosphatidic acid and 




Figure 4-1. The hydrolysis sites of action of a range of phospholipase enzymes.  
These PLs can be released from bacterial species as toxins able to hydrolytically degrade host 
membrane phospholipids, modulate host immune response and interfere with cellular 
signalling cascades, aiding the colonisation process.
15
  
Many other bacterial toxins hydrolyse phospholipids at the sites indicated in Figure 4-1, 
ensuring formation of pores within host membranes, for example α-toxin secreted from 
S.aureus.
16
 α-toxin, alongside other host-damaging proteins can be secreted from S.aureus 
during its’ stationary phase of bacteria growth; depicted in Figure 4-2, alongside many other 




Figure 4-2. The different surface and secretion proteins of S.aureus bacteria and their 




4.3.1 Relevant toxins 
The toxic components of bacteria which attribute directly to vesicle lysis have been 
investigated by other members of the group (W.D Jamieson and M. Laabei, papers with 
reviewers). The membrane lytic effect of P.aeruginosa has been found to be a result of 
phospholipase C, see Figure 4-1, and rhamnolipid interactions. Rhamnolipid is an 
opportunistic glycolipid bio-surfactant produced from P.aeruginosa, as well as other various 
bacterial species. Rhamnolipid is composed of one (mono) or two (di) rhamnose hydrophilic 
heads, coupled to one or two fatty acid hydrophobic tails.
18
 The general structure for a mono-
rhamnolipid is given in Figure 4-3.  
 
Figure 4-3. The general structure of a mono-rhamnolipid (Rha-C10). There are approximately 
60 homologues of four congeners; two di-rhamnolipids: Rha-Rha-C10-C10 and Rha-Rha-C10, 





The dirhamnolipid-induced leakage of contents from vesicles is known to be affected by 
membrane composition; where the presence of increased levels of PE lipids and cholesterol 
decrease the rate and extent of internal agent leakage.
18
 The mechanism of leakage is 
reportedly not due to membrane solubilisation, but in fact due to adsorption of the 
rhamnolipid onto the outer layer of the membrane, diffusion (flip-flopping) to the inner 
membrane, followed by intercalation to; and hence increased disorder of, the phospholipid 
hydrocarbon conformers. This effectively ensures a disruption to the phospholipid packing, 
and a lowering of the gel-to-liquid transition temperature Tc.
20
  
The membrane lytic effects of S.aureus are a result of δ-hemolysin and phenol soluble 
modulin (PSM) peptides. The peptide δ-hemolysin is α-helical and composed of 26-amino 
acids. Its amphipathic nature allows it to form aggregates in water, bind to membranes, and 
be soluble in both aqueous and organic solvents. The mode of action of δ-hemolysin depends 
on a threshold concentration, which varies according to lipid concentration and local 
environment. If the concentration is below this variable threshold, the δ-hemolysin is thought 
to either insert in the membrane between acyl chains and polar head groups, either in a 
parallel manner,
21
 a perpendicular manner,
22
 or a disordered manner.
23
 Following this the 
peptide can aggregate within the bilayer; resulting in the formation of pores. If the 
concentration is above the threshold, the δ-hemolysin is thought to act in a similar manner to 
the surfactant Triton X-100
TM
, (mechanism discussed in 3.4.4 Polydiacetylene polymers). 
The δ-hemolysin induces a detergent-like solubilization of the membrane,24 leading to the 
formation of disk shaped structures or micelles.
25
  
PSM peptides can be one of four short peptides (~20 amino acids - α-type), or two longer 
peptides (~40 amino acids – β-type). The amino acid sequences of α-type PSMs are similar to 
δ-hemolysin, indicating a similar mode of action at membranes. PSMs are reported to destroy 
host leukocytes, and therefore play a role in evasion of innate defences. The regulation of 
PSM production is carried out by the accessory gene regulator (AGR) quorum sensing 
system,
26





4.4 Vesicle response to bacteria 
The effect of the bacterial toxins on the stabilised vesicles developed in chapter 3 should be 
akin to the pattern indicated in the graph in Figure 4-4. The release of 5(6)-CF dye from the 
vesicles, indicating that degradation of the membrane has occurred, only happens after 
growth of bacteria and consequential release of lytic toxins. The release of lytic peptides 
following bacterial colonisation elicits a fast vesicle-lysis response with P.aeruginosa PAO1 
(PAO1) and a slightly slower, slightly lower intensity response with S.aureus MSSA 476 
(MSSA 476). The response with non-pathogenic non-toxin releasing E.coli DH5α (DH5α) 
should be similar to the stability of the nanocapsules in HEPES, although there is an 
insignificantly slight increase in fluorescence after about 8 hours – when the bacteria is in the 
middle of its’ exponential growth phase. These responses can be compared to the 
instantaneous reaction following addition of the surfactant triton. 
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Figure 4-4. The expected vesicle lysis response following inoculation with bacteria in broth, 
where A) is the fluorescence response of the vesicles to the bacteria, and B) is the absorption 
intensity (OD600) of the corresponding bacteria utilised as a measure of bacteria growth. The 
growth of bacteria in vesicles with HEPES buffer and triton is included to confirm that 
contamination of controls is not occurring. 
The growth curves of the bacteria in Figure 4-4 (B) can be compared to the standard growth 
curve depicted in Figure 2-3. Bacteria growth curve, and can be related to vesicle lysis. From 
this an assumption can be made about when in the growth cycles of PAO1 and MSSA 476 
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there is sufficient numbers of bacteria cells producing sufficient quantities of lytic toxins to 
ensure membrane degradation. The beginning of the PAO1 toxin induced vesicle lysis 
response occurs after approximately 8 hours of growth, in the middle of logarithmic cell 
growth. A slowing of fluorescence increase and therefore vesicle lysis occurs at 
approximately 11 hours. Despite this still being log-phase bacteria growth, this slowing 
response could be due to either the majority of vesicles having already been lysed, or the rate 
of production and quantity of lytic toxins being decreased. It is not until approximately 15 
hours that PAO1 growth reaches its’ stationary phase, at this point minimal additional vesicle 
lysis is occurring. 
MSSA 476 toxin-induced vesicle lysis response, within the time scale of this experiment, is 
less than the response measured from PAO1, after the same incubation time (16 hours = ~ 64 
% relative to PAO1). In addition to the decreased overall response, the lysis of vesicles is 
much slower than for PAO1, and this could be speculated to indicate a decreased lytic ability 
of the toxins produced or a decreased quantity of toxin. Despite this, the MSSA 476 toxin 
induced vesicle lysis response slowly begins after only approximately 5 hours of growth.  
It is important to note that the proportional relationship between optical density (OD600) and 
cell density only exists at approximately OD ≤ 0.4. Above this OD the growth curve is 
distorted, hence it can only be used as an indication of bacteria growth phase. Accurate 
measurements regarding the number of bacteria present would require dilutions and 
inoculations onto plates to find colony forming units per ml (cfu ml
-1
). 
There may be slight variations in the growth of bacteria and the consequential response of 
vesicles between different experiments, due to the different vesicle compositions present 
affecting bacteria growth, and the potential, but unlikely occurrence of point mutations within 
the bacteria cultures utilised. 
Ideally, the response of vesicles to all host-damaging lytic toxins would be equal, 
instantaneous, and yield a maximum indication (fluorescence) response, similar to that 
observed following addition of triton. However this is not the case. The growth and 
proliferation of bacterial cells does not occur at the same rate. This could be due to the 
inherent rate of multiplication of the bacterial cell and the conditions within the localised 
environment, such as presence of nutrients, pH fluctuations and host defences. In relation to 
this, the production, secretion and quantity of toxins from different bacterial species, even 
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within the same strain, (taking account of point mutations and location acquired: hospital and 
community)
26
 can occur at different rates.  
 
4.4.1 Selective sensitivity of stabilised vesicles 
From chapter 3, three stabilised vesicle candidates were chosen for further testing with regard 
to their sensitivity to bacteria. The vesicle types chosen were DOPC-DS, TCDA-DS and 
DSPG-DP (compositions can be found in Table 3-5). The other two potential candidates, 
DPPG-DP and DSPC/DSPE, were not used for further sensitivity testing. This was due to the 
structural similarity of DPPG being hypothesized to give a similar sensitivity response as 
DSPG, and the known inherent stability of vesicles composed primarily of DSPC and 
therefore the postulated lack of sensitivity to external stimulus (see Table 3-5 and its stability 
response parameter). 
The three vesicle compositions were incubated with pathogenic S.aureus RN4282; a relevant 
high TSST producing strain and P.aeruginosa PAO1, and non-pathogenic E.coli DH5α, and 
compared to the lytic response with the positive control: the surfactant triton, and the non-
lytic negative control response with HEPES buffer. This incubation was carried out with 
bacterial supernatant; the separated solution obtained from a bacteria culture following 
centrifugation and discarding of the pellet (whole bacterial cells), and with whole bacteria 
cells. This is shown in Figure 4-5, where the graph indicates vesicle response to bacterial 
supernatant, displaying actual fluorescence intensity values obtained, and the table indicates 
the stability response parameter (introduced in 3.4.1 Stability response parameter) of vesicles 
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Figure 4-5. Stabilised vesicle candidate sensitivity response to bacteria, where the graph gives 
response to supernatant of pathogenic S.aureus RN4282 (2), P.aeruginosa PAO1 (3) and 
non-pathogenic E.coli DH5α (4); triton (1); and a control (HEPES buffer) (5) after 2 hours.  
The table gives the stability response parameter (S) of vesicle candidates to the same 
pathogenic bacteria cells, triton and HEPES, after incubation for 16 hours. A large stability 
response parameter was desired for the vesicles treated with pathogenic bacteria and the 
positive control, conversely a small instability parameter was desired for vesicles treated with 
the negative controls. 
The supernatant data plotted within the graph shows final fluorescence intensity after 
incubation with the supernatant and controls for 100 minutes, however the majority of vesicle 
lysis was achieved within 30 minutes. The vesicles containing whole bacterial cells is 
displayed in a table in terms of the stability response parameter, S, where a ratio of final 
fluorescence (after 16 hours incubation) was compared to initial fluorescence at time = 0. A 
high S value was indicative of a large degree of vesicle lysis which was desirable for the 
pathogenic bacteria (S.aureus RN4282 and P.aeruginosa PAO1) and the positive control 
(triton). Conversely a small S value was desired for vesicles treated with the negative controls 
(E.coli DH5α and HEPES). 
From Figure 4-5, each of the three vesicle candidates can be seen to be having the desired 
response to pathogenic bacterial toxins, whilst remaining relatively unaffected by the non-
pathogenic bacteria. The extent of the response to bacterial toxins, and even to the surfactant 
triton, varies according to vesicle composition. This could be postulated to be due to 
differences between the growth and production of bacteria, and hence toxins, within the 
individual wells of a 96-well plate. It could also be due to the differences between the 
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localised charge distributions or availability of phase boundaries within the membrane; 
potentially affecting the quantities and availability of toxin-vesicle sites available for 
interactions.  
 
4.4.2 Observable response versus bacteria present 
The actual number of pathogenic bacteria within a wound required for a signal to be observed 
is an important parameter within the scope of this investigation. The difficulties associated 
with obtaining this number will be discussed further in Fluorescence response versus bacteria 
count. 
 
4.5 Accessory gene regulator 
The accessory gene regulator (AGR) quorum sensing system, is involved in the regulation of 
toxin production primarily within S.aureus bacteria.
27
 It is therefore important with regard to 
vesicle response in a burn wound environment. The complexity of the quorum sensing system 
and its role in down-regulation of surface proteins and up-regulation of secreted proteins 
during in-vitro growth
28
 is depicted in Figure 4-6. The AGR operon consists of four genes 
which are encoded within a two component divergently transcribed signal systems; the P2 
operon – which contains the AGRB, AGRD, AGRC and AGRA genes. The P3 operon consists 
of the regulatory effector molecule RNA III, which can act to repress self-repressing toxin 




Figure 4-6. Schematic representation of the two component AGR system. Within the P2 
operon, AGRA activity results in the secretion of the auto-inducing pheromone, AGRD. This 
short peptide is exported by AGRB and consequentially binds and activates the histidine 
kinase receptor, AGRC. When a sufficient concentration is achieved the response regulator 
AGRA is activated, which can then act upon the P2 and P3 promoters to up-regulate AGR 
genes and RNA III.,
29
  
The relevance and importance of this quorum sensing system is demonstrated by incubating 
the three stabilised vesicle candidates with S.aureus RN6390B, an AGR positive strain 
(AGR+ contains the up-regulatory system gene), and with S.aureus RN6911, an AGR 
negative strain (AGR- the gene that codes for the AGR system have been removed). The 
results are shown in Figure 4-7. 
110 
 































































































































































 24 hr + T





























Figure 4-7. The fluorescence intensity of three primary vesicle candidates after 24 hours with 
bacteria and 24 hours with bacteria and triton (T), where A) is TCDA-DS vesicles, C) is 
DSPG-DP vesicles and E) is DOPC-DS vesicles; and B) D) and F) show corresponding 
bacteria growth within the same time frame in each of the vesicle types. The growth and 
fluorescence kinetic profiles over 18 hours for each vesicle type and bacterial species, as well 
as the growth of each bacteria species in a comparative, non-vesicle containing solution 
(HEPES) and in ideal nutrient rich conditions (broth) after 24 hours are given in the SI (SI-
Figure 2 and SI-Figure 3).  
The important points of interest within the graphs in Figure 4-7 are highlighted with different 
coloured asterisks, where the effect of the AGR+ and AGR- toxins can be measured against 
the three different vesicle candidates. In all three cases, the presence of AGR+ (red asterisk) 
increases the toxicity of the bacterial strain to the vesicles compared to AGR- (blue asterisk). 
Interestingly, the comparative P.aeruginosa PAO1, which produces rhamnolipid and PLC 
lytic peptides, show a larger degree of toxicity to the vesicles. 
The production of different toxins within a bacterial strain is very complex, with the 
interaction of up-regulating and feedback systems playing a role in both expression and 
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quantity. Within a wound environment it is hence difficult to discern which toxins will be 
produced from the different bacteria present, their quantity, and the extent of their effect on 
the vesicles. It is possible, however to obtain wound exudate from paediatric burn patients, to 
attempt to imitate the conditions the vesicles would be exposed to, and measure their stability 
within this potentially bacteria containing medium. 
 
4.6 Vesicles in wound exudate 
The stability of the vesicles that would be placed within a dressing and applied to a wound 
environment is of paramount importance to this project. This project has attempted to emulate 
the conditions found at a wound interface, through manipulation of temperature, change in 
pH, dressing application (within a topical hydrogel – discussed in chapter 5), addition of 
bacteria, and even storage in simulated wound fluid (SimF - primarily composed of fetal calf 
serum). However, to increase the relevance of these studies, the vesicle stability could be 
tested in fluid that has been extracted from a paediatric burn wound afflicted patient. This 
fluid, henceforth called wound exudate (WE), can be extracted from the patient via syringe 
and stored on ice, if used on the day of collection, or frozen. 
As part of this investigation, WE (approximately 500 µl) was extracted via syringe from a 
young female patient and incubated at different percentage ratios with the three primary 
vesicle candidates. This incubation was for a time period of 16 hours at 37 °C, results shown 
in Figure 4-8. The WE was also streaked onto agar nutrient plates and incubated at 37 °C 
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to Triton-X100 with increased 
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Figure 4-8. The effect of wound exudate at different concentrations, 2, 4, 6, 8, and 10 % v/v 
on the three primary vesicle candidates, A) shows all of the data for all three vesicle types at 
time = 0 hours, time = 16 hours and following addition of triton. Promising stability 
following multiple readings and storage for 16 hours at 37 °C can be measured; however a 
decreased susceptibility to triton was identified linearly with increased wound exudate 
concentration. B) C) and D) show the individual data for TCDA-DS, DSPG-DP and DOPC-
DS vesicles respectively. The photos in E) and F) are taken under UV light, and allow for 
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observed differences in fluorescence to be monitored both pre (E) and post (F) Triton after 16 
hours. 
The results obtained in Figure 4-8 indicate favourable stability in the different concentrations 
of wound exudate. The decrease in fluorescence with increased wound exudate indicates an 
interaction is taking place between the WE and fluorophore, or WE and triton, and potential 
reasons for this are hypothesised following further investigation into long term stability. The 
stability of the vesicles in the same wound exudate, i.e. the same patient / same blister, from 
Figure 4-8, was carried out with 10 % v/v exudate at 5, 20 and 37 °C for 14 days, shown in 























































































































































































































































 Figure 4-9. The stability of the standard three vesicle types with wound exudate, SimF and a 
control at day 1, after 14 days and following addition of triton at a) 5 °C, B) 20 °C and C) 37 
°C. The photograph in D) shows the three vesicle types in wound exudate, SimF or in HEPES 
at 5, 20 and 37 
°
C, taken under UV light.  
The vesicle solutions stored at 37 °C suffered from dehydration effects, ensuring that there 
was not enough vesicle volume to aliquot out three samples of each, and although this affects 
the validity of the results, a general trend can still be measured and observed. The vesicles 
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show comparative favourable stability at 5 and 20 °C. The fluorescent switch on following 
addition of triton to vesicles in both WE and SimF followed the expected trend for TCDA-DS 
and DOPC-DS vesicles at 5 and 20 °C, however for DSPG-DP vesicles the increase is much 
less (approximately 0.5x). These results potentially suggest that the DSPG-DP vesicles are 
not present in as high a concentration, indicating formation issues during extrusion or 
following NAP-25 column separation from the unencapsulated dye. This effect was not 
observed during other experiments and so this response was therefore deemed to be an 
anomaly rather than an actual effect of the experimental conditions. 
Upon addition of triton to the vesicles incubated in WE, after the 14 day period, the expected 
increased fluorescence response was not observed. This potentially indicated that the WE was 
reacting with the triton, sequestering its ability to disrupt and dissolve membranes or 
preventing it accessing the vesicles. In addition to this the wound exudate could be 
interacting with the carboxyfluorescein and having a quenching effect. As shown in Figure 
4-8, as the concentration of the wound exudate is decreased, the fluorescence response 
increases in a linear fashion. This effect is potentially due to the changes in pH caused by the 
wound exudate, as it is well known that fluorophores are affected by pH changes.
30
  
The stability of vesicles in WE looks very promising, and these preliminary results indicate 
that the vesicles synthesised would maintain their structure successfully at a wound interface. 
Further experiments would be required to confirm and clarify these results. The use of pure 
toxins or incubation with common bacterial strains, as well as basic pH measurements, would 
be beneficial and provide more information about how sensitive the vesicles would be within 
a wound environment.  
Unfortunately, the constraint on this investigation is the availability of fresh viable wound 
exudate. The obtaining of a sample is wholly dependent on the presence of a burn in a 
paediatric patient, formation of an appropriate blister from which a large enough volume of 
exudate can be obtained (ideally <500 µl), consent from guardians being given and successful 
extraction of the wound exudate through a syringe being achieved. Notice of this process is 
given to relevant researchers approximately two hours before a sample is ready to be 
collected, hence there is only a small opportunity to ensure your potential experiment is 
prepared correctly. Alternatively, and more practically, the sample can be frozen following 





4.7 Vesicle sensitivity - conclusions 
The synthesis of vesicles that not only maintain stability over time and at different 
temperatures and pH values, but also release their active agents, in this case the dye 5(6)-CF, 
in a specific sensitive manner, i.e. in the presence of pathogenic bacterial toxins has been 
successfully achieved within this investigation. Each of the three potential candidates 
investigated in chapter 3 (TCDA-DS, DSPG-DP and DOPC-DS) have indicated selective 
sensitivity to the different relevant strains of pathogenic bacteria. The measured differences 
between the degrees of response between the different vesicle candidates to the bacteria 
strains investigated can be postulated to be due to two primary reasons. There may be 
differences between the growth and production of bacteria, and hence toxins, within the 
individual wells of a 96-well plate. Equally, there may be variations between localised charge 
distributions or availability of phase boundaries within the vesicle bilayer membrane; 
potentially affecting the quantities and availability of favourable toxin-vesicle interaction 
sites.  
In addition to this the importance of the AGR quorum sensing system on toxicity has been 
investigated with respect to the vesicle candidates. Initial results have indicated that the 
presence of AGR is important in ensuring vesicle lysis. The release of toxins is known to be a 
complex process; with large variations between expression, quantity, and even affectivity on 
membrane destruction varying. This was shown by the comparison of the three vesicle 
candidate’s fluorescence response following incubation with strains of S.aureus AGR+, 
S.aureus AGR-, and P.aeruginosa PAO1. 
The effect of wound exudate, obtained from a female paediatric patient with a small burn, 
was measured against the three vesicle candidates. The stability of vesicles in the WE looked 
promising, and these preliminary results indicate that the vesicles synthesised would maintain 
their structure successfully at a wound interface. However, following addition of triton to the 
vesicles incubated in WE after the 14 day period, the expected increased fluorescence 
response was not observed. This potentially indicated that the wound exudate is both reacting 
with the triton and disrupting its’ ability to dissolve membranes or preventing it accessing the 
vesicles. Alternatively the wound exudate could be interacting with the 5(6)-CF and having a 
quenching effect. Further experiments would be required to confirm and clarify these results. 
These could involve the use of pure toxins or incubation with the standard bacterial strains, 
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potentially providing more information about how sensitive the vesicles would be in a wound 
environment.  
The three selectively sensitive and stable vesicle compositions can now be used for 
incorporation into a wound-dressing prototype system that will allow delivery of the 
signalling system to a wound. The development of this is discussed further in chapter 5.  
The pathogenic bacteria strains used for investigating the sensitivity of vesicles to toxins have 
proven effective at lysing the membranes, ensuring effective release of the 5(6)-CF. The 
signalling aspect of this system is of large importance, however the incorporation of 
antibacterial agents within the vesicles, that could destroy the bacteria cells following release 
would prove beneficial; therefore it requires investigation. Preliminary further work results 
are discussed in the following section. 
 
4.7.1 Further work - encapsulation of antibacterial agents 
The encapsulation of antimicrobial and/or antibiotic agents into the vesicles, alongside a dye, 
offers a promising potential to create a system that could detect and treat an infection within a 
wound. It is hypothesised that following successful incorporation of an antibacterial agent 
within the vesicle the bacteria growth (measured through absorbance OD600) would follow 
that shown in Figure 4-10. 
 
Figure 4-10. Hypothesised growth curve of bacteria in the presence of vesicles containing an 
antibacterial agent, compared to normal bacteria growth in favourable conditions (with regard 




4.7.1.1 Antimicrobial agents 
An antimicrobial agent can be defined as a substance with inhibitory properties against 
microorganisms that has little or no effects on mammalian cells. This can include antibiotics 
and other synthetic compounds. An antibiotic agent is a substance produced by a 
microorganism that has the ability to inhibit the growth of (bacteriostatic) or kill (bactericidal, 
viricidal, fungicidal) other microorganisms. This term does not apply to purely synthetic 
agents; however chemical modification of antibiotics to improve properties such as spectrum 
of activity and stability can yield the more widely recognised semi-synthetic antibiotics.
3
 
Different agents can be classified according to their target mode of action. This can, for 
example include interference with the bacterial cell wall or membrane, or provoke a 
preventative mechanism against protein or nucleic acid synthesis. Examples of antimicrobial 
agents with different sites of action are given in Table 4-2. 
Site of action Antimicrobial agent 
Cell wall Penicillins, cephalosporins, vancomycin 
Cell membrane* Polymyxins* 
Protein synthesis Aminoglycosides, chloramphenicol, fusidic 
acid, macrolides, tetracyclines  
DNA synthesis Sulphonamide, Trimethoprim, Quinolones 
RNA synthesis Rifampicin 
Table 4-2. The site of action of different antimicrobial agents. *Cell membrane active agents 
are predicted to have a negative disruption effect on the stability of lipids prior to formation 




4.7.1.2 Minimum inhibitory concentration 
A minimum inhibitory concentration (MIC) assay can be used to determine the lowest 
concentration of an antibacterial (the maximum dilution), required to restrict the growth of 
bacteria over a given time period. Visual measurements were firstly utilised to gauge an 
appropriate range, followed by appropriate narrowing of agent concentration and consecutive 
growth measurements (OD600) for the same. The affectivity of an antibacterial agent was 
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tested against a gram negative and a gram positive bacterial species, in this case P.aeruginosa 
PAO1and S.aureus MSSA 476, both discussed in 4.2 Bacteria. From the approximate MIC 
concentration range identified, an accurate concentration range was investigated between the 
two values of growth and non-growth.  
From this data the concentration of an antibacterial agent required to inhibit a certain amount 
of bacteria can be estimated. The two most common values are the MIC50 and MIC100; the 
amount of antimicrobial required to inhibit 50 % and 100 % of the bacteria growth, 
respectively. Complete encapsulation of an agent into vesicles during the manufacturing 
process does not always occur; unencapsulated agents are separated during NAP-25 column 
separation. As a result of this a concentration slightly above the experimentally derived 
necessary amount was utilised to try and ensure that an MIC100 was available following 
vesicle lysis. 
An example of OD600 bacterial growth curves of S.aureus MSSA 476 versus different 
concentrations of doxorubicin HCl (see Table 4-3) is given in Figure 4-11. 










 1 mg/ml Dox HCl
 0.5 mg/ml Dox HCl
 0.1 mg/ml Dox HCl
 0.05 mg/ml Dox HCl








Time (hours)  
Figure 4-11. The growth of gram positive S.aureus MSSA 476 when incubated with different 
concentrations of doxorubicin hydrochloride, compared to growth in nutrient rich broth or 
water.  
 
4.7.1.3 Antibacterial agents 
The MIC100 of different antibacterial agents against gram+ S.aureus MSSA 476 and gram- 
P.aeruginosa PAO1 was determined, and this, along with their structure and activity, is given 






































































































Table 4-3. The structure and activity of different antibacterial agents, and the MIC100 against 
gram+ S.aureus MSSA 476 and gram- P.aeruginosa PAO1 (mol L
-1
) 
These antibiotic agents were investigated due to their broad spectrum of activity against 
gram+ and / or gram- bacteria, their mode of actions being potentially compatible with 
encapsulation in phospholipid vesicle membranes, and their good solubility profiles in 
aqueous solutions. 
 
4.7.1.4 Incorporation of antibacterial agents into vesicles 
Following MIC100 results, the different antibiotics were added to HEPES buffer at their 
required concentration, as an alternative to the 5(6)-CF dye, and this antibacterial solution 
was added to the vesicles following dehydration of membrane components into a thin film. 
Standard vesicles formulation procedures were followed from this point.  
Initial experiments investigating the success of each active agent encapsulation did not prove 
massively successful. Absorbance (OD600) measuring bacteria growth versus active-agent-
encapsulated-in-vesicles results indicated that either the active agent was potentially within 
the solution as well as in the vesicles, as no bacteria growth was detected, or the active agent 
was not within the vesicles solution at all, and standard bacteria growth was observed. To try 
and improve the separation of unencapsulated active agent from vesicles containing the active 
agent, ultra-centrifugation was utilised as a secondary purification technique, with speeds up 
to 30,000 rpm for 1 hour. 
Despite this, many of the antibacterial agents proved incompatible with encapsulation within 
vesicles, and promising results were not achieved. Although, the most promising results were 
achieved following the encapsulation of Dox HCl (0.5 mg/ml) into DSPG-DP vesicles and 
comparative growth curves of Dox HCl vesicles with bacteria and positive bacteria controls 
is given in Figure 4-12. 
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Figure 4-12. The growth of bacteria when incubated with DSPG-DP vesicles containing Dox 
HCl (0.5 mg/ml) where A) is the growth of bacteria with vesicles that have undergone 
standard separation procedures and C) is the growth of bacteria with vesicles that have 
undergone a secondary purification step using ultra-centrifugation (10,000 rpm, 10 min). B) 
and D) are the respective corresponding positive control: bacteria growth in nutrient rich 
broth. 
From Figure 4-12, the disturbance of bacteria growth from the standard bacteria control 
growth can be seen to be in a manner similar to that predicted and depicted in Figure 4-10, 
indicating the desired response has been achieved. Further confirmation of this result would 
be beneficial, and could be achieved using comparative bacterial strains that are both 
susceptible and resistant to Dox HCl. In addition to this the incorporation of Dox HCl into the 
5(6)-CF dye prior to encapsulation into vesicles would allow the progress to be monitored 
based on a fluorescence intensity assay. These results confirm the reported results relating to 
Dox HCl encapsulation in vesicles in the literature.
36
 It should be noted that a variation on 
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this system has already been commercialised; Avanti Polar Lipids (APL) manufacture a 
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Chapter 5 Dressing prototypes 
The creation of a prototype delivery system to ensure distribution of active-agent containing 
vesicles to a wound interface will need to fulfil certain requirements. These requirements 
include; good biocompatibility with the host – especially at the site of damage, an ability to 
provide a stabilising environment to the vesicles, and a network that ensures the released 
agents can diffuse out of the vesicles following lysis. In relation to this, the network must 
contain channels of a sufficient size as to allow bacteria and toxins to penetrate without 
actively promoting bacterial colonisation. These properties are in addition to those discussed 
in 1.3.5 Burn wound treatment protocol, where qualities such as a lack of adhesion to the 
wound bed, pain free application and removal, absorbency, antimicrobial activity, availability 
in a range of sizes, minimised healing time, decreased frequency of dressing change, reduced 




5.1 Active agent delivery using vesicles 
The utilisation of vesicles for the systemic or localised administration of a drug often faces 
challenges relating to controlled release. Mapping of pharmacokinetics can determine the 
drug activity profile; however bio-distribution is more difficult to control and assess.
2
 If 
delivery of the active agent to the required site is not achieved, there is the potential problem 
of toxic side effects at alternative sites, resulting in secondary complications. The use of 
mechanical devices can alter the pharmacokinetics, but does not influence bio-distribution to 
any large extent. However, the use of particulate drug carriers, such as vesicles; can have a 
positive effect. The use of particulate drug carriers as a drug delivery system (DDS) has been 
investigated successfully for a variety of drugs. These have been found to contain an 






As previously investigated and discussed in chapter 3, the morphology of vesicles; with 
relation to stability, reactivity, functionality and membrane permeability, is dependent on the 
bilayer composition and localised environmental conditions. An example of this is the use of 
large unilamellar vesicles (LUVs), between 50 to 200 nm, in systemic drug administration. 




As discussed in 3.1.2 Intelligent vesicles, the coating of a vesicle membrane surface with 
inert hydrophilic polymers, such as polyethylene glycol, has been shown to improve the 
biological stability and circulation time in vivo.
5
 As the efficiency in drug encapsulation has 
improved, techniques have been developed that allow ‘remote loading’ of preformed vesicles 
with drug molecules using gradients,
6
 primarily based either on pH or ammonium sulphate.
6, 7
 
The formulation of deliverable vesicles can be accomplished through incorporation into a 
solution, dry powder, aerosol, cream or lotion. As a result of this a wide range of 
administration routes can be considered. The administration of potent drugs through 
encapsulation in vesicles, either orally or externally, has proven popular, with reported uses 
including the stimulation of immune response and vaccination, treatment of infectious 
diseases, cancer therapy, and gene therapy.
8
 The topical delivery of vesicles containing active 
agents; incorporated within gels, creams and attached to medical dressings, has been 
continually developed, however if penetration of delivered active agents through the skin 
barrier is desired this can prove problematic. 
 
5.2 Burn dressings 
Globally, there are large variations between the specific methods of burn treatment and 
dressing utilisation within burn treatment centres. There is no ideal definitive dressing or 
treatment exists that fulfils all of the desired healing traits. There is insufficient data, limited 
in both quantity and methodological quantity, to support recommendation of a specific 
dressing as a treatment for all burns, and so many different types exist. Burn dressings can be 
divided into two categories: open methods, consisting of topically applied antimicrobials, and 
closed methods, which use occlusive dressings.
9
 
The performance of occlusive dressings, with regard to promoting healing and minimising 
discomfort and infection, used in the treatment of superficial and partial thickness burns, 
were analysed by the Cochrane Review.
10
 This review included hydrocolloid dressings, 
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polyurethane film dressings, hydrogel dressings, silicon coated nylon dressings, biosynthetic 
skin substitute dressings, antimicrobial (silver and iodine containing) dressings, fibre 
dressings and wound dressing pads.  
This investigation will focus on the development of an open topical dressing treatment, 
utilising biocompatible hydrogels for the incorporation and delivery of vesicles containing an 
active agent to a wound. 
5.3 Open topical wound dressings 
The topical open delivery of active agents via hydrogels, ointments, emulsions and creams to 
a specified site is commonly utilised in the management of skin related problems such as 
acne, eczema and psoriasis.  
Within burn injuries, traditional open topical dressings, for example silver sulfadiazine (SSD) 
creams have been used since the late 1960’s to minimize infection. SSD can be applied to a 
wound in combination with a paraffin/cotton wool layer dressing; however this system has 
not been without its problems. Issues have arisen from dressing adherence to the wound
11
 and 
a frequent requirement for dressing changes, both of which cause trauma to any re-
epithelialisation occurring; resulting in delays to the healing process. In the case of SSD 
cream there have been related reported toxic effects on regenerating keratinocytes; increasing 
the scarring damage, ensuring that its use has been discouraged.
12
  
Despite this, there is scope for development of an active agent-in-vesicle-in-topical-delivery 
system for applications in burn injuries. Importantly, within this investigation the passive 
diffusion of the 5(6)-CF (active agent) from within the vesicle can be investigated to indicate 
the membrane integrity during dispersion in the different potential delivery mediums.  
 
5.4 Delivery medium  
The delivery medium must be able to not only provide stability to the vesicles, but also 
provide a network through which the active agents can diffuse. Prior to this, adequate 
penetration of bacterial toxins must be possible. Hydrogel formulations may provide an ideal 





Hydrogels are water-swollen, superabsorbent polymers that can form cross-linked networks 
of structures based on hydrophilic homopolymers. The cross-links allow formation of swollen 
networks, and can be formed from covalent or ionic bonds, or weaker bonds, such as van der 
Waals forces and hydrogen bonds. Preparation of these networks can be achieved through 
chemical cross-linking, photo-polymerisation or irradiative cross-linking. 
The most efficient water absorbers are polymers that carry dissociated, ionic functional 
groups. Hydrogels absorb water through diffusion; forcing the polymer particles to move in 
an opposing direction to that of the water molecules. This disturbance elongates the chain and 
a proportional relationship exists between disturbance and water diffusion. The equilibrium 
reached between water concentration inside and outside the particle depends on the polymer 
structure and the liquid being absorbed. 
Diffusion is described by Fick’s law, Equation 5-1, relating the diffusional flow rate f to the 
concentration gradient ∆c/∆x of the diffusing substance in the sample, where f is the flow rate 
in the x direction, A is the cross-sectional area of the sample and D is the diffusion constant. 






    
  
  
 Equation 5-1 
The physical behaviour of a hydrogel is dependent on its equilibrium and dynamic swelling 
behaviour in water; however the localised environment can also have an effect. 
Environmentally responsive materials show drastic changes in their swelling ratio as a 
consequence of pH, temperature, ionic strength, nature and composition of the swelling agent 




5.4.2 Prototype hydrogels 
As part of prototype development many different hydrogel delivery matrices were 
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Table 5-1. The different hydrogel mediums investigated as potential vesicle delivery systems 
From preliminary formulations and initial vesicle stability investigations four of these 
different hydrogel mediums indicated the potential to act as an appropriate medium for the 
delivery of vesicles, whilst maintaining a structure appropriate for potential application to 
skin. These were gelatin, Carbopol 981P NF (C981), hyproxypropylmethylcellulose 
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(Hypromellose, HM) and agarose. Initially, osmotic pressure measurements were obtained 
and compared to the osmolality of the three stabilised and sensitive vesicles formulated in 
Chapter 3, to aid determination of longer term compatibility. 
 
5.5 Osmosis 
Osmosis is conventionally defined as the net movement of water across a selectively 
permeable membrane. This is driven by a difference in osmotic pressure across the 
membrane, from a region of low osmotic pressure to a region of high osmotic pressure.  
The osmotic pressure of a system is determined by the total number of particles, regardless of 
the molecular nature, and so is dependent on the degree of dissociation. Dissociation can be 
incomplete; some association between particles may exist, and this deviation from ‘ideal’ 
behaviour is accounted for using the osmotic coefficient. 
The importance of osmosis and osmotic pressure must be taken into account when 
considering the suitability of solutions for storage or delivery of vesicles. Osmometry can be 
used to measure the concentration of particles in a solution; the osmolar concentration,
42
 and 
can be expressed as osmolarity or osmolality. These terms are often confused with each other, 
and hence require careful distinction, especially within a clinical environment.
43
 Osmolarity 
is a measure of the mmol/L of particles in a sample solution, and osmolality is a measure of 





Dissolving a solute in a solvent will increase the osmotic pressure and boiling point, and 
decrease the vapour pressure and freezing point. These colligative properties can all be used 
individually to measure the osmolality, however the most common method is freezing point 
depression, and this was utilised within this project. As discussed in chapter 2, the freezing 
point depression of a sample can be compared against pure water to give the osmotic 
concentration. Pure water freezes at 0 °C; an aqueous undissociated ideal solution with an 




5.5.2 Osmolality and vesicles 
Osmolality provides a measurement of the number of milliosmoles/kg (mOsm/kg) of solvent 
present, and hence gives an indication of the compatibility between the vesicle and the 
hydrogel system. It is integral to the stability of the vesicles that the osmolality of the vesicles 
within the solution they are synthesised in be similar to the storage or topical gel matrix 
osmolality. If a large difference exists, diffusion of water can occur either into or out of the 
vesicles, through the semi permeable phospholipid membrane, causing the vesicles to burst as 
a result of osmotic pressure.  
The osmotic pressure values of the three stable vesicle candidates, discussed previously, were 
measured using a Löser Micro-Osmometer Type 15. These values were compared to those 
obtained for bacterial growth mediums (LB and TSB), SimF, and the four promising 

















TCDA-DS 215 0.88 Gelatin 224 5.24 
DOPC-DS 221 0.33 C981 338 1.45 
DSPG-DP 219 2.00 Hypromellose 224 0.88 
HEPES 211 1.73 Agarose 230 1.76 
LB 387 0.45 SimF 286 0.88 




Table 5-2. The osmotic pressure of the vesicles, HEPES buffer, different hydrogels, growth 
mediums and SimF (mOsm/kg H2O).  
The osmolality values of the vesicle and hydrogel systems give an indication of the 
compatibility between the systems, and from these values osmotic pressure ratios can be 
calculated, Table 5-3. A value close to 1 indicates a higher likelihood of compatibility 
between vesicle and hydrogel. 
 
 
TCDA-DS DOPC-DS DSPG-DP 
HEPES 1.02 (± 0.004) 1.05 (± 0.002) 1.04 (± 0.010) 
Gelatin 0.960 (± 0.005) 0.984 (± 0.002) 0.977 (± 0.01) 
C981 0.638 (± 0.003) 0.654 (± 0.001) 0.649 (± 0.006) 
Hypromellose 0.960 (± 0.004) 0.984 (± 0.002) 0.976 (± 0.009) 
Agarose 0.938 (± 0.004) 0.961 (± 0.002) 0.954(± 0.009) 
LB 1.80 (±3 x 10
-5
) 1.751 (±4 x 10
-6
) 1.767 (±0.002) 
TSB 1.446 (±0.001) 1.474 (±0.002) 1.420 (±0.002) 
SimF 1.330 (±0.004) 1.294 (±0.004) 1.355 (±0.004) 
Table 5-3. The osmolality ratio values of the vesicles in each of the hydrogels, growth media 
and SimF, based on the ratio of the osmotic pressure (mOsm/kg H2O) of each vesicle type 
against each solution. A value close to 1 is optimal.  
From the osmotic pressure ratio values calculated in Table 5-3, the gelatin, hypromellose and 
agarose hydrogel systems indicate that good compatibility could be achieved for storage and 
delivery of the vesicles. However, osmotic pressure ratios calculated for the C981 hydrogel 
indicate that this system is likely to be the least compatible hydrogel for storage and delivery 
of vesicles.  
 
5.6 Vesicles in hydrogels 
Following on from osmolality measurements, the four hydrogels, each with known 
applications at biological interfaces and formation at favourable pH values, were incubated 
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with each of the three stabilised vesicle candidates. An example of a vesicle candidate 
(DSPG-DP) in one of the hydrogels (C981) with and without addition of a lytic agent is 
depicted in Figure 5-1. 
 
Figure 5-1. The effect of a lytic agent on vesicles dispersed within a hydrogel (B and D), 
compared to un-lysed vesicles (A and C). Photo taken in white light (A and B) and UV light 
(C and D). 
The stability of the three stabilised, selectively sensitive vesicle candidates, when dispersed in 
different hydrogel based delivery matrixes, was investigated using the same fluorescence 
assay as for stability of vesicles during vesicle composition development in Chapter 3: 14 
days at 37 °C. The results are shown in  
Figure 5-2. Despite the incompatibility and hence predicted induced-vesicle-instability 
indicated by the C981 osmolality ratios, this gel was still formulated as a comparison. 
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Figure 5-2. The effect of hydrogel matrices with each of the three vesicle candidates. After 14 
days at 37 °C, S.aureus RN4282 supernatant was added to measure F100 %, or HEPES as a 
negative control. The supernatant (SN) from S.aureus RN4282 was added to each of the 
vesicle-in-gel or vesicle-in-HEPES systems, with a large increase in fluorescence being the 
desired response after 14 days incubation.  
S.aureus and the RN4282 strain are discussed in detail in chapter 4. Briefly, S.aureus 
RN4282 is a naturally occurring strain that produces and secretes small amounts of 
exoproteins but elevated quantities of TSST.
45
 It is responsible for the systemic toxin 
mediated disease TSS, which can be especially problematic in paediatric burns, making it of 
particular relevance to this investigation.
46
 From Figure 5-2, fluorescence results following 
incubation of the three vesicle candidates within the C981 gel system appear to indicate 
adequate stability after 14 days at 37 °C. This is despite initial predictions that it would 
provide a destabilising environment for the vesicles. However, following addition of SN only 
a small increase in sensitivity (measured through fluorescence) was observed. This could be 
due to the initial rapid destabilisation of vesicles with the released dye being locally quenched 
in the gel matrix, or the formation of a network of poly-acrylic acid cross links that is 
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impenetrable by the lytic toxins in the SN. These results confirm that C981 would not be an 
appropriate delivery matrix for the vesicles. 
The stability response parameter, S (developed in 3.4.1 Stability response parameter), was 
used to calculate the fluorescence intensity ratio between fluorescence after 14 days at 37 °C, 
and the fluorescence after addition of SN (considered maximum fluorescence - F100 %) for 
each of the vesicle-in-hydrogel systems, data displayed in Table 5-4. 
 TCDA-DS DOPC-DS DSPG-DP 
HEPES 2.19 (±0.05) 7.96 (±0.08) 1.71 (±0.03) 
Gelatin 2.57 (±0.06) 2.62 (±0.16) 3.08 (±0.03) 
C981 1.47 (±0.23) 1.51 (±0.06) 2.48 (±0.09) 
HM 1.42 (±0.12) 3.91 (±0.13) 1.92 (±0.11) 
Agarose 2.04 (±0.18) 2.05 (±0.59) 2.4 (±0.19) 
Table 5-4. The stability response parameter, S, for each of the vesicle-in-gel systems, with 
lysis after 14 days at 37 °C following addition of supernatant from S.aureus RN4282 (100 
minutes incubation).  
The fluorescence results depicted in Figure 5-2, and the corresponding stability response 
parameter, S in Table 5-4, can be used to clearly indicate which vesicle and hydrogel systems 
are compatible. The DSPG-DP vesicle had an increased stability in each of the hydrogels, 
with the best stabilisation-followed-by-response profile being measured in gelatin. The 
DOPC-DS vesicles have demonstrated favourable stability followed by response in the 
gelatin and agarose hydrogel, with the best profile being measured in HM. This could be 
hypothesised to be due to the formation of stabilising lipid and cholesterol rafts, which allow 
vesicle membranes to exist concurrently in gel and liquid forms.
47
 Comparatively with the 
other vesicle compositions, and the vesicle in HEPES buffer, the stability of TCDA-DS 
vesicles in each of the hydrogels was not favourable. 
The rheology of the hydrogels can differ at elevated temperature, as observed by the fluid 
‘sticky’ natures of C981 and HM at 37 °C, as opposed to agarose, which does not display 
‘sticky’ properties. Agarose in this formulation produces a product which has a solid-like 
viscosity, and this is important in the engineering of prototypes, where a firmer hydrogel will 
be preferred for ease of fabrication. Despite the favourable stability and sensitivity of vesicles 
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in gelatin, it can occasionally be unfavoured in prototyping, as a result of its animal 
derivitisation. This can make the related regulatory landscape with regard to its use in 
medical devices complicated and problematic. 
Following on from these results, and for further indicative information about the stability of 
the vesicles over the 14 day period, each of the three vesicle candidates were incubated in 
agarose gel at 37 °C and fluorescence intensity measurements were obtained every three 
days. The passive leakage assay of the vesicles is shown in Figure 5-3, where it can be seen 
that the dye is slowly passively released by all three vesicle candidates into the agarose gel.  

































Figure 5-3. The change in fluorescence of three stable vesicle candidates in agarose gel at 37 
°C over 14 days, followed by addition of S.aureus RN4282 supernatant.  
The diffusion of the dye over time indicates that this hydrogel system would not be suitable 
for the delivery of vesicles to a wound. However, it should be noted that a 2 fold increase in 
fluorescence can still be measured following addition of the SN after 14 days; equivalent to 
an S value of approximately 2 for each vesicle-hydrogel system. This relative doubling in 
fluorescence should be observable above the pre-lysed fluorescence intensity, ensuring that 
pathogenic bacteria and toxin presence can be identified. Despite this the inherent instability 




5.7 Fluorescence response versus bacteria count 
On application to a wound it is important to ensure that the signalling-dressing will be able to 
indicate pathogenic bacteria presence at the quantity that it will be at within a wound 
environment. It is therefore important to know how much bacteria is required for a response 
to be elucidated. However, there are many difficulties associated with obtaining this value, 
and this is for a variety of reasons. One primary reason for this is the difference between 
different species and strains of bacteria, and hence the synthesis time taken, amount and 
virulence of the toxins that they produce. This variance is widely acknowledged.
48
 Bioassays 
exist for measuring bacteria and enzyme toxicity, 
49
 and this has been the subject of intense 
investigations within the group (W. D. Jamieson – MRSA paper in preparation). A further 
reason for the variance is the imbalance of bacteria present.
50
 Uncontrollable localisation of 
bacterial colonisation within a wound, relating to the formation of patches of high densities of 
bacterial cells; biofilms, and patches of low densities of bacterial cells, can exist. This will 
have an effect on localised toxin production, and hence the lysis of vesicles in the dressing. 




colony forming units per ml (cfu/ml) of 
pathogenic bacteria (based on a small selection of strains) is required for a lytic response of 
the vesicles to be detected. 
 
5.8 Dressing prototypes – conclusion 
Four topical open hydrogel dressings have been investigated, with a focus on their ability to 
provide a stabilising environment (through the minimisation of passive leakage) for vesicles, 
whilst ensuring that sensitivity to pathogenic toxins is maintained. Three of the four hydrogel 
systems, namely gelatin, hypromellose and agarose, have indicated some compatibility with 
the vesicle candidates and have achieved the required sensitivity profile. However, the fourth 
hydrogel, C981, has proven insufficient at stabilising the vesicle candidates, and this was 
predicted based on osmolality data, and measured through the fluorescence intensity assay.  
The creation of prototype vesicle-in-hydrogel dipped fabrics could be developed based on the 
successful formulations created here, shown in Figure 5-4. This could potentially allow 
formation of occlusive closed dressings, and consequentially an alternative delivery method 




Figure 5-4. Representative image of hydrogel dressing embedded with vesicles. The dressing 
on the left is a control, and the dressing on the right is a dressing treated with the supernatant 
of S.aureus RN4282.
51
 Image acknowledgements to S. Hong.  
In addition to the stability and sensitivity profile required for incorporation of vesicles into a 
topical dressing, there are other important factors that have not been actively considered. 
These include analysing how the vesicle-hydrogel system affects the time required for the 
burn to heal, the number of dressing changes or reapplications required, the level of pain 
associated with application, and the overall cost of the dressing. In addition to this, the 
incidence of infection and whether the dressing will act as a bacterial growth promoter 
requires further investigation. This could be carried out by comparing the growth of bacteria 
in standard broth solutions to bacteria grown in hydrogel solutions, and obtaining cfu/ml 
following plate dilutions. 
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Chapter 6 Vesicle sterilisation  
The control of microbial growth in terms of reducing or eliminating bacterial loading and 
related effects is of huge importance. In some situations the reduction of bacteria, instead of 
complete elimination, is sufficient, for example in washing of fresh food or body surfaces. In 
these situations complete elimination, known as sterilisation, is not attainable or practical. 
Inhibition of microbial growth can be achieved through decontamination or disinfection 
processes. Decontamination involves the removal of contaminating microorganisms and their 
potential nutrients from a material to make it safe to handle. Disinfection involves the 
targeted removal of microorganisms, through the use of specialised chemicals or agents, 
however complete elimination may not be achieved. 
The complete elimination of microorganisms is required for certain applications, for example 
in the sterilisation of biological media, medical equipment and wound dressings. During this 
process all pathogenic cells, viruses and endospores (dormant, highly resistant cellular 
structures utilised for genetic material preservation at times of great stress for some bacterial 
species
1
) are destroyed. Sterilisation in-vivo can be challenging. Bacteriostatic or bactericidal 
agents can be utilised, however these agents must be able to selectively target reduction or 
prevention of bacterial cell growth, whilst causing no harm to host cells. In-vitro sterilisation 
is less challenging, a physical treatment can be applied to a product or device to eliminate 
bacterial loading. 
 
6.1 Medical product sterilisation 
The sterilisation of pharmaceutical products, medical devices and their related packaging is 
very important in controlling and preventing the spread of infection. This can be considered 
especially integral when one considers that the primary target users of these products are 
often immuno-vulnerable patients.  
It is important to note that if during the sterilisation process of a medical product even one in 
a billion organisms survives, there is the likelihood of rapid multiplication and re-
colonisation. However, there are often difficulties in obtaining absolute sterilisation as a 
result of the variations in resistance to chemical and physical sterilisation methods of 
microorganisms of different species, and even of the same species. The effect of sterilisation 
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on the stability of vesicles was investigated using different physical decontamination 
methods. 
 
6.2 Physical antimicrobial control methods 
The decontamination, disinfection and sterilisation of materials can be achieved using a 
variety of physical methods. These include sterilisation by applying radiation (particle or 
electromagnetic), increasing the temperature (heat), filtration (micro-porous membranes) and 
treatment with low temperature plasma. The sterilisation of vesicles has been investigated 
using the first three of these techniques. Additionally, in chapter 8 the application of low 
temperature plasma onto vesicles (within a sensor) for an alternative application is 
investigated. 
 
6.3 Radiation Sterilisation 
The processing potential of radiation was first investigated in the 1950s using electron beam 
radiation. Inconsistencies produced from the equipment used meant that this method was 
abandoned until the advent of the use of cobalt 60 (
60
Co) isotope in the 1960s. Following 
further developments and improved equipment there are now two primary means of radiation 
utilised, namely electron beam and gamma. The radiation effect may be classified into two 
groups, particle and electromagnetic. The different types of radiation in the electromagnetic 
spectrum can transfer the energy of a photon into characteristic ionisations in or near a 
biological target, resulting in bactericidal effects, discussed below. The term cold 
sterilisation, where there is no appreciable increase in temperature, has been coined as a 




6.3.1 Electromagnetic radiation 
Radiation based sterilisation within this project was carried out using electromagnetic 
radiation. There are four possible types generally utilised for the sterilisation of materials; 
microwave, ultra violet, gamma and x-rays. The bactericidal effects are identical in their 
nature, but differ in origin, and are caused by absorption of high-energy radiation, resulting in 
ionisation, production of free radicals, and activation of molecules.  
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The primary bactericidal effect from the absorption of high energy electromagnetic radiation 
is the ionisation of the material components. This is caused by direct or indirect interactions. 
Direct interactions involve charged particles dislodging ions and atomic particles, whereas 
indirect interactions involve photon interactions with atoms, causing electrons to be ejected. 
This ionisation results in the transfer of an atom or molecule from its ground state to a 
charged or excited state, which alters the exposed materials properties following treatment. It 
is important to note that the treatment of a material by radiation is not uniform; not all 
sections of a material are equally subjected to the ionising radiation energy. Ionisation 
radiation is discrete, and can therefore cause localised areas of intense treatment compared to 
surrounding areas. This can result in the secondary production of free radicals and excited 
atoms, which can, if they contain sufficient energy, continue to ionise and excite adjacent 
atoms. The process of breaking bonds and the formation of free radicals (known as excitation 





6.3.2 Effect of radiation on biological material 
The effects of radiation damage on microorganisms is likely to be through a wide variety of 
physical and biochemical reactions, however the primary loss of viability of the cell is 
reportedly due to intracellular DNA degradation.
3
 A correlation of radiation sensitivity to 
chromosome size, by Sparrow et al., has concluded that the larger the chromosome volume 
the more sensitive the organism is to radiation damage.
4
 Although, it is worth noting that the 
differences in apparent DNA sensitivity to radiation damage may be the result of some 
organisms’ ability to heal its DNA, as opposed to an inherent resistance to radiation damage.5 
The survival of a microorganism following treatment with radiation is defined by its’ ability 
to reproduce significantly in broth, or form colonies on a suitable nutrient containing 
medium. This potential for survival and reproduction occurs in geometric progression, shown 
in Figure 6-1. This means that the same fraction of organisms is inactivated following 




Figure 6-1. Ionising radiation survival curves representative of different bacteria, following 
treatment with 
60
Co and bacteria recovery.
6
  
A decrease in the initial population of an organism by 1 log is known as D10. This can be 
calculated by the straight line section of a survival graph, assuming exponential inactivation 
is taking place, using Equation 6-1 and Equation 6-2:  
           
 
 
 Equation 6-1 
      
    
                 
 Equation 6-2 
        is the most probable number of surving organisms per unit tested, n is the number of 
organisms, and q is the number of units that were succesfully sterilised. 
 
6.3.3 Radiation resistance  
The radiation resistance of a microorganism can be increased or decreased by altering the 
localised environment of the species during the ionisation process. These variations can 
include altering the atmosphere, adding protectors or sensitizers, and changing the 
temperature, water content or dose rate. An example environmental alteration could be the 
provision of an anaerobic atmosphere; which could decrease the resistance of an organism to 
radiation damage. 
Determination of the minimum required sterilisation dose for complete elimination of an 
organism from a material is not only dependent upon the organisms’ inherent resistance to 
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radiation damage. Other factors, such as the quantity of the bioburden present in the first 
place and the environmental conditions surrounding it have an effect. For example, presence 
of a support medium, geographic location, product design and size can all influence the 
amount of radiation required for complete elimination. 
 
6.3.4 Measurement of absorbed dose 
The absorbed dose is the fundamental radiation parameter used to measure the amount of 
energy deposited on a material, measured in Gray (Gy), with conversions given in Table 6-1. 
This measurement typically relates to absorbed dose in water, based on density similarities 
between a sample and water. The dose equivalent, measured in sievert and rem, can be used 
to express the quantity of dose used during radiation protection. 
Unit of measure for sterilisation or 
pasteurization 
Units of measure for personal 
safety 
1 Gray (Gy) = 1 joule/kg 1 Sievert (Sv) = 1 joule/kg 
1 Gray (Gy) = 10
2
 rad 1 Sievert (Sv) = 1 rem 
1 kilogray (kGy) = 10
5 
rad  
Table 6-1. Radiation measurement units and conversions 
The general absorbed dose required for achieving sterilisation, as well as other radiation-
processing applications is given in Figure 6-2: 
 





6.3.5 Gamma radiation 
The industrial treatment of a substance with gamma radiation requires specialised facilities. 
This includes a radiation shield, an isotope source, the facilities for safe storage when the 
isotope is not in use, and a method of transporting a sample through the radiation process. 
The requirement for this complex set up is as a result of the penetrating depth of gamma rays. 
Radiation of this type can pass through an organism, aluminium, and thin layers of lead and 
concrete, hence a radiation shield is commonly composed of concrete - with a thickness of 
nearly two metres.  
 
6.3.6 Gamma radiation of vesicles 
The use of gamma radiation on phospholipid vesicles has been a widely investigated 
technique for modelling the effect of irradiation on cells and food. In addition to this, there is 
precedence for the sterilisation of vesicle-based samples.
7, 8
  
The gamma sterilisation of different vesicle compositions was carried out using a Gammacell 
GC1000 with a Caesium 137 (
137
Cs) radioisotope source. 
137
Cs is a nuclear reactor by-
product that can be separated from nuclear waste, following which it can be protectively 
encapsulated. The radioisotope has a half-life of 30.1 years, and decay occurs to yield barium 
137 (
137Ba) through the emission of two beta (β) particles and one low-energy gamma (γ) ray, 
shown in Figure 6-3. 
 
 
Figure 6-3. The radiation decay of 
137
Cs to produce 
137Ba, through the emission of two β 
particles and one γ ray.  
The 
137
Cs source was used at a calibration of 7.713 Gy for 58 hours to give a sterilising 
gamma radiation dose of 25 kGy. This was carried out by Dr J. Sharpe at the Blonde 
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McIndoe Research Centre, UK. This sterilising dose should be sufficient to ensure absolute 
sterilisation, according to Figure 6-2, and the absorbed dose requirements. 
Initial investigations involved the sending of stable vesicle compositions containing quenched 
5(6)-CF, formulated as discussed in chapter 3, for gamma sterilisation treatment. On receipt 
of the vesicles back from the gamma treatment process it was possible to observe a colour 
difference between the vesicles that had been sterilised and those that had not, Figure 6-4.  
 
Figure 6-4. The observable effect of gamma sterilisation on vesicles containing self-quenched 
5(6)-CF. 
This colour change did not appear to indicate vesicle lysis. There was no significant 
difference in fluorescence intensity measurements between the gamma sterilised and non-
sterilised vesicles. However the effect of this colour change on the vesicle stability long term 
and the efficiency of the dye to act as a signalling agent following treatment required further 
investigation.  
In parallel with the radiated sample, control vesicles were sent to accompany the radiated 
sample to ensure exact mimicry of conditions aside from the gamma treatment. Both of these 
were then compared to the same vesicles that had been kept at room temperature (~20 °C) 
within the lab. The sensitivity and stability results for the vesicle named DSPG-DP is given in 
Figure 6-5, following addition of bacterial supernatant. The bacterial organisms utilised were 
those utilised previously within this body of work (namely P.aeruginosa PAO1, S.aureus 
MSSA 476 and E.coli DH5α) added in a 1:1 ratio. 
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Figure 6-5. The effect of gamma radiation on DSPG-DP vesicles. The photograph and 
fluorescence intensity graph indicates good observable and measurable fluorescence of all 
vesicles treated with lytic agents (M = MSSA 476, P = PAO1, T = triton), compared to the 
low fluorescence of all vesicles with non-lytic agents (H = HEPES, E = DH5α). 
Initial results indicated good stability of the vesicles to gamma sterilisation treatment, with 
maintenance of susceptibility to external pathogenic stimulus. Interestingly, the susceptibility 
of the treated vesicles compared to non-treated vesicles to MSSA 476 supernatant was 
increased. This result was also measured for DPPG-DP vesicles, shown in SI-Figure 4.  
 
6.3.7 Vesicle stability – radiation sterilisation 
Damage caused to the phospholipids and other vesicle components by the gamma radiation 
could be a result of the interaction and breakage of bilayer component bonds. This could have 
been achieved through direct or indirect rupture (secondary species activated by the gamma 
radiation e.g. radicals). This could lead to the reforming of the acyl chain without any 
physical changes and cross-linking and dimerisation between aligned structures. The 
irreparable breakage of bonds, such as formation of the dehydrogenation product 
phosphatidic acid; causing a physical change and a decrease in vesicle stability could also be 
occurring. 
Following gamma radiation of phospholipid vesicles, Zuidam et al. reported a size-dependent 
decrease in pH and a linear decrease in vesicle concentration.
7
 Hence, additional information 
about concentration count, pH and vesicle sizing following gamma treatment would be 
beneficial in aiding understanding of how the radiation affects the vesicle stability. Initial 
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results obtained indicate that the application of gamma radiation could provide a suitable 
sterilising technique for treatment of vesicles.  
 
6.4 Heat sterilisation 
The use of heat to obtain materials that are bioburden-free is perhaps the oldest and best-
recognised sterilisation technique. Sterilisation using this method can be achieved with moist 
heat – a fast process utilising saturated steam or boiling water, or with dry heat – a slower, 
higher temperature process with the benefit of increased permeability. The death of bacterial 
cells by thermal treatment is exponential, progressing through a first-order reaction 
mechanism which can be defined in Equation 6-3: 
        
    Equation 6-3 
Where No is the starting number of a population, Nt is the number surviving at any time, t, 





6.4.1 Thermal resistance 
The presence of heat resistant bacterial strains can cause deviations from the expected linear 
logarithmic nature of the survival curve. Often, an inactivation energy is required to initiate 
the destruction of microorganisms. The extent of dependency on this varies depending on the 
innate heat resistance of the strain, the temperature of the heat treatment applied to the 
sample, the local growth media conditions, such as pH and ion concentrations, and the initial 
incubation temperature of the sample. In addition to this the thermal resistance of a bacterial 




6.4.2 Moist (steam) sterilisation 
Steam sterilisation is an efficient technique for achieving bacterial spore elimination within 
short time frames, hence related equipment for it can commonly be found in hospitals, 
research environments and industrial facilities. This equipment commonly takes the form of 
an autoclave machine, capable of sterilising equipment through the application of high 
pressure saturated steam at ~120 °C for < 20 minutes. Despite its efficiency, problems can 
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arise from the deleterious effects relating to the rate of material degradation relative to the 
rate of biological inactivation. For example, proteins, and in the case of vesicles; 
carbohydrates and active encapsulated agents could suffer from degradation or 
caramelisation. It is also possible that undesired products with the potential to cause toxic 
side effects can form.
2 
 
6.4.3 Thermal treatment of vesicles
 
The stability of vesicles to thermal moist sterilisation treatment was carried out on three 
stable vesicle candidates containing 5(6)-CF, developed in chapter 3, namely DSPG-DP, 
DOPC-DS and TCDA-DS. This involved heating each of the vesicle samples up to 80 °C for 
10 minutes, 30 minutes and 60 minutes, and comparing the fluorescence response obtained 
following addition of the lytic surfactant triton and the control HEPES buffer. In addition to 
this, a comparison could be made with vesicle samples that were sterilised using a standard 
autoclave machine, with a treatment time of 60 minutes at 120 °C. The results for these 























































































































Figure 6-6. Heat sterilisation of three vesicle types; carried out at 80 °C for 10, 30 and 60 
minutes, and compared to control (untreated) vesicles, and autoclaving (120 °C, 60 minutes), 
all with HEPES and Triton; where A), B) and C) are fluorescence intensity measurement 
graphs of DSPG-DP, TCDA-DS, and DOPC-DS vesicles respectively.  
Total passive release of the dye or lysis of all vesicles present in each of the three samples 
was measured following sterilisation through autoclave treatment. Interestingly, the presence 
of the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) at 2 mol %, and even, 
to some extent, 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac glycerol) (sodium salt) (DSPG) 
at 10 mol % has decreased the passive release of the dye at 80 °C, compared to the 10,12-
tricosadiynoic acid (TCDA). 
 
6.4.4 Vesicle stability – thermal sterilisation 
As discussed in 3.1.6 Bilayer fluidity, phospholipids found within bilayers can exist in a low-
temperature solid-ordered (crystalline) phase or a higher temperature fluid-disordered (gel) 
phase. The temperature at which a transition occurs from one phase to the other is known as 
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the phase transition temperature Tc. The Tc and hence the creation of phases can be tailored 
depending on the phospholipid selected. Passive leakage of internal agents from a vesicle is 
at its greatest at temperatures around the Tc, due to the coexistence of two phases, and the 
resulting defects between the boundaries.
9
 From what is known and reported about 
phospholipid membrane bilayer susceptibility to degradation around the crystalline-to-gel 
transition temperature (Tc), the increased fluorescence response following heat treatment 
from all vesicle candidates was to be expected.  
The extent of passive leakage of internal agent from the vesicle compositions indicates that 
thermal sterilisation of vesicles through moist heat methods would not be compatible for 
stability of vesicles. It is also possible to conclude from this that sterilisation through dry heat 
would not be compatible for maintaining the stability of the vesicles. 
 
6.5 Filter sterilisation 
The development of commercial filtration membranes for the removal of bacterial 
contamination from liquids began in 1922, leading to the introduction and manufacture of 
membranes in two pore sizes: 0.45 µm and 0.80 µm. Prior to this, fibrous asbestos filter pads 
(Seitz filters), where separation was achieved based on absorption of bacteria to inner porous 
structure and random entrapment, were utilised. The efficiency of these commercial filtration 
membranes was questioned in the late 1960’s following the discovery of a pseudomonas 
species in a post-sterilised solution, leading to the introduction of 0.22 µm and eventually 0.1 
µm filters. 
Sterile filtration methods are employed extensively in the production of particle and bacteria 
free medical solutions. Although, this has proved problematic as the physiochemical and 
biological complexity of medical solutions has increased. There has hence been an elevated 
requirement for validation of filter efficiency against bacterial species, high standards of 
operation and activity-testing of the obtained sterilised ample.  
 
6.5.1 Filtration process 
The filter sterilisation process involves passing a mixture of fluids and particles through a 
porous medium capable of trapping the solids. This is achieved either mechanically or 
randomly, using a surface, depth or screen filter. The cost efficiency of filters used 
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individually to obtain a high volume of size-exclusion-solution is not favourable, hence a 
combination of filters is often utilised. Depth filters have a high dirt-handling capacity; large 
quantities of contaminants can be trapped in a torturous maze of flow channels. Surface 
filters trap large particles at the surface of the polymeric microfiber matrix; with some 
trapping of smaller particles occurring within the membrane matrix. Screen filters allow 




6.5.2 Filter contamination 
There are three possible sources of contamination to a filter membrane from a solution: 
dissolved impurities, suspended particles and microorganisms. Dissolved impurities can be 
inorganic (ionic) or organic particles and solid particles can be all manner of things, including 
colloidal solids, metals, cotton, dust and lint. However, it is the microorganisms that can 
prove most problematic; dead they can be responsible for premature filter blockages, and 
alive they can multiply at logarithmic rates, causing blockage and overburden of the filters. 
The extent of these contamination difficulties can be managed through manufacture area and 





6.5.3 Filter sterilisation of vesicles 
Filter sterilisation involved pressurising the vesicles through 0.1, 0.22 and 0.45 µm filter 
membranes. The 0.22 and 0.45 µm filter membranes, manufactured by Merck Millipore, were 
composed of mixed cellulose esters, and the 0.1 µm filter (also Merck Millipore) was 
composed of polyvinylidene fluoride (PVDF). Each of the filters had a process volume 
capability of 100 ml. 
The stability of vesicles to filter sterilisation treatment was carried out on three vesicle 
candidates containing 5(6)-CF, formulated in chapter 3 - Vesicle development - stability, 
namely DSPG-DP, DOPC-DS and TCDA-DS. Each of these vesicles was extruded through a 
100 nm porous membrane during formulation, giving vesicles of between 80 – 120 nm. The 
fluorescence intensity response of filtered vesicles following addition of the lytic surfactant 
triton (discussed in 3.3.5 Vesicle membrane solubilisation – a positive lytic control) and the 
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control HEPES buffer was compared to the same response of non-filtered vesicles, Figure 
6-7. 










































































































 Figure 6-7. Filtration of three vesicle types was carried out with 0.1, 0.22 and 0.45 µm filters, 
and vesicles obtained were compared to control vesicles; all with HEPES and Triton; where 
A), B) and C) are fluorescence intensity measurement graphs of DOPC-DS, DSPG-DP and 
TCDA-DS vesicles respectively; and D) is an actual photograph of the vesicles before and 
after filtration.  
Each of the vesicles were successfully pressurised through the filter membranes, i.e. a sample 
solution was obtained after filtration. Although each of the vesicle types indicated stability to 
sterilisation through a 0.1 µm filter, there was some loss of max-fluorescence on addition of 
triton. This potentially indicates that some of the vesicles are trapped on the filter. Despite 
this, the PVDF provided a favourable membrane material for passage of vesicles through the 
filter when compared to the mixed-cellulose filters. The fluorescence response of TCDA-DS 
and DOPC-DS vesicles following sterilisation with 0.22 and 0.45 µm filters was significantly 
small both with HEPES buffer and triton, indicating that nearly all of the vesicles were 
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trapped within the membrane pores, however this could have been proved definitively using 
DLS measurements. The anionically charged nature of the DSPG lipid (present at 10 mol %) 
can be assumed to be playing a role in ensuring elution of the vesicles through these cellulose 
filters. 
 
6.5.4 Vesicle stability – filter sterilisation 
Phospholipid vesicles are known to be stable to extrusion through nanoporous membranes; a 
process which is carried out during manufacture to ensure unilamellar monodisperse vesicles 
within this investigation. It is possible to conclude from this that vesicles should be stable to 
filtration through pores of 0.1, 0.22 and 0.45 µm. However, the trapping and sticking of some 
vesicle compositions onto certain filter sterilising membrane materials would be costly and 
problematic. This could potentially be overcome by using filter membranes composed of 
materials that would allow the free-flow of vesicles; such as PVDF which showed promising 
delivery of sterilised vesicles at a pore size of 0.1 µm. 
 
6.6 Vesicle sterilisation - conclusions 
Within this investigation, the emphasis was placed upon vesicle stability to sterilisation 
techniques, as opposed to actual sterilising efficiency of the technique employed.  
It is possible to conclude that radiative treatment of vesicles using a 
137
Cs gamma source 
showed excellent potential for ensuring structure of vesicle is maintained without passive 
diffusion of internal agents. The expected response to bacterial supernatant, following 
addition to both gamma-treated and control vesicles, was obtained. However the actual 
fluorescent intensity response of gamma treated vesicles following addition of P.aeruginosa 
supernatant and the surfactant triton was decreased compared to control vesicles i.e. it had a 
lower Fmax. This may be due to the gamma radiation interacting, sequestering and degrading 
the carboxyfluorescein, reducing its maximum fluorescence following unquenching. 
Interestingly, the fluorescent response of gamma treated vesicles following the addition of 
S.aureus MSSA 476 was greater than that measured for the control vesicles, although the 
maximum fluorescence level is still lower than that obtained following addition of the 
aforementioned lytic agents. 
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The thermal treatment of vesicles was unsurprisingly deemed to not be an appropriate 
technique for achieving sterilisation. This was a result of the low crystalline to gel transition 
temperatures of the phospholipids used. Above these temperatures, at the sterilising 
temperatures investigated within this study, passive leakage of the internal agent was 
increased.  
The use of filter sterilisation indicated a promising method towards obtaining bioburden-free 
stable vesicles when utilising membranes composed of PVDF (0.1 µm). The potential 
trapping of vesicles on the mixed cellulose membranes (0.22 and 0.45 µm) was indicated 
from a low fluorescence intensity following pressurisation through the filter. The composition 
of the obtained solution could be further investigated utilising DLS, which would enable 
measurements of the solute/vesicle sizes. Further work could be carried out investigating the 
use of PVDF or other membrane compositions as non-vesicle-trapping matrices at different 
pore sizes. 
Ultimately, the sterilisation of vesicles may be achieved prior to inclusion within, or more 
likely, following incorporation into the dressing. Two alternative sterilisation techniques are 
introduced, and the development of methods towards achieving sterile vesicles during 
formulation are discussed in the following sections. 
 
6.6.1 Alternative sterilisation technologies 
There has been increased interest into the development of low temperature sterilisation 
systems that can yield sterilised materials. An ideal technology would provide reduced 
process times, improved materials compatibility, decreased environmental impact, increased 
capacity and decreased costs. An example of a potential low temperature technique for 
sterilisation is vaporised hydrogen peroxide (vH2O2). This can be applied on its own, or 
alongside gas plasma or ozone and has shown good potential sterilisation of surfaces 
including re-usable metal and non-metal medical devices.
10
 This technique may not be 
appropriate for treatment of vesicles-in-a-dressing due to the high oxidising potential of 
vH2O2. The use of low temperature plasma for inactivation of microorganisms was 
commercialised in the 1990s due to its low toxicological profile, rapid processing time and 
low environmental impact.
2
 This is discussed in more detail in chapter 8 although its 




6.6.2 Alternative solution - solvent free vesicles 
An alternative pathway towards achieving self-sterilised vesicles is through solvent-free 
vesicle methodologies. This process could potentially be considered as self-sterilising, due to 
the high temperatures attained during synthesis.
11
  
The majority of vesicle preparatory methods require volatile organic solvents, such as 
chloroform and methanol, or detergents to solubilise the lipids. Although these residues can 
be minimised, traces of these solvents and detergents may remain in the final vesicle solution 
and potentially contribute to vesicle instability and final product toxicity.
12
 Development of 
methods in which the utilisation of solvents is avoided may prove beneficial, with regard to 
final product cost, toxicity and life cycle. The introduction of a novel method in 2005 by 
Mozafari et al., known as the heating method, fulfils these specifications.
11
 Mozafari et al. 
have since gone on to modify and improve this method, making it scalable and simple, for the 
delivery of plasmid DNA, reported in 2007.
13
 This proposed method was further modified for 
vesicle preparation in a preliminary study for the synthesis of solvent-free vesicles suitable 
for applications within this project. 
The response of solvent-free vesicles to the standard bacteria (S.aureus MSSA 476, 
P.aeruginosa PAO1 and E.coli DH5α bacteria - discussed in 4.2 Bacteria), and the growth of 
each of these bacteria within the solvent-free vesicles is given in Figure 6-8: 
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Figure 6-8. The response of solvent-free vesicles to S.aureus MSSA 476, P.aeruginosa PAO1 




A major difference between the solvent-free and standard-synthesis (normal) vesicle is the 
measured and observable fluorescence response. Although the measured fluorescence 
response given in Figure 6-8 (A) indicates a favourable sensitivity to S.aureus MSSA 476, 
there is no increased response to P.aeruginosa PAO1 and the intensity is not as great as that 
measured for normal vesicles, indicating that further development is required. However, the 
bacteria growth in solvent-free vesicles compared to normal vesicles could be considered 
slightly amplified. This could be due to trace amounts of glycerol, commonly found in 
growth media solutions where it can be utilised by bacteria as a carbon source. Although this 
may not be advantageous within a wound environment, within lab based experiments, this 
could be beneficial. The presence of EDTA within the normal-vesicle buffer solution used 
during manufacture could be problematic in bacteria growth, as it is known to increase 
bacterial membrane permeability and decrease cell viability.
14
 
Further development of this solvent-free methodology could prove advantageous for the 
synthesis of vesicles required on a large scale, or for medical and cosmetic application, with 
the potential self-sterilising aspect proving beneficial.  
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Chapter 7 Vesicle modification 
The importance of modification of vesicle structures to improve both the specificity and 
stability of vesicles has shown massive potential for increasing the applicability of vesicles. 
The development of so called intelligent vesicles, responsive to pH and temperature 
fluctuations, is discussed in detail in chapter 3 (3.1.2 Intelligent vesicles), and investigations 
within this work have yielded vesicles that have proven to be both stable and selectively 
sensitive. The potential scope of vesicles in medical products can be further expanded on 
through development of modifications to these capsules. 
 
7.1 Vesicle modifications 
Desired reactivities and stabilities of vesicles can be achieved through modifications of 
vesicle structure, (see Chapter 3) or through placement within a hydrogel (see Chapter 5); 
both investigated and discussed previously. An alternative approach towards achieving 
stability or altered sensitivity could be through conjugation of the vesicle to removable 
protective agents. The conjugated binding of vesicle bilayers to different capsule forming 
agents could be considered to provide a pseudo-secondary membrane. These coatings could 
be ionically or covalently bound to the vesicle, providing a stabilising environment, until the 
active agent within the vesicle is required.  
An example of such a vesicle modification system that has been widely investigated and 
reported upon is the development of PEGylated vesicles. The PEG is attached to the 
phospholipid head group and forms a stabilising protective coating around the vesicle, which 
aids its permeability, ensures a long-circulating profile in-vivo, and promotes host retention.
1
 
Importantly, under localised pathological conditions within a host, such as acidic pH 
conditions in tumours, the PEG-coating can be readily detached, ensuring delivery of active 
agents from the unprotected vesicle.
2
 
Within this investigation, hyaluronic acid (HA) is utilised to provide a biodegradable capsule 
around the vesicles. The HA can be degraded in the presence of hyaluronidase (HLase) 
enzymes, produced from pathogenic bacteria, depicted in Figure 7-1. Following degradation 
of the capsule, toxins released concurrently from the bacteria can lyse the selectively 




Figure 7-1. A schematic demonstrating the desired effect of vesicles coated with hyaluronic 
acid (HA) in the presence of hyaluronidase (HLase) producing bacteria (e.g. S.aureus). 
Encapsulation of an active agent within the vesicles can be used to indicate the presence of, 
or treat the cause of, infection.  
 
7.1.1 Hyaluronic acid 
Hyaluronic acid (HA), commonly referred to as hyaluronate, is a linear, very high molecular 
weight (average molecular mass from 10000, up to 1.2 million Da) glycosaminoglycan 
copolymer comprised of alternating D-glucuronic acid and N-acetyl-D-glucosamine units, 
shown in Figure 7-2. HA can be found in all connective tissue,
3
 it is naturally occurring; with 
up to 50 % of it being localised in the skin,
4
 and is both hydrophilic and nonimmunogenic. 







Figure 7-2. The copolymers of hyaluronic acid in their β-bond cross-linked form: [α-1,4-D-
glucuronic acid-β-1,3-N-acetyl-D-glucosamine]n  
The application of HA as a scaffold has developed as a result of its unique chemical 
properties. HA is available at a range of molecular weights, achieved by controlled 
degradation with HLase, it has the ability to be remodelled enzymatically in vivo and in the 
presence of specific cell types (e.g. mature cells unique to cartilage - chondrocytes), and it 
has the potential to be functionalised with reactive groups or undergo cross-linking reactions 
to form hydrogels.
6
 In addition to these attributes, HA is innately non-adhesive to cells,
7
 yet 




A primary advantage of using HA to coat the vesicles is its known role in angiogenesis, 
increasing cell motility and proliferation, proven by Trochon et al. using the cell receptor 
CD44, and a monoclonal antibody against CD44, and measuring the stimulating effect of 





Hyaluronidase (HLase) is the general term used to describe enzymes that are able to break 
down HA, and these can generally be divided into three types; hyaluronate-4-
glycanohydrolases, testicularly derived, hyaluronate-3-glycanohydrolases, produced 
primarily by leeches, and bacterial HLases. The first two types degrade HA to form 
tetrasaccharides, whereas bacterial HLases act as endo-N-acetylhexosaminidases; eliminating 




Figure 7-3. Potential sites of action of hyaluronidase on hyaluronic acid.  
HLase is produced by a wide variety of microorganisms; however gram negative organisms 
only produce the enzyme periplasmically, reducing its likelihood of playing a role in 
pathogenesis. As a result of this, it is the HLases produced by gram positive organisms that 
are excreted into the extracellular matrix that are of interest to this investigation. Gram-
positive organisms that are capable of producing HLases include Streptococcus, 
Peptostertococcus, Propionibacterium, Stretomyces, Clostridium and Staphylococcus. Many 
of these HLase excreting strains of bacteria are able to cause infection at a mucosal or skin 




7.1.3 Hyaluronic acid coated vesicles 
The hyaluronic acid was prepared by dissolving 10 mg ml
-1 
in HEPES buffer, followed by 
stirring for 4 hours; resulting in a clear gel with a favourable rheology, which following 
activation was added to relevant vesicles in a 2:1 ratio. The stabilised vesicles TCDA-DS 
developed and discussed in Chapter 3 - Vesicle development - stability, containing the self-
quenched dye 5(6)-CF, were utilised for this investigation; only differing in their size, 
following extrusion through 200 nm membranes. Specific attachment of the HA to the 




7.1.4 Incorporation of stearylamine into vesicles 
For specific HA attachment the TCDA-DS vesicles were modified by the incorporation of 6 
mol % SA; added from a 100 mM stock solution (in CHCl3), at the same point of formulation 
as the other membrane components, followed by the formation of the dehydrated thin film. 
The alignment of the SA is proposed to occur alongside the lipids in the membrane, with 
protrusion of the amine externally from the bilayer to allow attachment to occur, depicted in 
Figure 7-4. 
 
Figure 7-4. The proposed alignment of SA alongside phospholipids in a membrane. The 
amine protrudes outside of the membrane allowing conjugation to the hyaluronic acid in the 
presence of EDC and NHS.  
 
7.1.5 Hyaluronic acid – vesicle coupling 
Coupling of the SA-TCDA-DS vesicles to the HA was achieved using the coupling agents 
ethyl(dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS). The HA 
was first activated by the EDC, followed by addition of the NHS, and finally this was added 





Figure 7-5. Formation of the HA-SA(-vesicle) conjugate, achieved through activation of the 
carboxylic acid moiety of D-glucuronic acid from HA with EDC to form an unstable reactive 
o-acylisourea ester, followed by addition of NHS to form an amine reactive ester that readily 
reacts with SA(-vesicle) to form a HA-SA(-vesicle) conjugate.  
Proof of the formation of specific conjugation of the HA to SA-TCDA-DS vesicles was 
obtained through the use of dynamic light scattering (DLS) size measurements. Standard 
TCDA-DS vesicles were coated with activated HA and the size measurements were 





Figure 7-6. DLS of HA coated vesicles compared to uncoated vesicles. The HA coated 
vesicles are larger in size than their corresponding un-coated vesicles. 
The specific conjugation of HA to SA-TCDA-DS vesicles was evidently achieved, however 
non-specific binding of the HA to the TCDA-DS vesicles appears to be taking place too. This 
effect is probably due to the quaternary amine on the DSPE lipids reacting with the activated 
semi-stable amine reactive NHS ester. 
 
7.1.6 Proof of principle  
The specifically and non-specifically HA conjugated vesicles were compared according to 
their fluorescence response on addition of isolated delta (δ) toxin. δ-toxin is an amphipathic 
α-helical toxin, commonly secreted by S.aureus, which can insert into phospholipid bilayers 
and induce a detergent-like solubilisation of the membrane.
10
 The effect of δ-toxin on the 
coated vesicles was compared to the effect of coated vesicles that have been incubated with 
hyaluronidase (from bovine testes) prior to addition of the δ-toxin, shown in Figure 7-7. 
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Figure 7-7. The effect of δ-toxin with or without HLase on HA coated vesicles (0 % SA – 
non-specifically, 6 % SA – specifically conjugated). Fluorescence intensity is shown prior to 
addition of any agents, and following incubation with δ-toxin for 5 min. 
From Figure 7-7, it can be seen that the presence of HLase increases the susceptibility of the 
HA-coated vesicles to the δ-toxin, resulting in an amplified fluorescence value compared to 
the respective non-HLase treated vesicles of each type. Unsurprisingly, the specific binding 
from the vesicles containing 6 % SA provides a network that is more difficult to penetrate 
and degrade then the non-specifically bound (0 % SA) HA coated vesicles. The diminished 
diffusion of the δ-toxin to the vesicle surface was indicated by a decreased level of maximum 
fluorescence. Following on from the success of this preliminary proof-of-principal 
investigation, the reactivity of the HA-coated vesicles with bacteria strains was investigated. 
 
7.1.7 HA-coated vesicles with bacterial supernatant 
The specifically and non-specifically HA-coated TCDA-DS vesicles were treated with two 
S.aureus strains, a known HLase positive strain MSSA H560, which was first acquired from 
a hospital in Oxford, UK, and a HLase negative strain MRSA ST239µ2. The ST239µ2 is an 
attenuated strain of S.aureus with the same DNA sequence as MRSA TW20 (a highly 
resistant and transmissible strain), although it does not share its level of pathogenicity.
11
 
Hyaluronidase assays, carried out by J. Bean within the group, have indicated the HLase 
negative nature of ST239µ2, of which the data can be found in the SI (SI-Figure 6). 
Interestingly, TW20 is HLase positive. 
The two vesicle types were treated in a similar way to the δ-toxin experiment in the 
preliminary investigation. Supernatant (SN) from the two bacterial strains was incubated with 
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the vesicles, either immediately, or following addition of HLase, and the fluorescence 
response was measured, shown in Figure 7-8. 
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Figure 7-8. The addition of HLase positive (H560) and HLase negative (ST239µ2) bacterial 
SN to HA-coated vesicles, with additional HLase added to each vesicle type.  
Results from Figure 7-8 illustrate that the HLase positive strain MSSA H560 is able to 
diffuse its lytic peptides successfully through the degraded HA capsule, indicated by 
increased fluorescence intensity, without the addition of added HLase. However, following 
addition of extra HLase the fluorescence intensity is amplified, indicating an increasing ease 
of diffusion of the S.aureus lytic peptides through the degraded capsule. 
There is a reported, suspected link between HLase production and amplified toxicity of the 
bacterial strain,
4
 and this is of particular relevance here, where the pathogenic nature of 
ST239µ2 was shown to be not as effective as H560. It would be desirable to have a HLase 
negative strain of bacteria with an increased pathogenicity; however assays within the group 





7.2 Vesicle modifications – conclusions 
The creation of HA-coated vesicles which are responsive to both HLase producing bacteria 
and HLase with δ-toxin was achieved. The incorporation of the 5(6)-CF dye into the vesicles 
ensured that response measurements, based on capsule and vesicle susceptibility to HLase 
and bacterial toxins, could be made.  
The use of specific binding through the incorporation of SA into the vesicle bilayer may help 
to improve the quantity of HA coupled to the vesicle, as suggested by DLS measurements, 
which could be beneficial at a skin interface. However, the non-specifically bound HA, 
presumably conjugated to the quaternary amine of DSPE, provided an alternative coated 
vesicle system. This system had an increased capacity for susceptibility to HA capsule 
degradation with smaller quantities of HLase and therefore lysis from related bacterial lytic 
peptides was more easily achieved.  
Further work into the relevance and applicability of this system could be achieved following 
incorporation of different concentrations of SA into the bilayer; affecting the extent of 
bonding that can occur between the vesicles and the HA. This could affect the degradation 
ability of bacterial HLase and toxins through the coating and the bilayer, effectively 
increasing or decreasing the measured response. In addition to this, other hyaluronidase 
positive and negative bacterial strains could be investigated to increase the scope of this 
system. The stability profile of the vesicles, with different concentrations of SA incorporated, 
both free of- and attached to- HA could be measured using the protocol developed for the 
stability response parameter, introduced in chapter 3. The results from this would give a good 
indication of the possible protective role of a HA coating on vesicles. 
The development of vesicles conjugated to intelligent coatings capable of providing both 
protective and functional properties, achieved through HA-coupling within this investigation, 
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Chapter 8 Microplasma jet treatment of vesicles 
8.1 Plasma healthcare applications 
Plasma has been used as a germicide for sterilisation of medical equipment,
1
 industrial food 
packaging,
2
 and biomaterial devices such as implants.
3
 Advantages of plasma processing over 
alternative treatments include speed and cleanliness of treatment, depending on the gas 
chosen, environmental safety and relatively uniform process results.
4, 5
 Different plasma 
techniques include sputtering and etching, implantation, deposition and spraying.
6
 
Plasma surface modification (PSM) is often utilised for the etching, cross-linking and 
activation of surfaces, especially polymers. The gas composition and plasma conditions, ions, 
electrons, fast neutrals and radicals must be altered according to surface type to minimise 
degradation and aging effects.
7
 Importantly with PSM treatment, the bulk properties of the 







 may be manipulated to suit the application.  
Early medical related reports indicate that the use of plasma at wound interfaces can have 
positive medical applications. This is a result of the bactericidal and fungicidal effects 
resulting from the reactive species, charging reactions, ultraviolet radiation (UVR), optical 
and infrared emissions, and heat.
11
 The use of high temperature plasma to sterilise medical 
equipment in the removal and destruction, cutting and cauterizing of tissue and for cosmetic 
tissue restructuring is fairly well established.
12
 
Atmospheric plasma in treatment at wound interfaces has the potential to have an in vitro 
bactericidal effect on pathogenic bacteria.
13
 The sterilisation technique allows rapid non-
contact decontamination, with the potential for targeted application possible within small 




8.1.1 Plasma – a brief history 
Naturally occurring plasma state material predates the beginning of research into this field. 
The majority of the universe is in the plasma state - solids, liquids and gases are restricted to 
isolated regions. Plasma is now recognised as the key element to understanding the formation 
of magnetic fields in planets, stars and galaxies as well as other cosmic phenomena.
15
 
Commonly recognised and observable examples include stellar galaxies, nebulae, cosmic 
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rays, the sun, the ionosphere and aurora in the upper atmosphere, and lightning and corona 
discharges in the lower atmosphere.
16
 
The beginning of the field of plasma science is often attributed to the Nobel laureate Irving 
Langmuir who, in 1929,
17
 coined the term ‘plasma’ to denote the ionised gas containing equal 
densities of electrons and protons, known as quasineutrality, in the comparatively field-free 
region between the sheaths in an arc discharge tube. Active research into electrical discharges 
had been carried out by prominent physicists including J. J. Thomson, J. S. Townsend and W. 
Crookes in the preceding fifty years. 
Recent advances since the 1960’s and commercialisation of research relating to plasma 
physics have resulted in modifications of surfaces in biological, automotive, aerospace, 
packaging and electronics industries. Cost effective modifications of surfaces, including 
cleaning, ablation, cross-linking and chemical modification,
5
 can be achieved at exposure 






 state of matter 
Plasma is known as the fourth state of matter, (depicted in Figure 8-1) and is generally 
defined as being a partially or fully ionised gaseous species of high energy that makes up 
over 99 % of the universe. A distinction can be made between the strength of bonds that hold 
their constituent particles together. The state of the substance depends on an equilibrium 
between the random kinetic energy (thermal energy) of the substances’ atoms or molecules, 
and the interparticle binding forces. Increasing the energy within a solid or liquid substance 
leads to a phase transition, when the binding potential within a substance is overcome. The 
transition from a gas to a plasma is not a thermodynamic phase transition, as it occurs from 
interactions with an external magnetic or electric field of external or self-induced origin.
16
 It 
can also occur following a gradual increase of the substances’ temperature; an atomic gas is 
formed as a result of particle collisions, with an increasing fraction of the atoms possessing 
sufficient kinetic energy to overcome the binding energy of the outermost orbital electrons, 






Figure 8-1. The fourth state of matter: Plasma. The addition of energy ensures progression 
from a) the solid state, where molecules are tightly bonded together, to b) the liquid state, 
where molecules have restricted movement, to c) the gas state, where molecules are 
unbounded and free to move, and finally to d) the plasma state, where some ionisation occurs 
and quasineutrality is achieved.  
Plasma is comprised of photons, positive and negative ions, atoms, free radicals and excited 
and non-excited molecules. These can all potentially exert an influence on their surroundings. 
The extent of this influence, in addition to the mode of action of the plasma, can depend upon 
the plasma gas and on the doses and fluxes of plasma-activated species, as well as the 
configuration of the plasma device and the microstructure of the plasma. Secondary effects, 
such as etching/ablation, dehydration, temperature increases, pH changes, electrical currents 
and generation of activated species downstream of the plasma in the surrounding air and 
biological environment, are also likely to be important.  
 
8.1.3 Plasma medicine 
The non-thermal nature, selective targeting properties of plasma jets, coupled with non-
destructive characteristic claims on biological material,
20, 21
 has led to a potential paradigm 





 and for antibacterial activity
24, 25




carried out. In addition to this, blood coagulation is routinely carried out using thermal 
plasma and high temperatures.
26
  
Mapping of the cellular response to plasma jets has limited reporting in the literature. Until 
recently, more effort has been dedicated to studying the effect of non-equilibrium plasma on 
prokaryotic cells; however structural differences between complex eukaryotes and 
prokaryotes indicate that the response would differ substantially.
27
 Preliminary mammalian 
cell work has been carried out investigating conditions of jet use that result in necrosis (cell 
death due to catastrophic injury), or apoptosis (an internal process of cell self-destruction). A 
power of 50 mW for one second was found to be favourable for avoiding apoptosis, with cell 
detachment still observable.
20, 28
 Cell detachment, reattachment and surface functionalization 
of human hepatocytes (HEPG2) has also been shown with a miniature atmospheric-pressure 
glow discharge plasma torch.
29
 
Work completed by Ermolaeva et al. discusses the use of a rat model with a superficial slash 
wound infected with P.aeruginosa and S.aureus. Initial results suggested increased wound 
closure, and the elimination of P.aeruginosa, however S.aureus was still present in the 
plasma treated model, and wound healing eventually slowed to less than the control (18 days 
compared to 15 days).
25
 These results suggest selective antimicrobial properties of plasma 
treatment, but indicate a potential negative effect on the surrounding wound environment.  
The risks associated with the use of plasma in medicine for direct treatment often relate to the 
plasma temperature, power transfer from the plasma, UVR, radicals, generation of toxic 
gases
30
 and electromagnetic fields which could induce electrolysis in the tissue or stimulation 




8.1.4 Atmospheric plasma 
Atmospheric gaseous plasma has shown potential as a promising emerging technology in 
healthcare applications.
32, 33
 Cold atmospheric plasmas have temperatures of approximately 
300K (room temperature), and are classified as either direct, indirect or hybrid (barrier corona 
discharge) systems. Direct plasma systems utilise the material that is being treated (sample 
surface or tissue) as one of the plasma electrodes, ensuring the flow of UVR, charged and 
uncharged particles, and the current, through the desired treatment medium.
32
 Indirect plasma 
systems use two separate electrodes and a carrier gas to ensure effective delivery of active 
agents to the material that is being treated.
11, 34
 Hybrid plasmas use a grounded wire mesh 
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electrode with a lower electrical resistance than the material that is being treated, allowing the 
current to pass through the mesh.
13
 
The link between prevalence of bacteria colonisation in a wound and subsequent rate of that 
wound healing
35
 has indicated the necessity for a treatment that can kill bacteria non-
specifically without damaging surrounding eukaryotic tissue. In 2005, the Max Plank 
Institute for Extra-terrestrial Physics, Germany, introduced the MicroPlaSter (ADTEC 
Plasma Technology Co. Ltd.); a plasma source capable of providing contact-free and painless 
sterilisation of wounds. This source reportedly ensures homogenous delivery of the active 
particles using argon gas, from a distance of about 20 mm, with a treatment area of 
approximately 5 cm in diameter. In 2010, Isbary et al. reported a prospective phase II in vivo 
clinical trial investigating the effect of regular MicroPlaSter cold plasma treatment on 




Additionally, there is evidence from cell culture studies that treatment with plasma could 
encourage rate of cell growth.
36
 In one such study, an application of 30 s or 4 J cm
-2
 of 
plasma treatment increased the rate of proliferation of endothelial cells by double in 
comparison to un-treated cultures (five days post treatment). This proliferation is accredited 
to the plasma-initiated release of reactive oxygen species mediated fibroblast growth factor-2 
(FGF2), which, along with other signals, activate invasion of local cells into surrounding 
tissue to form new blood vessels (angiogenesis).
37
 Although longer exposure times (>60 s or 
8 J cm
-2




8.1.5 Microplasma jet 
The term microplasma describes a special class of electrical geometries where at least one 
dimension is in the sub-millimetre length scale.
39
 Microplasma jets are uniquely characterised 
by atmospheric / high pressure stability,
40
 non equilibrium thermodynamics,
41, 42
 non-
Maxwellian electron energy distribution functions (EEDFs)
43
, high electron densities
42
 and 
versatility of use. Microplasma jets have the potential to provide a safe plasma source, being 







8.2 Proposal: a synthetic biological sensor 
A synthetic biological sensor, containing vesicles, can be developed to monitor the 
interaction of plasma with soft, hydrated biological material. Incorporation of vesicles, 
containing the self-quenched dye 5(6)-carboxyfluorescein, (as discussed in Chapter 3 -
Vesicle development - stability), into a hydrated proteinaceous environment comprising 5 % 
(w/v) gelatin, can be used to map any plasma induced damaging effects through vesicle 
destruction. Gelatin was introduced in Chapter 5 (for favourable properties see Table 5-1), 
and showed favourable vesicle stabilising potential for delivery of the vesicles in topical form 
to a wound.  
The depth of plasma penetration into the sensor matrix can be measured, and the angle of 
treatment investigated, to monitor if these factors significantly influence the nature and level 
of damage. This can be achieved through observation of the release of the quenched 
fluorescent dye from within the vesicles and subsequent un-quenching. 
This sensor model can potentially be used to unravel the roles of different plasma species and 
the direct effect of whole plasma contact, from those of primary and secondary species. 
Primary effects involve those emanating directly from the plasma and secondary effects 
involve those species created in the 'target' tissue. This type of insight could be useful in the 
future development of safe and effective plasma medical technologies. 
 
8.3 Plasma jet treatment of the synthetic sensor 
8.3.1 Plasma jet parameters  
An initial range finding experiment was carried out to ensure that the plasma jet made visible 
contact with a synthetic sensor sample mounted on a silica sheet. A range of helium gas flow 
rates (0.05-1 Lmin
-1
), voltages (3.5-6 kV) and distances from the sample (1-7 mm) were 
investigated. The minimum distance and helium flow rate required for contact at each voltage 






















































































Figure 8-2. Plasma jet contact with vesicles on a silica backed sample with a range of helium 
gas flow rates, voltages and distances from the sample. The minimum distance and flow rate 
required for visible contact to be observed at different voltages is shown; distances where no 
contact is made have been omitted. A frequency of 10 KHz was maintained for each 
condition.  
From the initial results, a voltage of 5.5 kV and a relatively low flow rate of 0.1 Lmin
-1
 were 
selected for continued experiments. A low flow rate was desirable to prevent dehydration of 
the vesicles (which resulted in osmotic induced lysis). Further operational parameters were 
investigated for the interaction of the micro plasma jet with the synthetic biological sensor, 
namely treatment time, distance (d) and treatment angle. 
  
8.3.2 Sensitivity of the biological synthetic sensor 
Vesicle lysis can be artificially induced through physical (e.g. dehydration), thermal or 
chemical agents (e.g. surfactants), or through biological agents (e.g. pathogens, bacterial 
toxins or enzyme digestion).
45
 This known sensitivity of vesicles was investigated using the 
synthetic biological sensor. This allowed a comparison to be made between the lytic effects 
of the surfactant triton (a chemical agent introduced in 3.3.5 Vesicle membrane solubilisation 
– a positive lytic control), the supernatant of S.aureus RN4282 and phospholipase A2 
(biological agents introduced in 4.2.1.2 The relevance of MSSA RN4282 and 4.3 Bacterial 
toxin interactions with membranes, respectively) and following treatment with the plasma jet 
at a d of 3 mm for 300 s (physical). As discussed previously MSSA RN4282 is a naturally 
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occurring strain of S.aureus that produces and secretes small amounts of exoproteins but 
elevated quantities of toxic shock syndrome toxin (TSST).
46
 Phospholipase A2 is an enzyme 
that catalyses the hydrolysis at the sn-2 position of membrane phospholipids, resulting in the 
liberation of arachidonic acid (AA)
47
 and the consequential destabilisation of cells / vesicles 
(see Figure 4-1). 
The synthetic biological sensor was added (100 µl) to a 96 well plate followed by either 
treatment with the plasma jet at a d of 3 mm for 300 s or incubated with 50 µl of the lytic 
reagents at 37 °C for 2 h. Fluorescence intensity measurements were obtained using a 
Fluostar Omega microplate reader (λext = 485 ± 12 nm and λem = 520 nm). 
A similar level of damage was measured following plasma jet treatment when compared to 
the natural (biological) and synthetic (chemical) cytolytic agents, Figure 8-3, indicating a 
similar level of rupture of vesicles. 




























Figure 8-3. The comparative fluorescence of the sensor after 2 h of incubation with a control 
(HEPES buffer), S.aureus RN4282 supernatant (SN), Triton X-100, Phospholipase A2 (Phos 
A2) and after treatment with the plasma jet (perpendicular to the sample surface) at a d of 3 
mm for 300 s was measured.  
The data from Figure 8-3 indicates that the plasma jet can potentially induce a similar level of 




8.3.3 Treatment and analysis of the synthetic biological sensor 
The synthetic biological sensor was treated for three different amounts of time (15, 60 and 
300 s) and at two separation distances between the end of the glass capillary tube and the 
surface of the sensor (2 and 3 mm). Treatment times of 15, 60 and 300 s were used as a proof 
of principle study range representative of an ‘appropriate’ range of times to potentially 
guarantee observation of the regimes of interest. Comparative treatments were carried out 
using neutral helium gas (i.e. no plasma was generated) directed onto the sensor using the 
same parameters. Further controlled comparative treatments were also carried out using 
plasma directed onto a gelatin matrix containing non-encapsulated (5(6)-CF.  
 
8.3.3.1 Brightfield and fluorescence Microscopy  
Brightfield and fluorescence microscopy was utilised to visualise and analyse the effects 
following treatment of the synthetic sensor with plasma and neutral helium, and compare the 
results were compared to a plasma treated control. The resultant images following 
perpendicular treatment of the synthetic biological sensor at a d of 3 mm for 15, 60 and 300 s 




Figure 8-4. Perpendicular treatment of synthetic sensor with the plasma jet for 15 (A-C), 60 
(D-F) and 300 (G-I) s at a d of 3 mm. The figure shows brightfield (A, D and G), 
fluorescence (B, E and H) and combined (merged) brightfield and fluorescence (C, F and I) 
images. Scale bar = 200 µm. 
The plasma jet can be observed to be puncturing a hole through the gelatin after 15 s of 
treatment and longer treatment times. A star-shaped pattern of microchannels formed within 
the gelatin matrix after a plasma jet treatment time of 300 s (brightfield images) and a higher 
level of fluorescence indicated an increased level of vesicle damage within these 
microchannels.  
The resultant images following perpendicular treatment of the synthetic biological sensor at a 





Figure 8-5. Perpendicular treatment of synthetic sensor with the neutral gas flow only (i.e. no 
plasma) for 15 (A-C), 60 (D-F) and 300 (G-I) s at a d of 3 mm. The figure shows brightfield 
(A, D and G), fluorescence (B, E and H) and combined (merged) brightfield and fluorescence 
(C, F and I) images. Scale bar = 200 µm.  
Images A, D and G in Figure 8-5 display a central dark circular region for each of the 
treatment times, indicating damage to the synthetic tissue directly in the line of sight of the 
helium gas flow from the capillary tube. However, no significant increase in the fluorescence 
of the 5(6)-CF at the damaged area of the gelatin was measured (B, E and H). 
The plasma jet had a very different effect on the synthetic biological sensor when compared 
to the effect of the neutral gas treatment. A hole in the gelatin matrix region (upon the area 
directly exposed to the plasma jet), was observed after 15 s of plasma treatment (see Figure 
8-4, A), indicating a greater depth of damage in comparison to the neutral gas. After 
treatment for 60 s, a star shaped pattern of microchannels was observed, developing within 
the sensor matrix and radiating from the centre of the treatment area (D, F). This pattern 
becomes larger and more distinct after 300 s of treatment (G, H, I). A marked increase or 
pattern of fluorescence, matching the star-shape obtained for 60 s, was not observed for 
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treatment times of 15 and 60 s (B, C, E and F), however an increased fluorescence following 
the same star pattern etching into the damaged gelatin was detected (H, I). 
To confirm that the increased fluorescence signal observed in the synthetic biological sensor 
was the result of plasma jet damage to the vesicles, the effect of plasma treatment on the 
gelatin matrix prepared with the 5(6)-CF dye suspended freely within it (i.e. no vesicles) was 
measured, given in Figure 8-6.  
 
Figure 8-6. Perpendicular plasma jet treatment of the gelatin matrix prepared with 5(6)-CF 
freely suspended within the matrix, without the presence of vesicles. Treatment was carried 
out for 15 (A-C), 60 (D-F) and 300 (G-I) s at a d of 3 mm. The figure shows brightfield (A, D 
and G), fluorescence (B, E and H) and combined (merged) brightfield and fluorescence (C, F 
and I) images. Scale bar = 200 µm  
The same pattern of microchannels formed (A, D, F, G, I - Figure 8-6), however the 
fluorescent signal from the gelatin-5(6)-CF matrix did not appear to change. This confirms 
that the change in the fluorescence signal within the biological sensor was caused by vesicle 




8.3.3.2 Fluorescent intensity profiles 
The fluorescence intensity profile of the treatment area of the synthetic sensor was measured 
and used to quantify the level of vesicle damage caused by the neutral gas and the plasma jet. 
This was achieved using fluorescence intensity values from 60 data points by measuring 20 
different positions at a distance of 45 µm across the center of each treatment area, results 
shown in Figure 8-7. To enable a direct comparison between each image, all of the images 
were taken using the same camera exposure times (48 ms) and gain settings. 
 
Figure 8-7. Analysis of 5(6)-CF fluorescence intensity profiles of the synthetic tissue after 
perpendicular treatment with the neutral gas (A and C) and plasma jet (B and D). Graphs A 
and B show representative fluorescence profiles of the treatment area after treatment for 
different times at a fixed d of 3 mm. Graphs C and D show the fluorescence intensity values 
measured at the centre of the treatment area after different treatment times at a d of 2 and 3 
mm. *Plasma jet treatments carried out for 300 s were statistically significantly different to 
the 300 s gas only treatments (p < 0.0001 for both treatment distances). 
Results from Figure 8-7 indicate that a treatment time of 300 s with the neutral gas or plasma 
jet resulted in an enhancement of fluorescence from the synthetic tissue. This indicates that 
both processes damage the vesicles, although plasma jet treatment for 300 s resulted in a 
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significantly higher level of damage to the vesicles compared to the other treatment 
conditions.  
The 5(6)-CF fluorescence intensity profiles of the synthetic tissue after neutral gas and 
plasma jet treatment show a higher fluorescence signal level in the centre of the treatment 
area (Figure 8-7, A and B). An increase in treatment time increased the fluorescence response 
signal for both the neutral gas and plasma jet treatment (C and D). This indicates a higher 
level of vesicle damage at the centre of the treatment area directly exposed to the gas flow 
and plasma jet, and that the level of sensor damage is directly related to treatment time. A 
higher level of 5(6)-CF fluorescence within the gelatin matrix was detected after plasma jet 
treatment for 300 s, which was statistically higher than the neutral gas treatment at the same 
time point. Based on this specific configuration a conclusion can be drawn that a plasma jet 
exposure time of 300 s was required to induce a significant level of sensor damage. This 
conclusion was consistent for treatment distances of both 2 and 3 mm. 
  
8.3.3.3 Confocal microscopy 
Confocal microscopy was used to analyse the depth of damage to the vesicles within the 
synthetic biological sensor following plasma jet treatment, shown in Figure 8-8. In 
corroboration with the fluorescence images and data obtained, the level and depth of damage 
to the vesicles, and hence the fluorescence intensity, appeared to increase with longer plasma 




Figure 8-8. Confocal microscopy images of the synthetic tissue after perpendicular plasma jet 
treatment for 15 (A and D), 60 (B and E) and 300 (C and F) s at a d of 3 mm. The vesicles 
were damaged at a depth greater than 150 µm below the surface of the gelatin matrix. 
Horizontal and vertical scale bars = 100 µm.  
At each treatment time, the distribution of the damaged vesicles could be monitored due to 
the high sensitivity of the confocal microscope. Analysis utilising Z-stacking measurements 
to form vertically stacked cross-sectional images for each treatment time allowed the depth of 
plasma treatment damage to be determined. For each of the treatment times the vesicles 
within the gelatin matrix were damaged by the plasma jet at a depth of over 150 µm (D – F). 
 
8.3.4 Parallel plasma jet treatment  
Comparative treatment of the synthetic biological sensor with the plasma jet was carried out 
in parallel to the surface (i.e. 180°), at a separation distance of 3 mm. This treatment enabled 
the plasma plume to flow across the surface of the sensor rather than direct, head on contact. 
This angle appeared to significantly reduce the level of damage to both the vesicles and 
gelatin. Damage caused by the plasma jet was only detected after 300 s of treatment, shown 
in Figure 8-9. The neutral gas did not damage the synthetic sensor at all following this 




Figure 8-9. Parallel treatment of the synthetic sensor with the plasma jet where A) shows a 
brightfield micrograph of the plasma jet treated synthetic tissue and B) shows the 
corresponding confocal microscope image. Treatment was carried out at a d of 3 mm for 300 
s. Horizontal and vertical scale bars = 100 µm.  
At an angle of 180° to the sensor, the plasma jet etched a single microchannel into the gelatin 
matrix and damaged the vesicles only at the walls of the channel. This microchannel can be 
seen to taper to a fine point following the path of the gas flow and the corresponding confocal 
microscope image indicates only minimal damage to the vesicles at the walls of the 
microchannel.  
 
8.3.5 Plasma jet treatment through a vesicle suspension 
In addition to the synthetic biological sensor, comparative treatment of vesicles in a 
suspension with a plasma jet bubbled through was investigated. The vesicle suspension 
solution, HEPES buffer, was significantly less viscous than gelatin, allowing an easy flow of 
plasma through the sample. The sensitivity of this system to external agents ensured that any 
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fluorescence resulting from vesicle rupture and release of the fluorophore into the suspension 
was detectable. No significant damage was caused to the vesicles by either the gas flow or 
plasma jet, shown in Figure 8-10.  





























Figure 8-10. Plasma jet treatment of a suspension of vesicles.  
This application of plasma through the vesicle suspension and lack of significant damage 
indicates that the HEPES buffer may shield the vesicles from the plasma jet and any primary 
or generated reactive species or collisional movement of free moving particles may diffuse 
the potential damaging agents, at the doses investigated in this study. Work carried out with 
help from N. T. Thet. 
 
8.4 Microplasma jet treatment of vesicles - conclusions 
The effect of plasma jet on the synthetic biological sensor synthesised has enabled controlled 
analysis of the degree of rupture of vesicles under different conditions (time, distance and 
angle), allowing conclusions with regard to the plasma jet mode of action to be drawn. The 
damage caused by the comparative neutral gas treatment colliding with the sample resulted in 
a movement of the gelatin matrix creating a hole of ~0.2 mm
2
 (smaller than the capillary tube 
internal diameter of 0.8 mm
2
). The damage caused by the plasma jet was significantly 
greater, with movement of the gelatin matrix up to an area of 7.5 mm
2
.  
The differences between the damage measured allow conclusions to be drawn about the 
interactions occurring at the sensor. Upon head-on contact of the neutral gas with the gelatin 
matrix, the sample, at point of contact and in surrounding areas for longer treatment times, is 
most likely partially dehydrated as the helium gas flow penetrates the sample. Additionally, 
some physical movement of the soft gelatin tissue away from the path of the gas flow is 
observed. The plasma jet induced damage is more complex, with the creation of star shaped 
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microchannels radiating out from the centre of the treatment area. Speculation with regard to 
what is occurring can be made based on pertaining literature relating to plasma jets. The 
plasma jet contains charged (active) species within a succession of hypersonic propagating 




much faster than the neutral gas velocities (~10 ms
-
1
). The helium gas can penetrate through the surface of the sensor and ensure conduction of 
the active plasma bullets into the matrix.
49
 The presence of mutually repulsive ion charges 
carried within the helium stream causes the cylindrically symmetric plasma streams to split 
into an integer number of channels. The plasma bullets continue to carry the gas through the 
sample as a result of ion momentum transfer to the neutral gas, forming equally spaced radial 
spokes.
50, 51
 The reactive species propagated into the sample with the neutral gas are then able 
to damage the vesicles within the formed micro channels. The number of microchannels 
formed can vary, and this can be accredited to subtle differences within the matrix 
environment (e.g. gelatin composition). 
The formation of microchannels allows for the penetration of the reactive oxygen and 
nitrogen (RONS) into the sample, achieving a depth of damage / treatment of ˃ 150 µm. 
Importantly the rigidity of the treated material is known to have a strong effect on the depth 
of penetration. This microchannel formation effect was not observed after similar plasma jet 
treatments of a rigid organic polymer (treated areas are circular),
52
 indicating that different 
plasma jet components are involved. 
A lower level of vesicle damage was induced by the neutral gas compared to the plasma jet, 
and this decreased amount of vesicle damage is expected as rupture was only achieved 
through dehydration or pressure.
53
 Damage caused to the sample as a direct result of plasma 
treatment can include etching,
54





 or cleavage of the chemical bonds 
by activated plasma species.
56
  
The directional nature of plasma jets has proven to play an important role in the depth and 
quantity of vesicle damage within the sample, as proven by the microstructures formed within 
the gelatin when applied head-on or in parallel to the sample. The reactive species (RONS) 
can be considered to react laterally across surfaces, in particular rigid surfaces, resulting in 
larger treatment areas than the capillary jet delivery tube.
52
 In corroboration with these 
findings, Leduc et al. demonstrate that the plasma treatment of biological cells is highly 
directional; with their data showing that the plasma components responsible for cell 





Within the scope of this investigation, it was considered that the directional nature of the 
plasma jet was responsible for the micro structural changes within the sample. This was 
particularly relevant with regard to formation of RONS, due to the short effective activity 
distances. RONS can be considered secondary plasma species, i.e. not directly created within 
the plasma, and based on existing literature, their mode of action on bilayer vesicle rupture 
could be from the initiation of lipid peroxidation leading to chemically induced vesicle 
rupture and the consequent release of the fluorescent dye.
14, 29, 57
 
A study by Lademann et al. showed that the stratum corneum can be permeabilised by 
plasma treatment to increase the depth of penetration of a topically applied model drug, in the 
form of a fluorescent dye, through the skin barrier.
58
 This effect was speculated to be due to 
plasma damage of the lipid bilayers, and correlates with the results obtained within this 
investigation; providing further proof that the microstructural changes observed could prove 
an ideal pathway for the penetration of topical agents. 
The directional nature of the plasma can be further highlighted following treatment in parallel 
with the surface of a sample. Damage from the plasma can only occur from propagated 
bullets directly along the surface, creating a single micro channel with reduced vesicle 
damage. This observation can be explained by a lower concentration of excited species 
impacting on the sensor. 
The complexity of natural tissue raises questions about the validity of the relatively simple 
synthetic sensor utilised in this study. However, at a basic level the membrane of the vesicles 
emulates the membrane surrounding eukaryotic cells with the collagen derived gelatin acting 
as the extracellular matrix.  
 
8.4.1 Soft tissue plasma treatment 
The results obtained within this investigation, whilst only preliminary, could provide 
important information on ideal operating parameters of plasma sources on soft tissue 
treatment applications. For example, a homogenous plasma treatment area could be achieved 
using an array of plasma jets
51
 or by raster scanning the plasma source across the tissue.
59
 In 
addition to this, further attention may be given to the effects of potentially damaging plasma 
components, e.g. radicals and RONS,
60
 and the negative health effects on the patient 
following their diffusion and migration into the body. 
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A major advantage of the synthetic biological sensor is the lack of variation between samples 
commonly seen in cell and tissue-based assays. The low level of protein content (5 % (w/v)) 
and a potentially increased fragility and sensitivity of the ‘cells’ may allow detection of 
effects more readily. However, the proof-of-principle sensor established for this investigation 
could potentially have a level of sophistication and increased biological relevance built in; for 
example by increasing the protein concentration to allow a closer resemblance to a tissue-
system. Comparable studies reporting treatment of proteins and organic polymers suggest the 
primary response would be ablation, surface oxidation and cross-linking,
61
 hence an 
increased protein sensor system would be predicted to be less sensitive - making subsurface 
effects more difficult to measure.  
Additional sophistication to the synthetic sensor could be made by the introduction of RNA 
and DNA, proteins, enzymes or cells, alteration to the gelatin matrix rigidity and engineering 
of the vesicle through modification of their sensitivity to external agents or addition of 
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Chapter 9 Conclusions 
This work investigated the stabilisation, modification, delivery and treatment of phospholipid 
based vesicles for applications in advanced wound management. A primary focus of this was 
towards engineering a dressing suitable for use on paediatric burn wounds, and development 
of this product was discussed in chapters three, four, five and six. Chapters seven and eight 
offer a variation on the advanced wound management theme. Chapter seven introduces a new 
protective and selectively responsive coating based on coupled hyaluronic acid to the 
vesicles, suitable for placement in a wound dressing. Finally, chapter eight discussed the 
utilisation of vesicles as a synthetic sensor / tissue mimic to model any damaging effects of 
micro plasma jet treatment. Overall conclusions can be drawn based on each chapter of work; 
and good progression was made towards achieving a dressing suitable for wound 
management.  
Chapter three has presented the development of a range of different stabilised vesicles, with 
the creation of a library of over 70 different compositions. The encapsulation of a fluorescent 
self-quenched dye (5(6)-CF) ensured that lysis of bilayer membranes and passive leakage of 
internal components could be tracked and measured following release and un-quenching. 
Five potential candidates displayed the desired stability at 37 °C for 14 days, and 
comparisons between these were made using the stability response parameter. These vesicle 
formulations were then subjected to further investigations with regard to varying pH values 
(5, 6, 7 and 8 - representative of a wound environment) and temperature ranges (5 °C, -20 °C, 
-80 °C and flash freezing – representative of potential storage conditions) for 14 days. Three 
successful vesicle compositions were then utilised collectively or individually in the work 
that followed, namely TCDA-DS, DOPC-DS and DSPG-DP.  
Chapter four has presented an investigation into the selective sensitivity of the three 
aforementioned successfully stabilised vesicles to two strains of pathogenic bacteria, 
P.aeruginosa PAO1 and S.aureus MSSA476, in comparison to the non-pathogenic strain 
E.coli DH5α. Vesicle lysis and release of the encapsulated dye was desired in the presence of 
the pathogenic bacterial toxins only, and the extent of this effect varied depending on the 
vesicle bilayer composition. This was postulated to be due to the interaction and repulsion 
between localised charge distributions on the vesicle membrane or the availability of phase 
boundaries within the membrane at 37 °C. In addition to this the effect of burn wound 
exudate on vesicle stability and sensitivity was measured. Stability results following 
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incubation are promising against passive diffusion of the encapsulated agents. However, it 
can be postulated that sequestering of added lytic agents by the wound exudate may be 
occurring, potentially preventing vesicle lysis from occurring. The three vesicle candidates 
successfully demonstrated selective sensitivity to the pathogenic bacteria, and good stability 
in wound exudate, and so were utilised for incorporation into a wound dressing prototype 
system. 
Chapter 5 has presented work on the development of a prototype dressing, based on a topical 
open hydrogel formulation. This formulation was required to be able to incorporate stable 
vesicles without increasing passive diffusion of internal agents at 37 °C for 14 days, whilst 
maintaining the pathogenic bacteria sensitivity profile that is essential for this project. Of the 
four hydrogels investigated, three have indicated some promising stabilising compatibility 
with the vesicle candidates and, importantly, have ensured that the required selective 
sensitivity profile following addition of bacterial toxins is still achieved (gelatin, 
hypromellose and agarose). The fourth hydrogel (Carbopol 981P NF), proved insufficient at 
stabilising the vesicle candidates over the desired time period. Further investigations are 
required to determine whether any of the compatible hydrogels display any probiotic 
properties. In addition to this development of occlusive systems based on these hydrogel 
formulations may prove beneficial within a wound environment.
1
 
Chapter 6 has presented an introductory investigation into vesicle stability to sterilisation 
techniques. The emphasis of this investigation was not on the actual sterilising efficiency of 
the technique employed. Instead the ability of the vesicles to maintain their structure, 
including continual encapsulation of their internal agents following treatment was of primary 
concern. Although, each of the sterilisation techniques investigated were carried out to an 
extent that would have ensured that complete sterilisation of the vesicle solution was 
achieved (gamma radiation, autoclaving and filter treatment with pores smaller than 0.22 
µm). Results indicated that radiation treatment of vesicles using the isotope 
137
Cs as a gamma 
source showed excellent potential for ensuring structure of vesicle is maintained without 
passive diffusion of internal agents. The thermal treatment of vesicles was (unsurprisingly) 
found to significantly increase the extent of passive leakage of internal agent. This was due to 
the known increased sensitivity of the vesicle compositions at temperatures above their Tc. 
The use of filters to achieve sterile vesicles was encouraging; membrane material was found 
to play a role in the ability of the vesicles to diffuse through the pores. 
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Chapter 7 has investigated the modification of vesicle structure through conjugation to a HA 
protective and responsive coating. The HA-coupled vesicles were found to be able to respond 
to a prototype system using purified δ-toxin and HLase, and the more bio-relevant response 
was observed following incubation with bacteria supernatant of a HLase producing strain 
(S.aureus MSSA H560) compared to a negative strain (S.aureus MRSA ST239µ2). The 
protective and responsive nature of the HA-coupled vesicles to HLase producing bacteria 
could provide an innovative method towards achieving protected, stabilised and selectively 
sensitive vesicles. 
Chapter 8 has presented an investigation into the interaction of an atmospheric micro plasma 
jet with a synthetic biological sensor, composed of phospholipid vesicles in a gelatin matrix. 
Atmospheric plasma has been extensively researched for treatment of chronic skin wounds,
2
 
however the mapping and reporting of cellular response to treatment is limited. This study 
has enabled analysis into the degree of damage caused by the plasma treatment based on a 
variation of experimental parameters, such as treatment time (15, 60 and 300 s), distance 
from the jet (2 and 3 mm) and direction of jet (parallel or perpendicular). Following 
perpendicular treatment, the plasma jet was found to create star shaped microchannels 
radiating out from the centre of the treatment area, presumably from active species within the 
plasma, allowing penetration of RONS into the sensor; and this resulted in measurable vesicle 
damage. The complexity of natural tissue compared to the relatively simple synthetic sensor 
utilised in this study is important to note. However, at a basic level the membrane of the 
vesicles emulates the membrane surrounding eukaryotic cells with the collagen derived 
gelatin acting as the extracellular matrix.  
This project has successfully investigated the development of advanced wound management 
techniques, with the outcomes including a prototype selectively sensitive topical wound 
dressing, a selectively responsive, protected vesicle coated system, and a synthetic biological 
sensor suitable for mapping atmospheric plasma damage. Wound management 
improvements, innovation and new technologies are highly desirable, and the importance of 
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Stabilising agent Long term 
stability 
14 days / 37 °C 
DMPC/DPPE DMPC 78% Cholesterol 20% 
DMPE 2% 
None Poor 
TCDA-DM1 DMPC 68% Cholesterol 20% 
DMPE 2% 
TCDA 10% Poor 
TCDA-DM2 DMPC 63% Cholesterol 20% 
DMPE 2% 
TCDA 15% Poor 
TCDA-DM3 DMPC 63% Cholesterol 15% 
DMPE 2% 
TCDA 20% Poor 
TCDA DM4 DMPC 40% Cholesterol 20% 
DMPE 2% 





































































TCDA 15% Excellent 
TCDA-DS5 DSPC 63% Cholesterol 25% 
DSPE 2% 










TCDA 25% Good 
DPPC-DS DSPC 63% Cholesterol 25% 
DSPE 2% 




































DPPG-DP4 DPPC 53% Cholesterol 20% 
DSPC 15% 
DPPG 10% 
DPPE 2%  
Excellent 
DSPG-DP1 DPPC 53% Cholesterol 20% 
DSPC 15% 
DSPG 10% 
DPPE 2%  
Excellent 





DPPC/DPPE DPPC 78% Cholesterol 20% 
DPPE 2% 
None Good 










DSPC-DP3 DPPC 53% Cholesterol 20% 
DPPE 2% 
DSPC 25% Good 
DHPC/DHPE DHPC 78% Cholesterol 20% 
DHPE 2% 
None Good 





DSPC-DH2 DHPC 63% Cholesterol 20% 
DHPE 2% 
DSPC 15% Good 
DSPC-DH3 DHPC 53% Cholesterol 20% 
DHPE 2% 
DSPC 25% Good 
DHPC-DS1 DSPC 73% Cholesterol 20% 
DSPE 2% 
DHPC 5% Good 
DHPC-DS2 DSPC 63% Cholesterol 25% 
DSPE 2% 
DHPC 10% Good 
DHPC-DS3 DSPC 68% Cholesterol 20% 
DSPE 2% 
DHPC 10% Good 
DHPC-DS4 DSPC 63% Cholesterol 20% 
DSPE 2% 
DHPC 15% Good 
DHPC-DS5 DSPC 53% Cholesterol 20% 
DSPE 2% 
DHPC 25% Good 
DHPC-DS6 DSPC 58% Cholesterol 25% 
DSPE 2% 
DHPC 15% Good 
DHPC-DS7 DSPC 53% Cholesterol 25% 
DSPE 2% 
DHPC 20% Good 
DHPC-DS8 DSPC 48% Cholesterol 25% 
DSPE 2% 
DHPC 25% Good 
DHPC-DS9 DSPC 43% Cholesterol 25% 
DSPE 2% 
DHPC 30% Good 
DHPC-DS10 DSPC 58% Cholesterol 30% 
DSPE 2% 
DHPC 10% Good 
DHPC-DS11 DSPC 53% Cholesterol 35% 
DSPE 2% 
DHPC 10% Poor 
DHPC-DS12 DSPC 48% Cholesterol 40% 
DSPE 2% 
DHPC 10% Poor 
DHPC-DP1 DPPC 73% Cholesterol 20% 
DPPE 2% 
DHPC 5% Good 




DHPC-DP3 DPPC 53% Cholesterol 20% 
DPPE 2% 
DHPC 25% Good 
Chol-DS1 DSPC 63% DHPC 10% 
DSPE 2% 
Chol 25% Good 
Chol-DS2 DSPC 58% DHPC 10% 
DSPE 2% 
Chol 30% Good 
Chol-DS3 DSPC 53% DHPC 10% 
DSPE 2% 
Chol 35% Good 
Chol-DS4 DSPC 48% DHPC 10% 
DSPE 2% 
Chol 40% Good 















Bio-DM1 DMPC 68% Cholesterol 30%  DPPE-biotin 2% Poor 







DPPE-biotin 2% Good 
Bio-DP2 DPPC 79% Cholesterol 20%  DPPE-biotin 1% Good 
Bio-DP3 DPPC 78% Cholesterol 20% 
DPPE 1%  
DPPE-biotin 1% Good 
Bio-DP4 DPPC 76% Cholesterol 20% 
DPPE 1% 
DPPE-biotin 3% Good 
 Bio-DP5  DPPC 53% Cholesterol 20% 
DPPE 1%  
DPPE-biotin 1%  
DHPC 25% 
Good 
Bio-DP6 DPPC 51% Cholesterol 20% 
DPPE 1% 






 Bio-DP7  DPPC 53% Cholesterol 20% 
DPPE 1%  
DPPE-biotin 1%  
DSPC 25% 
Good 
Bio-DP8 DPPC 51% Cholesterol 20% 
DPPE 1% 
DPPE-biotin 3%  
DSPC 25% 
Good 
Bio-DP9 DPPC 54% Cholesterol 20%  TCDA 25% 
DPPE-biotin 1% 
Good 





Bio-DP11 DPPC 51% Cholesterol 20% 
DPPE 2%  
DSPC 15% 
DPPE-biotin 2%  
DPPG 10% 
Good 
Bio-DP12 DPPC 76% Cholesterol 20% 
DPPE 2%  
DPPE-biotin 2%  Good 
Bio-DP13 DPPC 61% Cholesterol 20% 




Bio-DS1 DSPC 79% Cholesterol 20%  DPPE-biotin 1% Good 





DSPC/DSPE DSPC 78% Cholesterol 20% 
DSPE 2% 
None Excellent 
DDAB-DP1 DPPC Cholesterol 20% DDAB 0.1% Excellent 
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SA 0.5%  
TCDA 15% 
Excellent 
SA-DS2 DSPC 62% Cholesterol 20% 
DSPE 2% 
SA 1%  
TCDA 15% 
Excellent 
SA-DS3 DSPC 61% Cholesterol 20% 
DSPE 2% 
SA 2%  
TCDA 15% 
Excellent 
SA-DS4 DSPC 59% Cholesterol 20% 
DSPE 2% 
SA 4%  
TCDA 15% 
Excellent 
SA-DS5 DSPC 57% Cholesterol 20% 
DSPE 2% 















SA 2%  
DDAB 0.1%  
TCDA 15% 
Excellent 




Coenzyme A 2% Good 
CoenzymeA-DP2 DPPC 73% Cholesterol 20% 
DPPE 2% 
Coenzyme A 5% Good 
SI-Table 1. Vesicle compositions synthesised and an indication of their thermal stability at 14 
days / 37 °C. The following terms indicate stability according to Equation 3-29 (referenced 
from thesis): Poor = vesicles form but are very leaky (S = 1) over a period of 14 days, Good = 
vesicles from and are stable at 4 °C and 37 °C for greater than 1 day (S = 1.50 - 2.50), 
Excellent = vesicles form and are stable at 4 °C and 37 °C for a period of 14 days (S = 
2.51+). Vesicles are named according to their stabilising agent, followed by their primary 






























































































































SI-Figure 1. The fluorescence kinetic profiles over 25 hours for the three primary vesicle 
candidates following incubation with the three standard bacterial species; E.coli DH5α (non-
pathogenic), S.aureus MSSA 476 and P.aeruginosa PAO1 (pathogenic), relating to the end 













































































 TCDA DS HEPES
 TCDA DS E.coli
 TCDA DS AGR+
 TCDA DS  AGR-
 TCDA DS Triton











































 DSPG DP HEPES
 DSPG DP E.coli
 DSPG DP AGR+
 DSPG DP  AGR-
 DSPG DP Triton




























































































SI-Figure 2. The growth and fluorescence kinetic profiles over 18 hours for three vesicle 
types with AGR+ and AGR- bacterial species, compared to the standard pathogenic strain 
P.aeruginosa PAO1 and non-pathogenic strain E.coli DH5α, relating to the end point data 


























































































































SI-Figure 3. The kinetic growth of AGR+ and AGR- bacteria species in a comparative, non-
vesicle containing solution (HEPES) and in ideal nutrient rich conditions (broth), and end 
growth after 24 hours, compared to the standard pathogenic strain P.aeruginosa PAO1 and 







































 DPPG DP at 20 °C 
 
SI-Figure 4. The effect of gamma radiation on DPPG-DP vesicles. The fluorescence intensity 
graph indicates good measurable fluorescence of all vesicles treated with lytic agents (M = 
MSSA 476, P = PAO1, T = triton), compared to the low fluorescence of all vesicles with 











































































































































































































































































































































SI-Figure 5. Heat treatment of three vesicle types carried out at 80 °C, -20 °C and -80 °C for 
10, 30 and 60 minutes, and compared to control vesicles, flash freezing with liquid nitrogen 
(5 minutes) and autoclaving (120 °C, 60 minutes), all with HEPES and Triton. A), C) and E) 
are fluorescence intensity measurement graphs of TCDA DS, DOPC DS and DSPG DP 


























































S. aureus ST239 2
 
SI-Figure 6. The HLase assay results of the HLase negative strain ST239µ2, which shows the 
growth of bacteria over 25 hours, and the corresponding lack of production of the hyaluronic 
acid breakdown-component N-acetylglucosamine, measured per ml / per min / per OD600 
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